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 Melanoma accounts for 90% of skin cancer-related deaths in humans. Treatment options 
for metastatic melanoma in people is very limited. Melanoma is considered to be an immunogenic 
tumor, spurring interest in development of immunotherapies for the treatment of metastatic 
melanoma. Oncolytic virotherapy has been widely investigated. The first ever oncolytic 
virotherapy to receive FDA-approval is an HSV-1-based virus (Talimogene Laherperavec (T-Vec) 
or Imlygic) containing a transgene for human GM-CSF to enhance anti-tumor immune responses 
after injection. Durable response rate in human patients was only 16% despite impressive efficacy 
in anti-tumor effects in vitro and in murine tumor models. Novel viruses with enhanced immune-
stimulating properties and improved efficacy and safety profiles are needed. Further, the lack of 
concordance of preclinical murine studies with results in human clinical trials highlights the need 
for improved murine tumor modeling strategies. 
 Our laboratory developed the live-attenuated HSV-1 (VC2) vaccine strain, which has 
shown efficacy in protection against lethal intravaginal HSV-1 and HSV-2 challenge after a single 
intramuscular injection in mice. VC2 replicate efficiently in permissible cells but does not enter 
ganglionic axons. Further, VC2 is highly immunogenic generating strong cell-mediated and 
humoral immune responses. We developed an immunocompetent double-labeled murine 
melanoma model for testing the immune-modulating and adjuvant effects of oncolytic 
herpesviruses. Intratumoral virotherapy using VC2 resulted in significant increases in CD3+ T 
cells and IBA-1+ macrophages in the tumor microenvironment, but reduced expression of 
arginase-1, a marker of the M2, pro-tumorigenic macrophage phenotype. Median survival times 
(MST) of VC2 treated mice were nearly twice that of mock-treated controls.  We also found that 
bioluminescence allows for more sensitive assessment of anti-tumor responses during the acute 
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inflammatory phase of treatment during which pseudoprogression can result in misleading 
increases in tumor volumes using traditional caliper measurements. Our findings suggest that the 
remarkable immunogenicity of VC2 makes it a good candidate as a vector for tumor vaccine 
development and our model allows for sensitive assessment of response to therapy in the face of 
marked acute inflammation. These findings represent significant progress in viral vector 




CHAPTER I: INTRODUCTION 
Statement of Problem and Hypothesis 
HSV-1, an alphaherpesvirus with a lytic life cycle known for causing cold sores in 
people, is considered to be an excellent candidate for oncolytic virotherapy development due to 
its large, well-characterized genome with a number of non-essential genes that can be deleted for 
safety and/or replaced with therapeutic transgenes. Deletions in neurovirulence genes such as 
ɣ34.5 are common and intended to enhance safety but dampen viral replication and reduce 
effectiveness. T-VEC, an FDA-approved oncolytic HSV-1 virotherapy, showed robust efficacy 
in vitro and in a murine lymphoma tumor model during preclinical development, but a durable 
response rate of only 16% was observed in clinical trials for metastatic melanoma in people and 
some adverse effects were reported. Poor concordance of preclinical murine data with results at 
clinical trial highlights the need for a clinically relevant murine melanoma model for testing 
novel oncolytic virotherapies. Further, availability of more efficacious and safe viruses for vector 
development for cancer therapy are urgently needed.   Availability of an immunogenic virus that 
replicates efficiently without compromising safety would be a huge improvement over current 
oncolytic herpesviruses under investigation.  We hypothesized that the B16F10 syngeneic 
murine melanoma model would be a good model for human melanoma patients that are currently 
poorly responsive to oncolytic virotherapy and other immune-modulating therapies due to its low 
immunogenicity and lack of expression of nectin-1, an important receptor for HSV-1 entry. We 
hypothesized that utility of the model could be enhanced by utilizing reporter genes, eGFP and 
firefly luciferase, to evaluate tumor growth and progression in response to immune-stimulating 
therapy. We hypothesized that the VC2 live-attenuated vaccine strain generated in our laboratory 
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could stimulate strong immune responses in the tumor microenvironment with beneficial effects 
in controlling tumor growth and extending survival in mice.   
Statement of Research Objectives 
The specific aims of this research include: 
I. To characterize the growth kinetics and spontaneous metastasis of B16F10 murine 
melanoma tumors in C57BL/6J mice.  
a. To evaluate the effect of engraftment location 
b. To evaluate the effect of propagation technique  
c. To evaluate the effect of cell density of inoculum 
II. To develop and validate a model system using B16F10-fLuc-eGFP for 
bioluminescent imaging to monitor melanoma progression and eGFP for detecting 
metastasis. 
a. To compare in vitro proliferative capacity of B16F10-fLuc-eGFP to the parental 
B16F10 cell line 
b. To determine if photon emission correlates with cell number in vitro (in vitro 
luciferase assay) 
c. To demonstrate in vivo luciferase expression of B16F10-fLuc-eGFP and 
determine if photon emission correlates with cell number in vivo (in vivo 
luciferase assay) 
d. To demonstrate eGFP expression of B16F10-fLuc-eGFP in vivo and demonstrate 
enhanced detection of micrometastasis through fluorescent microscopy 
e. To determine engraftment efficiency using B16F10-fLuc-eGFP   
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III. To determine the importance of nectin-1 in replication and cytolysis in B16F10-fLuc-
eGFP tumor cells 
a. To create a stably transfected B16F10-fLuc-eGFP cell line expressing human 
nectin-1 
b. To compare in vitro proliferative capacity of B16F10-fLuc-eGFP-nectin-1 in 
comparison to parental cell line B16F10-fLuc-eGFP   
c. To compare dose response curves and cytolysis in B16F10-fLuc-eGFP-nectin-1 v. 
B16F10-fLuc-eGFP using VC2 in vitro 
d. To evaluate photon emission for detecting tumor cell death using VC2 as a 
cytolytic agent (bioluminescent cytotoxicity assay) 
e. To compare viral replication of VC2 in B16F10-fLuc-eGFP and B16F10-fLuc-
eGFP-nectin-1 murine melanoma cells in vitro  
IV. To determine therapeutic benefit to intratumoral VC2 treatment and characterize any 
anti-proliferative effects of VC2 on B16F10-fLuc-eGFP tumors and immune-
stimulating/adjuvant properties in the tumor microenvironment (TME) in comparison 
to mock-treated mice.  
a. To evaluate tumor lysis  
b. To determine Ki-67 proliferation indices 
c. To determine microvascular density 
d. To characterize the infiltration of immune cells using immunohistochemistry for 
CD3, IBA-1, and arginase-1.  
Overall, results from this work indicate that: 
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I. Tumor engraftment of B16F10 murine melanoma cells in the mouse pinna generates 
more uniform tumor morphology than engraftment in the subcutis of the interscapular 
region. In vivo propagation of B16F10 tumor cells enhanced synchronization of tumor 
development and resulted in increased metastatic efficiency to sentinel lymph nodes. 
Decreasing the cell density of the inoculum at the time of engraftment increased the 
lag time to tumor development but resulted in enhanced synchronization and 
metastatic efficiency.  
II. B16F10 murine melanoma cells expressing eGFP and firefly luciferase (B16F10-
fLuc-eGFP) proliferated as well as the B16F10 parent cell line in vitro. Photon 
emission during bioluminescent imaging correlated with tumor cell number in vitro 
and in vivo. Detection of micrometastasis was enhanced using fluorescent microscopy 
at postmortem examination. Engraftment efficiency was acceptable at 80%.  
III. Nectin-1 expression increased sensitivity to cytolysis by VC2 and resulted in more 
efficient viral replication in B16F10-fLuc-eGFP-nectin-1  cells in vitro. Photon 
emission was reduced in association with cell death in vitro after treatment with VC2.  
IV. Intratumoral VC2 treatment resulted in prolonged median survival times (MST) 
almost twice that of mock-treated mice. Ki-67 proliferation indices were decreased in 
treated mice. There was significant infiltration of T cells and macrophages, but 
reduced expression of arginase-1 in the tumor microenvironment. Overall, VC2 
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CHAPTER II: LITERATURE REVIEW 
Melanocyte Biology 
In human skin, the basal layer of the epidermis contains melanocytes, the cells from 
which melanoma develops (Figures 2.1 and 2.2). 
 
Melanocytes are also typically found within hair follicles, where they contain larger 
melanosomes and occur in larger proportions to keratinocytes (1:5) than those found in the 
epidermis (1:10). In mice, melanocytes are most often found in hair follicles as opposed to the 
basal layer of the epidermis. 
Figure 2.1: Anatomy of the skin. Human skin consists of epidermis, dermis, and subcutaneous 




Melanogenesis is a biochemical process whereby melanocytes produce melanin within 
melanosomes. Melanin production results in pigmentation that protects keratinocytes from 
harmful UV radiation associated with sun exposure.4 There are two major types of melanin in 
human skin, eumelanin and pheomelanin, which differ in color and in the biochemical pathways 
leading to their synthesis. Eumelanin is the pigment responsible for determining skin color and is 
more photoprotective than its redder counterpart, pheomelanin. For this reason, lighter skin is 30-
40 times more likely to develop skin cancer than darker skin. Normal human melanocytes adhere 
to and communicate with approximately 30-40 epidermal keratinocytes via E- and P-cadherins 
through which melanin granules can be transferred but, in general, melanocytes do not adhere to 
each other under normal circumstances.4 Exposure to the sun causes melanocytes to increase the 
production of melanin in order to protect the skin from damaging ultraviolet rays. Increased 
pigmentation results in the appearance of a sun tan. At the molecular level, increased 
melanogenesis may at least in part be due to the production of a number of factors from the 
Figure 2.2: The basal cell layer of the skin. Melanocytes are in the layer of basal cells at the 




keratinocytes including interleukin-1 (IL-1), adrenocorticotropic hormone (ACTH), alpha-
melanocyte-stimulating hormone (α-MSH), prostaglandin E2 (PGE2), prostaglandin F2alpha 
(PGF2α), granulocyte-macrophage colony-stimulating factor (GM-CSF), and bone morphogenetic 
protein 4 (BMP-4) under the influence of intense ultraviolet (UV) radiation.4  The normal ratio in 
human skin of melanocytes to keratinocytes is 1:10, but extensive UV radiation may cause 
keratinocytes to produce a number of factors that can influence adjacent melanocytes in a paracrine 
fashion, at least in vitro, causing them to not only increase melanin production but also undergo 
increased cellular proliferation.  Clusters of melanocytes cause moles, freckles, birthmarks, and 
age spots. Melanoma results when mutations occur that cause melanocytes to become malignant.  
Melanoma in Humans 
Incidence, Epidemiology, and Risk Factors of Melanoma in People. Melanoma is the 
most aggressive and lethal malignancy of the skin. Melanoma arises from melanocytes which are 
derived from the neural crest and disseminate throughout the body to the skin, eye, meninges, 
esophagus and other tissues during development.5,6 Three subtypes of melanoma include 
cutaneous melanoma, which accounts for 90% of cases in humans, mucosal melanoma, and uveal 
melanoma.6,7 Regarding cutaneous melanoma, incidence has risen 3-8% per year since the 1960s, 
rising faster than any other malignancy.6 In the United States, 1 in 56 women and 1 in 37 men will 
be diagnosed with melanoma in their lifetime.8 In comparison to the median age of diagnosis for 
most solid malignancies, which is older than 65 years, the median age of melanoma diagnosis is 
relatively young at 57 years of age.6  
Environmental and genetic factors can affect a person’s risk of developing melanoma. In 
the U.S., 98.2% of reported cases are in Caucasians.7 Red-haired, fair-skinned people are at 
increased risk due to decreased skin pigmentation related to a polymorphism in the melanocortin1 
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receptor (MC1R) gene, a melanocyte cell surface receptor that induces pigment production after 
activation by alpha-melanocyte stimulating hormone (MSH). The reduced pigmentation results in 
increased sensitivity to ultraviolet (UV) light and increased risk of developing melanoma.9   UVB 
exposure is a strong risk factor. People with more than five severe sunburns during adolescence 
have a two-fold increase in the risk of developing melanoma later in life.6,10-12 UVA also poses an 
increased risk of melanoma in patients that receive it as treatment for psoriasis.13,14 Tanning beds 
emit UVA rays and are associated with a 75% increase in risk of melanoma development; sunbeds 
have been formally classified as a human carcinogen.6 Immunosuppressed individuals, such as 
those receiving organ transplants, are at a demonstrably higher risk, presumably due to the 
importance of the immune system in immunosurveillance and elimination of cancer cells.15,16 
Diagnosis. Patients typically present to a dermatologist for evaluation of specific lesions. 
Dermatologists reach a clinical diagnosis through evaluation for asymmetry, irregular borders, 
inhomogeneous color, and diameter of greater than or equal to 5 mm in diameter (ABCD) (Figure 
2.3). Dermoscopy can help clarify the diagnosis. Characteristics of melanoma on dermoscopy 
include atypical pigmented network, irregular brown to black dots or globules, streaks and 
pigmentation with multiple colors asymmetrically distributed, blue-white veil, and polymorphic 
vessels.17 
 
Figure 2.3: Clinical appearance of melanocytic lesions from mole (A) to dysplastic nevi (B &C) 
to melanoma (D & E) demonstrating the ABCD criteria of clinical melanoma diagnosis. 
A B C D E 





Lesions that are diagnosed or suspicious for melanoma clinically should be submitted for 
histopathologic evaluation. Histopathologic features including clinico-pathologic variant, tumor 
thickness (mm) (Breslow’s depth), presence or absence of ulceration, number of mitoses per mm2, 
presence or absence of microsatellites, and lateral and deep excision margins are included in the 
report for prognostic information and treatment planning.18 Histologic features used by the 
pathologist to reach a diagnosis of malignancy of a melanocytic neoplasm include cytologic 
features (necrosis, mitotic index, atypia of melanocytic cells), architectural features (asymmetry, 
size, spreading, poor circumscription), epidermal features (confluent and atypical nesting), and 
dermal features (depth/invasiveness and inflammation).19 Due to overlap of some of these features 
with some benign melanocytomas or melanocytic nevi, discernment between a benign lesion and 
a malignant one can be challenging histologically; however, presence of neoplastic cells within 
vessels is always seen as a sign of malignancy. There are various histologic types and subtypes of 
melanoma described in people, which have varied histomorphologic features. The most common 
histologic type is the superficial spreading melanoma. Other commonly described types/subtypes 
include nodular melanoma, lentigo maligna melanoma, and acral and mucosal lentiginous 
melanoma.20 
Prognosis. Factors that have predictive value in melanoma prognosis include histopathological 
features, patient demographics, biochemical measures, and genetic mutations. The American Joint 
Committee on Cancer (AJCC) has a published staging system to classify patients and determine 
treatment options (Table 2.1).21  
Patient Features with Prognostic Value. Anatomic site of the primary tumor has 
prognostic implications. Melanoma arising on the trunk, head, and neck carry a worse 
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prognosis than melanoma arising on the limbs.22-24 Patient age and gender also have prognostic 
value.25-28 Worsening outcomes are reported with increasing age. Females with Stage I-II 
disease also fare better than men in the same stage of disease.  
Pathologic Characteristics with Prognostic Value. Tumor thickness (Breslow’s depth) 
and ulceration are considered to be the strongest independent prognostic factors for cutaneous 
melanoma in humans.29-31  Ten-year survival is 96% for lesions less than 1 mm thick which 
drops to 54% at greater than 4 mm thick. 6 Ulceration of the primary tumor is a negative 
prognostic indicator at all thicknesses.22 Mitotic rate is another significant prognostic feature. 
While less than 1 mitosis/mm2 indicates a 10-year survival rate of 93%, survival rate is 
decreased to 48% in patients with greater than 20 mitoses/mm2 .32,33 Tumor vascularity and 
lymphovascular invasion are also considered poor prognostic indicators.34-36 
The most common first site for metastasis in melanoma patients is the sentinel lymph node 
(SLN). Sentinel lymph node biopsy is the most sensitive staging test for cutaneous 
melanoma.17 The presence of lymph node metastasis has prognostic implications. The 10-year 
survival rates for melanoma patients are decreased to 63% if microscopic lymph node 
metastasis is present and 47% if macroscopic lymph node metastasis is present.22,37 Distant 
metastasis is also associated with worsening prognosis.  
Serum lactate dehydrogenase (LDH) level is an independent prognostic indicator, 
predicting a 50% decrease in survival in patients with metastatic disease when LDH is 
elevated.38 S100 has also shown promise as a predictive serum biomarker for patients with 




Table 2.1. Staging system for melanoma.17 
Stage Primary tumor (pT) 





0 In situ tumor None None 
IA ≤1.0 mm, no ulceration None None 
IB 
≤1.0 mm with ulceration or ≥1/mm2 None None 
1.01–2.0 mm, no ulceration None None 
IIA 
1.01–2.0 mm with ulceration None None 
2.01–4.0 mm, no ulceration None None 
IIB 
2.01–4.0 mm with ulceration None None 
>4.0 mm, no ulceration None None 
IIC >4.0 mm with ulceration None None 
IIIA Any tumor thickness, no ulceration Micrometastases None 
IIIB 
Any tumor thickness with ulceration Micrometastases None 
Any tumor thickness, no ulceration Up to three macrometastases None 
Any tumor thickness ± ulceration 




Any tumor thickness with ulceration Up to three macrometastases None 
Any tumor thickness ± ulceration 
Four or more 
macrometastases, or lymph 
node involvement extending 
beyond capsule, or satellite 
and/or in-transit metastases 
with lymph node 
involvement 
None 




Molecular Pathogenesis of Melanoma 
 Some canonical hallmarks of cancer include the capability of cells to resist cell death, 
sustain proliferative signaling, evade effects of growth suppressing signals, and enable 
replicative immortality (among others) (Figure 2.4).1 A number of genetic gain-of-function 











There are several mutations associated with melanoma in people (Figure 2.5). 
Approximately 25–40% of malignant melanomas in a familial distribution are associated with 
mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A)41-43  and less commonly mutations 
in CDK4 (cyclin-dependent kinase 4).41,44 CDKN2A encodes two tumor suppressor proteins, p16 
(INK4A/inhibitor of kinase 4A) and p14 (ARF/alternate reading frame), both of which are 
involved in cell cycle regulation.41,45-47  p16 normally inhibits CDK4 and is considered a 
negative regulator of the cell cycle. During mitosis, CDK4 is complexed with cyclin D, which 
phosphorylates the retinoblastoma (Rb1) protein, which releases E2F-1 to allow the cell to enter 
the S phase.6,46  
Figure 2.4. The Hallmarks of Cancer This illustration encompasses the six hallmark 
capabilities originally proposed in 2000. The following decade witnessed remarkable progress 




















One of the most important genetic mutations in malignant melanoma involves receptor 
tyrosine kinases and the downstream NRAS/BRAF/ERK (neuroblastoma rat sarcoma/v-raf murine 
sarcoma homologue B/extracellular-related kinase) and phosphotidylinositol 3′-kinase 
(PI3K)/PTEN pathways.41,48 Lentigo maligna melanoma is associated with BRAF-activating 
(70%) or NRAS-activating (20%) mutations. In contrast, mucosal and acral melanomas are 
associated with mutations or genetic amplification of KIT (CD117) in up to 40% of cases.41,49,50 
Although benign nevi and malignant melanomas may share some genetic alterations such as 
Figure 2.5: Drugs developed to treat melanoma (top) and their targets (below) in 
several of the main pathways involved in melanoma initiation, progression and 
maintenance are indicated by different colors. Shown is the Ras/Raf/MEK mitogen-
activated protein kinase (MAPK) signaling module, the PI(3)K pathway, the 
involvement of signaling by NF- B, IAPs and Bcl-2 (anti-apoptotic factors), and 
VEGF and cytokines (which partake in angiogenesis). The schematic includes 
interactions between MAPK, PI(3)K and NF- B signaling. The p16INK4a/RB and ARF 
signaling pathways are also important, as their disruption can lead to melanoma by 




mutations in BRAF and NRAS, melanomas often show recurrent patterns of chromosomal losses 
(chromosomes 6q, 8p, 9p and 10q), along with chromosomal gains (1q, 6p, 7, 8q, 17q and 20q) by 
comparative genomic hybridization (CGH) or karyotyping. Nevi, however, show no detectable 
chromosomal aberrations by CGH.41,51-54 BRAF mutations are associated with poorer prognosis in 
melanoma patients.55Upregulation of MAPK (mitogen-activated protein kinase; Ras-Raf-MEK-
ERK) and the phosphoinositide 3-kinase-AKT (also known as protein kinase B/PKB) pathways 
are seen in most malignant melanomas. Both pathways play major roles in melanoma 
progression.41,56,57 Alterations in cell cycle proteins cyclin D1, pRb and p16 have a role in 
transformation and progression in melanocytic tumors. Even though there is an increase in 
expression of pRb and cyclin D1 in the progression of melanoma, these two cell cycle proteins 
interestingly reveal a relative decrease in thick and metastatic malignant melanoma. Progressive 
loss of p16 is seen in transformation of benign nevi to melanoma and metastatic melanoma.41,58 
Immunopathogenesis of Melanoma 
Melanoma is known to be an immunogenic cancer. Nearly all major principles and 
breakthroughs in the field of tumor immunology have occurred in the study of melanoma. 
Immunogenicity of tumor cells is evidenced by spontaneous regressions in some melanoma 
patients with tumor infiltrating lymphocytes (TILs) that are cytotoxic against autologous tumor 
cells.59 Melanoma cells display antigens and peptide epitopes that are targetable through both 
humoral and  cell-mediated immunity.59 Both innate and adaptive immunity are key components 
of anti-tumor immune responses. 
 Innate Immune Responses 
 Natural Killer Cells. Natural killer (NK) cells recognize “stressed” cells such as tumor 
cells or viral-infected cells. Cytotoxicity of NK cells against tumor cells was originally 
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demonstrated in vitro and in xenograft murine tumor models.59-63 During immunoediting, tumor 
cells may downregulate MHC-I receptors and make them more susceptible to NK cell killing. 
However, NK cell killing alone is not sufficient for controlling disease. Early results in clinical 
trials using NK adoptive cell therapy have been disappointing, but NK cells are still believed to 
play a critical role in anti-tumor immune responses.    
Macrophages. Macrophages play important roles in innate immunity by eliminating 
pathogens via phagocytosis and generation of reactive oxygen species (ROS) and also presenting 
antigens via either MHC-I or MHC-II receptors to effector cells of the adaptive immune response. 
Macrophages are plastic in nature and may exist within a spectrum of phenotypes. At one end of 
the extreme are M1 or classically activated macrophages, which are activated by IFNɣ, known to 
produce type I pro-inflammatory cytokines including IL-1β, IL-12, TNFα, and IFNɣ, and have 
tumor-suppressing properties. At the opposite end of the spectrum are M2 or alternatively activated 
macrophages, which are typically activated by IL-4 and IL-13, produce type II immunosuppressive 
cytokines such as IL-10, and have tumor-promoting properties. M2 macrophages are among the 
most prevalent cell-types found in the tumor microenvironment of solid tumors and, in many tumor 
types, are associated with poor prognosis and aggressive disease. 
Lactic acid produced during aerobic glycolysis (Warburg effect) also has the potential to 
polarize macrophages to the M2 phenotype along with immunoglobulins derived from B cells in 
the tumor microenvironment (TME).64-66 In hypoxic areas of the TME, tumor associated 
macrophages (TAMs) typically exhibit low levels of MHC-II expression, making them poor 
antigen presenters, and their functions become more aligned with characteristics typical of healing 
including promotion of angiogenesis and dampening of immune responses.  
17 
 
Regarding immunosuppression by macrophages, M2 macrophages are thought to be the 
major source of IL-10, a cytokine known to be associated with anti-inflammatory properties. 
Specifically, IL-10 inhibits expression of IL-12 by dendritic cells (DC)  and subsequently 
decreases cytotoxic CD8+ T cell activation.67,68 
IKKβ inactivation resulting in NFκβ disruption is one mechanism of M2-M1 
repolarization.69 TNF-α and miR155 have also been demonstrated to play a role in macrophage 
phenotype switching.70,71   
Adaptive Immune Responses 
 Humoral. Recent work in murine tumor models suggests that IgG isotype and engagement 
of FcR antibody receptors may be an important factor in tumor immunology.72,73 Early studies 
evaluating humoral immune responses in human melanoma patients did confirm circulating anti-
melanoma antibodies; however, specificity was difficult to prove since allogeneic tumor cell lines 
were used in early studies.74 Several years later, autologous tumor cells were utilized for serologic 
testing and IgM and IgG antibodies specific for cell-surface antigens on melanoma cells, and other 
cancer types, was demonstrated.75 Ultimately, many melanoma antigens were identified that were 
recognized by T cells and IgG antibodies, which provided evidence that CD4+ T cell help was also 
important in generating serologic immune responses against melanoma.76 
 Cell-Mediated 
Cytotoxic T cells. CD8+ cytotoxic T cells are naturally of interest in cancer immunology 
due to their ability to recognize MHC-I receptors and elicit cytotoxic anti-tumor immune 
responses. Cytotoxic T cells with specificity and ability to lyse autologous and allogenic tumor 
cells have been demonstrated in melanoma patients and have been isolated from blood and tumor 
microenvironment.59,77 Unique tumor-specific antigens exist which could be targeted by cytotoxic 
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T cells (Table 2). The first such antigen is known as melanoma-associated antigen-1 (MAGEA-
1).78 Since recognition of this first antigen, hundreds more have been identified.78 Known tumor 
antigens recognized by T cells typically fall into one of four categories: 1.) tissue differentiation 
antigens (e.g. melanoma differentiation antigens (MDA) gp100, MART-1, tyrosinase, TRP1, and 
TRP2), 2.) products of mutated genes (neoantigens), 3.) viral antigens, and 4.) cancer germline 
antigens or cancer-testis antigens (expressed as a result of epigenetic alterations). Additionally, T 
cells can recognize antigens associated with tumor stromal cells and vasculature.78 
 Helper T cells. CD4+ T cell responses are complex. It was already alluded to that they 
play a role in educating B cells to generate melanoma specific IgG responses. Melanoma antigens 
can be presented on MHC-II molecules by antigen-presenting cells to CD4+ cells. Additionally, 
some melanoma cells may express MHC-II, albeit less commonly than MHC-I. CD4+ T cells may 
then interact with B cells to help produce anti-melanoma antibodies or can take on regulatory 
functions that may suppress CD8+ T cell function and contribute to anergy.59  
Tumor Antigens.  The discovery that melanoma cells can elicit immune responses in 
human patients led to a search for antigens with epitopes that are recognized by patients’ immune 
cells. A number of antigens have been discovered and their epitopes defined (Table 2.2).59  
Table 2.2. Examples of melanoma-associated antigens, peptides, and MHC molecules presenting 
those peptides59 
Proteins Peptides Presenting MHC 
MAGE-A1a EADPTGHSY HLA-A1 & B37 
MAGE-A1a TSCILESLFRAVITK HLA-DP4 
MAGE-A1a EYVIKVSARVRF HLA-DR15 
MAGE-A3a EVDPIGHLY HLA-A1 
MAGE-A3a FLWGPRALV HLA-A2 
MAGE-A3a VIFSKASSSLQL HLA-DR4 
NY-ESO-1a SLLMWITQC HLA-A2 
NY-ESO-1a MPFATPMEA HLA-B51 
                    (table cont’d)  
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Proteins Peptides Presenting MHC 
NY-ESO-1a EFYLAMPFATPM HLA-DR1 
Melan-A/MART-1b (E)AAGIGILTV HLA A2 
Melan-A/MART-1b EAAGIGILTV HLAB35 
Melan-A/MART-1b ILTVILGVL HLA-A2 
Melan-A/MART-1b AAGIGILTVILGVL HLA-DR1 
Tyrosinaseb MLLAVLYCL HLA-A2 
Tyrosinaseb SSDYVIPIGTY HLA-A1 
Tyrosinaseb SYLQDSDPDSFQD HLA-DR4 
gp100/pmel17b KTWGQYWQV HLA-A2 
gp100/pmel17b LIYRRRLMK HLA-A3 
gp100/pmel1b GRAMLGTHTMEVTVY HLA-DQ6 
CDK4c ACDPHSGHFV HLA-A2 
beta-cateninc SYLDSGIHF HLA-A24 
N-rasc ILDTAGREEY HLA-A1 
 
Immune Evasion by Cancer Cells 
 The fact that there is ample evidence that melanoma patients mount humoral and cell-
mediated specific anti-tumor immune responses against melanoma-specific antigens, raises the 
question—why are these responses ineffective in eliminating cancer cells in most melanoma 
patients? Evasion of immune response is now considered to be one of the basic hallmarks of cancer 






Figure 2.7. Emerging Hallmarks and Enabling Characteristics. Research suggests that two 
additional hallmarks of cancer are involved in the pathogenesis cancer. One allows cancer cells 
to evade immunological destruction by T and B lymphocytes, macrophages, and natural killer 
cells. Inflammation by innate immune cells designed to fight infections and heal wounds can 




Several factors contribute to immune escape during melanoma progression. During early 
development, the mutational load may be relatively low and tumor cells do not express many 
antigens that are significantly different from “self”. Some tumor cells may be eliminated during 
this point, but some tumor cells avoid detection and survive since T cell responses may be weak 
in response to mostly self-antigens. Immune cells may still respond and eliminate tumor cells at 
the same rate as tumor cell proliferation for a time during a phase termed equilibrium.  During 
equilibrium, the population that evades immune destruction will become increasingly resistant to 
detection and elimination by the immune system. Additionally, chronic inflammation at the site 
leads to an immunosuppressive tumor microenvironment (TME) consisting of an influx of M2-
type macrophages that produce immunosuppressive cytokines such as interleukin 10 (IL-10) and 
transforming growth factor beta (TGF-β) in addition to vascular endothelial growth factor (VEGF), 
which stimulates angiogenesis to support tumor growth. The generation of TGF-β results in 
increased fibrosis, further providing scaffolding for tumor growth. Additionally, 
immunosuppressive cytokines generated by immune cells and even tumor cells themselves can 
suppress effective anti-tumor immune responses by antigen-presenting cells and T cells. The 
recruitment of immune cells with suppressive phenotypes including myeloid-derived suppressor 
cells (MDSCs) and regulatory T cells further inhibits response. Tumor cells and immune cells in 
the tumor microenvironment may begin to express programmed death ligand-1 (PDL-1), which 
causes apoptosis of T cells when binding with its receptor PD1. T cells also express cytotoxic T-
lymphocyte activation 4 (CTLA4) after activation, which competes with CD28 for co-stimulation 
with co-stimulatory ligands on antigen-presenting cells. Melanoma cells, in addition to producing 
immunosuppressive cytokines and/or expressing PDL1  to evade immunity, also evolve intrinsic 
features to make them less identifiable by the immune system such as downregulating MHC-I 
21 
 
receptors and develop mutations in tumor antigens that make them unable to be efficiently 
recognized by T cells.  
 The demonstrated immunogenicity of melanoma cells in human patients as well as the 
recognition that immune evasion plays a significant role in melanoma progression have resulted 
in significant interest in development of immunotherapies for the treatment of melanoma. These 
strategies will be described below in our discussion of the current options for the treatment of 
melanoma in people.  
Melanoma Treatment 
Surgery. Surgical excision with safety margins +/- sentinel lymph node dissection (SLND) 
is the treatment of choice for primary melanoma.  
Radiation Therapy. When surgical excision is not possible without severe disfigurement, 
the primary tumor may be treated with radiation therapy with curative intent in rare cases. Patients 
with metastatic disease have few options.   
Cytotoxic chemotherapy. For patients with evidence of metastasis, traditional cytotoxic 
chemotherapeutics have shown no effect on overall survival and have severe adverse effects on 
quality of life. Cytotoxic chemotherapy is therefore generally not used in patients with metastatic 
melanoma except as second or third line treatment after targeted or immunotherapies. Response 






Table 2.3. Monochemotherapy and polychemotherapy for advanced cutaneous melanoma 







Middleton 2000  
250 mg/m2 i.v. daily for 5 d every 3–4 weeks 12.1–17.6% 
Chiarion Sileni, 2001, 
Young 2001 
800–1200 mg/m2 i.v. daily on 1 d every 3–4 weeks 5.3–23% 
Temozolomide 
Bleehen 1995, 
 Middleton 2000 
150–200 mg/m2 p.o. daily for 5 d every 4 weeks 13.5–21% 
Fotemustine 
Jacquillat 1990,  
Mornex 2003  
100 mg/m2 i.v. on days 1, 8 and 15; then 5 week pause, then 
repeat single dose every 3 weeks 
7.4–24.2% 
CarboTax 
Rao 2006  
Carboplatin AUC6 i.v. day 1, after four cycles reduce to 
AUC4Paclitaxel 225 mg/m2 i.v. day 1 every 3 weeks, after 




Verschraegen 1988  
DTIC 450 mg/m2 i.v. days 1 + 8 
Vindesine 3 mg/m2 i.v. days 1 + 8 
Cisplatin 50 mg/m2 i.v. days 1 + 8 every 3–4 weeks 
24% 
 
Targeted Therapy. Depending on underlying mutations, a number of targeted therapies 
are available and listed in Table 2.4 along with response rates. These therapies take into 





Table 2.4. Targeted therapy for advanced cutaneous melanoma described in prospective 
randomized trials or phase II studies, if phase III trials were not available.17 
 
 





Long 2014, Robert 
2014  
2 × 150 mg p.o. daily until tumor progression 
 





Ribas 2014, Larkin 
2014  
2 × 960 mg p.o. daily until tumour progression 
 





Guo 2011  














Immunotherapy. Adjuvant immunotherapy has shown some benefits in melanoma 
patients. Interferon-alpha was the first substance to show significant improvement in distant 
metastasis free survival (DFS) and also impact overall survival (OS), although severe toxicity is 
observed.17 IL-2 treatment also showed promise early in uncontrolled clinical trials. However, 
neither of these cytokines have shown improvement in survival in randomized clinical trials. 
Vaccination strategies have also been explored but none have demonstrated reliable efficacy. 
Immune checkpoint blockade has shown the most promising results among immunotherapies so 
far (Table 2.5). Systemic therapy using CTLA4 antibodies (Ipilmumab) is approved for treatment 
of stage III melanoma patients. Ipilmumab was the first immunotherapy to show OS benefit in two 
controlled trials in metastatic melanoma.17  Serious autoimmune reactions occur in some patients. 
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The response rate is only about 15% but durable remissions are observed in some patients with 
stage IV disease that failed other treatments.17 Ipilmumab is no longer currently used as first line 
treatment but is now combined with PD-1 inhibitors, Nivolumab or Pembrolizumab, which are 
approved for use in nonresectable melanoma. Nivolumab had improved progression-free and OS 
compared to Pembrolizumab. Combination therapy is better than Nivolumab alone. However, the 
incidence of adverse effects is increased and severe toxicities are occasionally seen.  
Table 2.5. Checkpoint blockade therapies for advanced cutaneous melanoma described in 




Ipilimumab 3 mg/kg i.v. every 3 weeks for four cycles 12–19% 
Nivolumab 3 mg/kg i.v. every 2 weeks until tumor progression 40–44% 
Pembrolizumab 
Robert 2015  




Larkin 2015  
3 mg/kg i.v. every 3 weeks for four cycles 
 
1 mg/kg i.v. every 3 weeks for four cycles, continuation with 
3 mg/kg every 2 weeks until tumor progression 
58% 
 
Oncolytic Virotherapy. In addition to cytotoxic chemotherapy, targeted therapies, and 
immunotherapies, oncolytic virotherapy, a novel treatment strategy, has been explored for the 
treatment of melanoma and other cancers. The first oncolytic virotherapy, Talimogene 





Oncolytic Virotherapy (OV) Overview 
Viruses that preferentially lyse cancer cells are described as being “oncolytic” or tumor-
lysing. Oncolytic virotherapy works by directly killing tumor cells and stimulating an immune 
response. Viruses used for this method fall into three major categories: 1.) wild type animal 
viruses that do not normally infect human cells but are cytotoxic to human cancer cells, 2.) 
attenuated mutants of human viruses in which genes important for virus replication that are not 
needed for growth in cancer cells have been mutated or deleted, and 3.) viruses that have been 
attenuated by serial passage in culture like most live virus vaccines. The idea to use viruses as 
cancer therapy originated in the early 1900’s when it was observed that occasionally viral 
infections would result in remission in some cancer patients. Many different live viruses have 
been tested as potential therapy for cancer in the last century, beginning as early as 1910, when a 
live-attenuated Rabies vaccine was observed to result in regression of cervical cancer in a 
patient.79 Other viruses known to infect humans including Epstein-Barr, adenovirus, and hepatitis 
virus were investigated with variable results in efficacy in the mid-1900’s.80-82 Safety concerns 
regarding using live viruses in cancer patients markedly limited the field of oncolytic virotherapy 
until the development of molecular tools enabling genetic engineering in the 1990’s.83  The field 
has now expanded to include many different viruses and has become increasingly sophisticated 
as molecular tools to create purposeful viral genetic mutations that enhance cancer-killing 
abilities and safety have become more widely available.   
Oncolysis. Some viruses have a natural lytic phase in their life cycle and have a natural 
affinity for rapidly dividing cells (e.g. α-herpesviruses and parvoviruses). The affinity for rapidly 
dividing cells can be enhanced through careful, selective genetic engineering; further, cellular 
tropism can be similarly altered to retarget viral infections to limit them to transformed cells, 
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thereby sparing normal tissues. Nonessential genes associated with virulence can also be deleted 
for enhanced safety while maintaining the ability to replicate. 
In addition to direct lysis, oncolytic viruses may also cause cell death indirectly through 
immunogenic cell death (ICD) where ER stress results in expression of danger associated 
molecular patterns (DAMPs) as has been shown with adenoviruses84, coxsackie B3 virus85, and 
measles virus86. Adaptive immune responses have been demonstrated for reoviruses87, herpes 
simplex virus-1 (HSV-1)88,89, and vaccinia virus90.  
Some viruses may inhibit tumor growth due to direct disruption of tumor-associated 
vasculature through infection of endothelial cells. In some instances, infection of endothelial 
cells by certain viruses is dependent on expression of high levels of VEGF and FGF, which are 
often present in the tumor microenvironments. Selective destruction of tumor-supporting 
components of the tumor microenvironment including tumor-associated vasculature has been 
shown for vesicular stomatitis virus (VSV), vaccinia virus, and HSV-1, which can all infect 
endothelial cells.91-93  
Delivery of Oncolytic Viruses (OV). The ability of replication competent viruses to act 
as a self-sustaining intralesional therapeutic is an advantage. Systemic administration of cancer 
therapeutics can result in significant toxicity and local administration of many therapeutics may 
be quickly cleared. While intralesional oncolytic virotherapy is practical for easy-to-access 
tumors like melanoma or squamous cell carcinoma, administration for internal or widely 
disseminated cancers has been less practical, largely due to the fact that safe and efficacious 
systemic viral delivery presents inherent challenges. One is that intravenous delivery poses the 
risk of systemic infection and complications. Retargeting the virus via genetic manipulation 
could be one solution; however, as mentioned, efficacy would be expected to be limited in a 
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strict target-dependent strategy due to heterogeneity of expression of targets within and between 
patients. Further, high doses may be necessary in order to achieve an efficacious systemic dose 
since a percentage of injected virus is likely to be sequestered in the liver after intravenous 
injection and since patients may already have, or may develop during therapy, circulating 
neutralizing antibodies in the serum which may result in rapid elimination of virus before it can 
reach the tumor.94-96 In general, it is thought that the majority of virus injected intravenously is 
cleared within about 2 minutes.97  It is estimated that 50-80% of humans possess neutralizing 
antibodies to HSV.94,98 Efforts to reduce elimination of oncolytic viruses after systemic delivery 
have included pretreatment with cyclophosphamide/cobra venom to exhaust complement and 
IgM in mouse models.99-102 However, cancer patients already have suppressed systemic 
immunity. Further suppressing the immune system could result in severe off-target distribution 
leading to disseminated infection and a marked increase in adverse events/toxicity.   
Development of improved systemic delivery strategies are underway. One potential method that 
has been explored is copper chelation intended to increase stability of oncolytic herpes simplex 
virus (oHSV) in the serum.103 Another general strategy is retargeting of the virus, which can be 
accomplished in a number of ways including 1.) altering the viral envelope to contain single 
chain antibodies (scFv) or peptide ligands specific for a desired receptor104-108 , 2.) 
adapters/soluble receptors that recognize tumor and virus to facilitate binding109-111, 3.) inserting 
glycoproteins with a receptor from other viruses99,112,113, and 4.) use of carrier cells.97 
Currently, intratumoral delivery is considered to be the most viable delivery strategy, and 
the most reliable method to deliver oncolytic herpesviruses (oHSV).99,114 The ability of a live 
attenuated virus to create a replication niche in the tumor and microenvironment and to even 
amplify its presence and effect through replication and lysis prevents the need for frequent 
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injections. Some oncolytic viruses even develop a syncytial phenotype which can facilitate rapid 
spread throughout the tumor and could be helpful when entry receptor expression is low in some 
instances. A major challenge to utilizing HSV-1 in oncolytic virotherapy is infection efficiency 
of tumor cells.99,114 Strategies to improve viral spread after intratumoral injection are necessary. 
Such strategies have so far included injecting multiple tumors or injecting a single tumor in 
multiple sites; it is advised that doses be given as 3-5 injections or, when given as a single 
injection, that the volume compose 10-100% of the tumor volume.99Improvement in intratumoral 
delivery has been investigated through the use of ultrasound for cell membrane permeabilization 
and sonoporation and co-injection of collagenase for improved intratumoral distribution as 
examples.114,115 Chemically sensitizing tumors using small molecules such as histone deacetylase 
inhibitors to limit IFN activity to improve viral spread has also been explored.116 
Some studies have shown that rapid infection and spread in vitro predicts better in vivo 
response; however, such studies have been performed in xenogeneic models and therefore do not 
account for immune responses.117,118 Some would argue that spread, persistence and continued 
replication within the tumor and/or microenvironment are less important than immunogenicity of 
the virus and the immune response in the early stages of viral infection and replication.119 In fact, 
it has been reported that, regarding oncolytic HSV, in vitro cytotoxicity and viral persistence in 
vivo do not correlate with anti-tumor efficacy; it has instead been shown that expression of 
markers of immunogenic cell death, such as heatshock protein 70 and elevated levels of serum 
high mobility group box 1 (HMGB1), increased antigen presenting cells, and CD8+ T cell 
responses may be more likely associated with HSV-associated therapeutic benefits.119  
Advantages and Challenges. There are advantages and disadvantages to all candidate 
oncolytic viruses. In many regards, treating tumors with virus is a form of targeted therapy since 
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the lytic effect often depends on the ability of the virus to enter through specific receptors, 
replicate, and lyse cells. Viral entry receptor expression by tumor cells can vary and may 
represent a significant challenge. As tumor cells evolve in the tumor microenvironment and new, 
increasingly malignant subclones emerge, cells that would normally express an entry receptor, 
may lose expression or expression may become extremely heterogeneous within the tumor.  
These challenges can potentially be overcome by using viruses that can enter through multiple 
receptors, such as HSV-1, which can enter through nectin-1, HVEM, or other receptors. Other 
strategies include retargeting viral tropism through genetic engineering; however, mutations may 
reduce replication efficiency; additionally, even after retargeting to another receptor type, the 
same challenge may exist in that receptor expression may be heterogeneous.  
 Another challenge is limiting replication to tumor cells, which can present a safety issue. 
In some instances, intrinsic properties of some tumors naturally allow more efficient replication 
in comparison to non-transformed, normal cells, such as reovirus’s exploitation of cancer cell 
RAS pathway activation.120-122 Alternatively, genetic modifications can limit replication by 
knocking out a factor necessary for replication that is made in excess in rapidly dividing cancer 
cells. For example, thymidine kinase (TK) is an enzyme known to have increased expression in 
dividing cells in the G1 phase of the cell cycle and is also necessary for HSV-1 replication since 
it is critical for DNA synthesis and repair.123 Deletion of thymidine kinase in HSV-1 therefore 
prevents replication in cells that are not dividing, greatly reducing the virus’s ability to replicate 
in normal tissue.124-126 
Preclinical Testing in Mice.  Challenges also exist in preclinical development and 
testing of oncolytic viruses. Testing in xenogeneic mouse models where human tumor cell lines 
are implanted may generate misleading results.94 These models don’t account for the potential 
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for rapid immune clearance of the virus which would limit efficacy. Conversely, therapeutic 
benefit of immune response to virotherapy cannot be assessed in xenogeneic models using 
immunodeficient mice.  Models involving immunodeficient mice also can’t account for any 
unintended immunotoxicity or immune-mediated and/or autoimmune reactions that could occur 
with viruses generating anti-tumor immune responses that could have off-target immune effects. 
Testing with syngeneic models has been proposed as a possible solution; however, viral 
permissibility/activity may be different in mouse cells as compared to human.94  
Oncolytic Herpesviruses (oHSV) 
Herpes Simplex Virus type-1 (HSV-1) has long been hailed as a promising virus for the 
development of oncolytic virotherapy. The reasons cited are many. HSV-1 has a large genome 
with a number of non-essential genes that can be deleted to reduce pathogenicity or to insert 
therapeutic transgenes. Additionally, antiviral drugs exist that can control infection in the event 
of viral dissemination and/or adverse events.  In the 1990’s, the prospect of using viruses to treat 
tumors became reality when an attenuated TK-negative HSV mutant showed promise in treating 
gliomas in a xenogeneic mouse model after intratumoral injection.127 Twenty-five years later, the 
first ever oncolytic virotherapy was approved by the FDA, a mutated HSV-1 virus referred to as 
Talimogene Laherperepvec or Imlygic. Genetic engineering of virus has allowed rapid 
development of viruses with enhanced safety and anti-tumor effects. 
Targeting Cancer Cells. Wild-type herpesviruses do not require cells to be actively 
cycling in order to replicate since they are DNA viruses that encode their own viral homologues 
of nucleotide metabolism and DNA synthesis enzymes.98 One strategy to limit viral replication to 
tumor cells is to delete viral genes that encode DNA synthesis enzymes which would be 
overexpressed in tumor cells but not quiescent, non-dividing cells. Deletion mutants enhance 
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safety but also limit viral effectiveness.128 One example of this is the dlsptk HSV-1 mutant, 
which contains a deletion in UL23 encoding a viral homologue of thymidine kinase (TK), which 
was the first virus genetically engineered for testing as oncolytic virotherapy.127,129-131 While 
deletions affecting TK may limit growth to rapidly dividing cells with overexpression of cellular 
TK to enhance safety in comparison to wild-type HSV-1125, the mutation also creates resistance 
to acyclovir and other nucleoside analog-based antiviral drugs, limiting the ability to contain 
viral dissemination in the event of adverse effects; however, it may be possible to control 
infection using drugs that target HSV DNA polymerase such as foscarnet and cidofovir.131,132 The 
hrR3 HSV-1 mutant has an insertion of Lacz in the UL39 gene encoding a large ribonucleotide 
reductase (RR) enzyme also known as ICP6; therefore, replication only occurs in cells 
overexpressing RR.133,134  
As a safety feature, most oncolytic herpesviruses in development have included a 
mutation in ɣ34.5, a gene whose protein, ICP34.5, is important in viral replication, egress, 
blocking synthesis of the early protein shutoff gene, and neurovirulence. HSV-1 mutant R3616 
contains deletions in both copies of the gene, and is therefore only able to replicate in cells with 
uncontrolled protein synthesis (actively cycling cancer cells).135,136 HSV-1 mutant strain 1714 
also has deletions in both copies of ɣ34.5. A recombination of 1714 with the parent strain 17 
resulted in the common oncolytic strain 1716, which also is unable to express ICP34.5.137 Early 
results in preclinical testing of these first generation oHSV strains were relatively mixed138-140, 
but generated interest in using herpesviruses to target and kill cancer cells.128 Another well-
known oHSV generated around the same time is NV1020. NV1020 has a deletion in one copy of 
the ɣ34.5 (RL1) deletion in addition to UL55, UL56, RS1, and RL2, which encode for (p)UL55, 
(p)UL56, ICP4, and ICP0, respectively; only one copy of the genes encoding ICP4 and ICP0 was 
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deleted. NV1020 was developed to be a vaccine for HSV-1 and -2 and therefore had insertions 
for genes encoding HSV-2 glycoproteins in place of the deleted genes. Although NV1020 was 
unsuccessful as a live-attenuated vaccine141,142, it showed potential as an oHSV in several murine 
models including head and neck squamous cell carcinoma143 and prostate cancer144.   
 G207 contains the ɣ34.5 deletion plus deletion of gene encoding ICP6. oHSV HF10 has 
a deletion in UL56 and a duplication in UL53 (encoding gK), UL54 (encoding ICP27), and 
UL55. HF10 has shown promise in an immunocompetent murine tumor model and phase I 
human clinical trials.128,145,146 A number of oHSVs with varying genetic mutations have been 
explored as cancer therapy and are listed in Table 2.6 and Table 2.7.   





Gene(s) mutated Description 
dlsptk KOS UL23 Internal deletion within UL23. 
hrR3 KOS UL39 Insertion of LacZ (encodes β-
galactosidase) in UL39. 
R3616 F RL1 Fragment of both copies of RL1 deleted. 







Gene(s) mutated Description 




F UL23, UL55, UL56, RL1, 
RL2, RS1 
Deletion of UL23, as well as the region 
encoding UL55, UL56, and one copy of 
RL1, RL2, and RS1 (though not the RS1 
promoter). HSV-2 region encoding pUS2, 
pUS3, and glycoproteins D, G, I, J, and 
part of E inserted in the deletion. UL23 
reinserted in the deletion such that 
expression is under the RS1 promoter. 
3616UB R3616 RL1, UL2 Insertion of LacZ within UL2. 
HF10 HF UL53, UL54, UL55, UL56 Spontaneous deletion of UL56 as well as 
duplication of UL53, UL54, and UL55. 
G207 R3616 RL1, UL39 Essentially R3616 with the hrR3 LacZ 
insertion in UL39. 
MGH-1 R3616 RL1, UL39 Same as G207. 







Gene(s) mutated Description 
SUP Patton RL1, US11, US12 RL1 replaced with β-glucuronidase under 
control of the RL1 promoter. Deletion 
within US12 which places expression of 
the normally late US11 gene under the 
immediate early US12 promoter. 
G47Δ G207 RL1, UL39, US11, US12 Deletion of the overlapping US11 
promoter/US12 region, putting expression 
of the normally late US11 gene under the 
immediate early US12 promoter. 
KM100 KOS/17 RL2, UL48 Insertions within RL2 and UL48. 
Expressed pUL48 lacks C-terminal 
transactivation domain. 
Fu-10 G207 RL1, UL39, 
glycoprotein(s)? 
Random mutagenesis resulted in 
unidentified mutations, most likely in 
glycoprotein(s). 
Baco-1 17 RL1, packaging signal RL1 deleted. DNA packaging signal is 
restored. 







Gene(s) mutated Description 
Synco-2 Baco-1 RL1, packaging signal Gibbon ape leukemia virus fusogenic 




Baco-1 RL1, packaging signal, 
glycoprotein(s)? 
Essentially Synco-2 with the Fu-10 
glycoprotein(s) mutation. 
 
Table 2.7. Summary of viral genes modified in oHSVs128 
Gene Protein Function 
RL1 ICP34.5 Major neurovirulence gene. Prevents cellular inhibition of protein synthesis 
by mediating dephosphorylation of eIF2α. Binds to Beclin-1, inhibiting 
autophagy. 
RL2 ICP0 Multifunctional. Involved in transcription of viral genes. Has ubiquitin ligase 
activity. 
Inhibits interferon response. Alters the cellular environment to promote viral 
replication. 




Gene Protein Function 
RS1 ICP4 Represses expression of viral immediate early genes and activates expression 
of viral early and late genes. 
UL2 Uracil DNA 
glycosylase 
Removes uracil from DNA. 




Involved in the synthesis of deoxyribonucleotide thymidine triphosphate. 
UL27 gB Part of initial attachment of the virus to the cell by binding to heparan sulfate. 
With gH/gL, enables fusion of the envelope with the cell membrane. 
UL39 ICP6 Major subunit of ribonucleotide reductase. 
UL44 gC Forms the initial attachment of the virus to the cell by binding to heparan 
sulfate. 
UL48 pUL48/VP16 Initiates transcription of immediate early genes. 




Gene Protein Function 
UL53 gK Essential for cytoplasmic envelopment, egress, and cell fusion. 
UL54 ICP27 Multifunctional. Inhibits cellular mRNA splicing. Recruits necessary proteins 
involved in viral transcription and translation. Activates cellular pathways to 
promote viral replication. 
UL55 pUL55 Tegument protein. Function unknown. 
UL56 pUL56 Binds to neuron-specific kinesin KIF1A, an axonal transport motor protein. 
US6 gD Binds to HVEM and/or nectin-1, leading to a conformation change that 
initiates fusion. 
US11 pUS11 Binds to and is phosphorylated by PKR, preventing cellular inhibition of 
protein synthesis and autophagy. 
US12 ICP47 Inhibits TAP/MHC class I presentation. 
Abbreviations: eIF2α, elongation initiation factor 2α; g, glycoprotein; HVEM, herpesvirus entry 
mediator; ICP, infected cell protein; MHC, major histocompatibility complex; oHSV, oncolytic 
herpes simplex virus; p, protein; PKR, protein kinase R; RL, repeat long; RS, repeat short; TAP, 







oHSV-1 Regulation of Cell Cycle. Evidence suggests that HSV-1 has evolved a complex 
and sophisticated ability to modulate the cell cycle in order to limit cellular DNA production to 
limit competition for the nucleotide pool while also inducing pathways that mimic or partially 
elicit entry into the cell cycle for more efficient viral replication later in infection.147  Blocking the 
cell cycle may have an advantage when the infected cell is an inflammatory cell since limiting 
proliferation or inducing apoptosis would result in a decreased ability to mount an antiviral 
immune response; this effect could also be advantageous when the cell infected is a cancer cell in 
the context of oncolytic virotherapy.  
Cell Cycle Block.. L particles lacking DNA are able to block the cell cycle, but do not 
induce apoptosis.148 This may be in part related to immediate early protein ICP0, which is also a 
virion component. Therefore, replication is not necessary to achieve cell cycle block using oHSVs. 
G1/S Phase Block. In infected cells, protein kinase R (PKR) becomes activated and 
phosphorylates eukaryotic translation initiation factor 2 (eIF-2), resulting in a halt in transcription 
and, therefore, protein synthesis. HSV-1 protein, ICP34.5 activates the eIF-2 phosphatase so that 
eIF-2 can resume activity and protein synthesis can resume later in infection.149 HSV-1 infection 
leads to the accumulation of a repressive form of E2F; high levels of E2F result in binding with 
Rb preventing binding with the cell cycle promoting form of E2F. Specifically, E24 translocates 
to the nucleus and binds with p107 leading to cell cycle arrest.150 ICP0 is involved in G1/S block 
by induction of p53, p21, gadd45, and mdm2.151,152 HSV-1 infection also leads to a loss of 
phosphorylation of pRb, which causes it to bind with the cycle- promoting form of E2F and prevent 
it from initiating S phase. HSV-1 inhibits cyclins D1 and D3 and prevent formation of active cdk2 
and cdk4.153 Specifically, HSV-1 infection has been reported to result in suppressed activity of 
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cyclin D-cdk4 and cyclin D-cdk6. Cyclin E-cdk2 activity was also reduced; specifically, there is 
loss of cyclin E and lack of translocation to the nucleus by cdk2. 154 
 G2/M Phase Block. ICP0 is involved in G2/M block by induction of p53.151,152 Chk2 is 
required for ICP0-mediated block.155 HSV-1 infection also has the ability to prevent the cell from 
exiting the M phase by interference with kinetophores.    
Cell Cycle Progression. Whether HSV-1 promotes or inhibits cell cycling may be 
dependent on external environmental or cellular factors. Most evidence that points to cell cycle 
block was performed in experiments with adequate serum; experiments where increased cyclin-
cdk function were observed, cells were serum-starved.156 In those experiments where activity was 
increased, cdk4 activity was unaffected, cyclin A activity was induced, cyclin E activity was not 
induced, and cdk2 activity was transiently induced.156 ICP34.5 has a homologous carobxy-terminal 
domain to GADD34/MyD116 or growth arrest and DNA damage-inducible protein 34, which can 
restore protein synthesis in infected cells.157 
Replication and Lysis. Cell death is a common defense mechanism against viral 
infections. In the battle of life and death between virus and cells, multiple factors affect who is 
victorious. Cells may die to entry, replication and lysis of cells. Factors such as pathways of entry 
may vary by cell type and affect cell response; once virus has entered, the most desired outcome 
for the cell is to die to limit spread to other cells. HSV-1 desires to keep the cell alive because it’s 
machinery is necessary for viral replication. HSV-1 can destroy cancer cells as a result of viral 
replication and lysis or as a result of early shut-off of protein synthesis.158 In HSV-1 mutants that 
lack ICP34.5, PKR-induced inhibition of protein synthesis cannot be reversed;149,159 this 
machinery is also necessary for viral replication, so lack of ICP34.5 would therefore greatly limit 
viral replication in addition to cellular protein production. Cell death in cancer cells infected with 
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ICP34.5 mutants may therefore result from an apoptotic pathway due to lack of the ability to 
produce cellular proteins necessary for normal homeostasis of the cell. HSV-1 viruses that express 
ICP34.5 are expected to replicate better for the aforementioned reason; cancer cell death would be 
expected to be more consistent with lysis/necrosis rather than apoptosis as would be expected for 
ICP34.5 mutants. Since apoptotic cell death results in minimal inflammatory response, this may 
be less advantageous than a mechanism that results in oncolysis/necrosis, which would be expected 
to produce a robust immune response that could facilitate development of adaptive immunity to 
tumor antigens.    
Apoptosis. Anti-apoptotic proteins which interfere with caspases and are expressed by 
HSV-1 include gD, gJ, Us3, LAT, and the ribonucleotide reductase large subunit (R1).160-164 
Immediate-early genes ICP4, ICP27, and ICP24 have been shown to inhibit apoptosis160,165-167; 
regarding ICP27, the C-terminal is required for an anti-apoptotic effect, but the N-terminal is not 
required.168 Glycoprotein D inhibits FAS by NFkB activation through binding with HVEM, a 
member of the TNF receptor family.169,170 In cells where virus enters via endocytosis and entry 
receptors are not used, there is no NFkB activation through this pathway and apoptosis potentially 
cannot be inhibited via the aforementioned mechanism. R1 proteins ICP6 and ICP10 also prevent 
apoptosis through the TNFa and FASL-induced pathways.160 Us3 inhibits cytochrome c release 
inhibiting the intrinsic pathway. 171  The product of UL14 has also been shown to inhibit apoptosis 
and has heatshock protein-like properties similar to HSP70 and HSP27, which are known to block 
caspases.160,172,173 LAT inhibits caspases 8 and 9 and therefore inhibits both the intrinsic and 
extrinsic apoptotic pathways in neurons.174,175 R1 binds caspase 8 and inhibits the extrinsic 
pathway of apoptosis.161  
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ICP0 is a known trigger for apoptosis through activation of caspase-3.160,176 Induction of 
apoptotic pathways occurs independent of receptor binding, fusion, translocation to the nucleus, 
or replication. In fact, ICP0 is referred to as an “apoptoxin”.176 The exact mechanism is uncertain, 
but, based on molecular modeling studies, the possibility that ICP0 results in the formation of 
hairpin structures or double stranded RNA that could be recognized by cellular proteins has been 
suggested.176 Essentially, it seems that HSV-1 initiates apoptotic pathways initially, and then 
blocks them during replication. 
Necroptosis. When HSV-1 is successful in preventing apoptosis, necroptosis is another 
pathway by which the cell can trigger its own death to limit viral spread and replication.160 HSV-
1 ICP6 can limit TNF-induced necroptosis in human cells.177 The RHIM domain of ICP6 is 
necessary due to its association with RIP1 and RIP3.178 HSV-1 protein R1 regulates necroptosis 
through RHIM-dependent inactivation or activation of RIP3 in a species-specific manner.177 R1 
prevents necroptosis in human cells, but not in mouse cells, where RIP3 is efficiently activated by 
ICP6 after HSV-1 infection in a manner independent of TNFR, TLR3, or DAI.178,179 This is one 
factor responsible for limiting viral replication in mouse cells, a nonnatural host. This is important 
to keep in mind when performing preclinical mouse studies.   
oHSV-1-Induced Immune Response. oHSVs are at times regarded as immunotherapies 
since anti-tumor immune responses are occasionally seen in patients receiving virotherapy. There 
is significant interest in enhancing the capability of viruses to stimulate anti-tumor immune 
responses.180,181 In addition to direct lysis, oncolytic viruses may also destroy cancer cells 
indirectly through immunogenic cell death (ICD) and through development of adaptive immune 
responses. HSV-1-based oncolytic viruses have been shown to generate adaptive immune 
responses in some tumor models. 88,89 
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 Several strategies to enhance anti-tumor immune effects have been evaluated in murine 
models, and in some instances, clinical trials. One strategy is the deletion of ICP47, which 
normally inhibits MHC-I presentation by binding to transporter associated with antigen 
presentation (TAP).182,183 Another strategy involves using HSV as a vector to express tumor 
antigens. An example of this is strain oHSV bPΔ6-hPAP, which expresses a human prostate tumor 
antigen, prostatic acid phosphatase (PAP), and demonstrated efficacy in a murine mouse model 
bearing murine prostate cancer cells.128,184 Potentially one of the most popular strategies has been 
insertion of immune-stimulating transgenes that encode cytokines. These have included IL-12,185-
188 IL-15,189 IL-18186, tumor necrosis factor alpha190, granulocyte macrophage-colony stimulating 
factor185,191, CD80186, and fms-like tyrosinase kinase 3 ligand192. The premise is to encourage 
recruitment, activation, and proliferation of NK cells, T cells, dendritic cells, macrophages, and B 
cells. The benefit of using a viral vector is local sustained delivery of these cytokines without the 
toxic side effects associated with systemic delivery in addition to presumed adjuvant effect of the 
virus. Further, cytokine producing oHSVs have been as efficacious and safe as the parent viruses 
in mouse models.128  
oHSV-1-Induced Effects on Cancer-Associated Fibroblasts (CAF) and Tumor-
Associated Vasculature (TAV). Some viruses may inhibit tumor growth due to disruption of 
tumor-associated vasculature through infection of endothelial cells. In some instances, infection 
of endothelial cells by certain viruses are thought to be dependent on expression of high levels of 
vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which are often 
present in the tumor microenvironment. HSV suppresses synthesis of fibronectin, collagen, and 
thrombospondin, which could inhibit production of adequate scaffolding for tumor cell growth; 
this effect is independent of viral replication, but dependent on the dose of the initial viral inoculum 
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.128,193 Strains 1716 and hrR3  have demonstrated direct anti-angiogenic effects and decreased 
microvascular density in tumors through infecting and lysing endothelial cells in tumor-associated 
vasculature.93,194 Additionally, strains have been generated that express anti-angiogenic factors 
such as thrombospondin-1195, endostatin194,196, angiostatin196, and vasculostatin.197 Efficacy results 
using this strategy were mixed but delay in disease progression was seen in a xenogeneic brain 
tumor model.196 Some research suggests combining certain anti-angiogenic therapies with 
oncolytic virotherapy results in a synergistic therapeutic effect, likely due to off-target inhibition 
of cellular antiviral defense proteins that disable innate antiviral immune responses.198,199 
Talimogene Laherperavec (T-VEC)/Imlygic (Oncovex) 
T-VEC is a mutated oncolytic HSV-1 based virus with mutations in infectious cell protein 
(ICP) 34.5 and ICP47, while expressing US11 and human granulocyte macrophage-colony 
stimulating factor (GM-CSF). The deletion of ICP47 results in the upregulation of US11 and 
expression as an immediate early (IE) gene rather than a late gene because it is now under control 
of the promotor that would normally regulate expression of the IE gene for ICP47.191 US11 is a 
ribosome-associated viral protein that inhibits the activity of PKR.200 The increased expression of 
US11 reduces phosphorylation of eIF-2 and increases transcription and protein translation 
improving viral replication in absence of ICP34.5.201,202 It has been demonstrated that enhancing 
the function of US11 improves tumor cell-killing while not affecting the reduced pathogenicity 
achieved by the ɣ34.5 deletion.191,203,204 ICP47 is involved in inhibiting TAP (transporter 
associated with antigen presentation), and normally would inhibit translocation of MHC receptors 
to the plasma membrane of infected cells to limit immune response to the virus183,205,206. Deletion 
of the gene encoding ICP47 would therefore have the expected effected of limiting the virus’s 
ability to downregulate MHC expression and potentially result in increased antigen expression for 
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recognition by the immune system. Viral expression of human GM-CSF was intended to improve 
antitumor immune responses and expression of GM-CSF by HSV-1 vectors has demonstrated 
efficacy in some murine tumor models.207 
 Preclinical Development. Preclinical work involved development of the mutated virus 
from a clinical isolate, strain JS1.191  The JS1 strain is genetically similar to the +17 strain most 
often used in oncolytic HSV-1 development. JS1 was shown to be superior over +17 in killing 
human tumor cell lines SK-MEL-28 (melanoma), MDA-MB-231 (breast adenocarcinoma), and 
HT-29 (colon adenocarcinoma) via trypan blue exclusion assay at multiplicity of infection (MOI) 
of 0.1 and 1 at 24 and 48 hours.191 After deletion of ɣ34.5 in both JS1 and +17, JS1/ ɣ34.5- was 
assessed as demonstrating superior cell killing over the course of 72 hours at MOI’s of 0.1, 1, and 
5 when the aforementioned tumor cell lines as well as a human prostate adenocarcinoma cell line 
(LNCaP, FGC) and glioblastoma astrocytoma cell line (U-87 MG) were infected.191 Efficacy in 
tumor destruction was not compared in vivo for the +17 and JS1-based viruses; however, the study 
did demonstrate tumor growth inhibition in experiments involving xenogeneic mouse models 
where JS1-based mutants inhibited tumor growth in comparison to mock-treated mice. Authors 
further showed that this effect was enhanced in the JS1/ ɣ34.5-/1CP47- mutant as compared to the 
JS1/ ɣ34.5- mutant. Since experiments were performed in immunocompromised mice, the anti-
tumor effect from those experiments can be presumed to be largely due to direct destruction of 
tumor cells by the virus. In order to assess generation of an anti-tumor immune response, a 
syngeneic murine lymphoma model was used involving induction of bilateral A20 lymphoma 
tumors in the flanks of BALB/c mice. Tumor growth inhibition or regression was observed in 
JS1/ɣ34.5-/1CP47-treated mice in comparison to mock-treated animals; the effect was enhanced 
in mice treated with JS1/ ɣ34.5-/1CP47-/GM-CSF. Growth inhibition was more pronounced in the 
45 
 
directly injected tumors, but contralateral tumors also showed some response; responses appeared 
to occur in a dose-dependent manner. ICP47 does not inhibit TAP in mouse cells, only in human 
cells. They also importantly showed that pre-immunization with wild-type HSV-1 had no effect 
on the therapeutic effects of intratumoral treatment with the mutant.  
 Clinical Trials. According to the FDA, a study was performed using the drug Imlygic in 
436 patients with metastatic melanoma. The therapeutic protocol involved injecting visible tumors 
every two weeks for 6 months. A little over 16% of patients receiving Imlygic saw a reduction in 
the size of their skin and lymph node lesions compared to only 2% of the subset who received 
GM-CSF therapy. The FDA states that, thus far, the drug has not been shown to have an effect on 
overall survival or metastatic melanoma lesions. Additionally, the drug is contraindicated in 
immunosuppressed patients limiting its use in some cancer patients. 
 While impressive efficacy of Imlygic was demonstrated in vitro and in murine models, 
results in human patients were underwhelming in clinical trials. The abscopal effect seen in mice 
has not been observed in humans as evidenced by the fact that all melanoma lesions must be 
injected in human patients for response. New approaches to oncolytic virotherapy testing that more 
adequately predict clinical response and safety are urgently needed. Further, development of novel 
HSV-1-based virotherapies should aim to stimulate strong anti-tumor immune responses.    
VC2 Live-attenuated HSV-1 Vaccine Strain 
 Deletions in gKΔ31-68 and UL20Δ4-22 from the HSV-1 laboratory F strain using the 
double-Red recombination protocol (Figure 2.8) 208-210, resulted in the generation of a mutant virus, 
VC2. Our laboratory previously  demonstrated that the amino termini of gk and UL20 interact with 
gB and that these interactions modulate virus-induced cell fusion mediated by the gK/UL20 
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complex.208-211 The aforementioned mutations in gK and UL20 resulted in 30-40% smaller viral 
plaques than wild-type, parental virus in vitro.210   
 
In vivo attenuation of pathogenicity of VC2 was confirmed in experiments in mice 
involving inoculations of 107 PFU intranasally or intramuscularly; no clinical signs of disease were 
observed in any mice inoculated.210 Further, no viral DNA could be detected via PCR from the 
trigeminal or dorsal root ganglia.210 Our laboratory has also shown that the deletions in gKΔ31-68 
and UL20Δ4-22 results in the inability of HSV-1 to enter ganglionic neurons through the ocular 
route.212 The mechanism whereby the VC2 strain is unable to infect neurons and establish latency 
has not been definitively elucidated. However, recently, we showed that the amino terminus of gK 
is required for viral fusion.213 Glycoprotein B binding to AKT results in the release of calcium and 
Figure 2.8. Schematic of the construction of VC2..(A) The top line represents the prototypic 
arrangement of the HSV-1 genome, with the unique long (UL) and unique short (US) regions 
flanked by the terminal repeat (TR) and internal repeat (IR) regions. Shown below are the 
expanded genomic regions which encompass the open reading frames of UL20 and 
glycoprotein K. In black are the approximate deletions within their respective genes. (B) A 
depiction of the gK UL20 complex interacting with gB. Areas between the black lines on the 





fusion with cell membranes during HSV-1 infection. Our laboratory specifically showed that gB 
of wild-type virus interacts with AKT to release calcium in SK-N-H human neuroblastoma cells, 
while virus containing the gKΔ31-68 deletion did not interact with AKT. Additionally, AKT 
inhibitor, miltefosine, prevented efficient entry of wild-type virus in SK-N-H neuroblastoma cells 
efficiently, while virus with the deletion in gKΔ31-68 was still able to enter, suggesting an 
alternative primary mechanism of entry, such as endocytosis.213   Importantly, when this 
hypothesis was tested, endocytosis inhibitors, pit-stop 2 and dynasore prevented entry by gKΔ31-
68 mutated virus, while wild-type entered efficiently.213 This difference in entry by HSV-1 with 
the gKΔ31-68 deletion could be one mechanism whereby VC2 would fail to establish latency in 
ganglia post-infection. The ability to infect most permissible cell types, while not infecting 
ganglionic axons and establishing latency, represents a significant safety advantage in generating 
an ideal mutant for vaccine or virus vectored therapy.    
Regarding replication, VC2 replicates as well as parental F strain at an MOI of 5. Although 
replication is slower at a lower MOI of 0.1, by 36 hours post infection, peak viral titer is similar to 
wild-type F strain.210 In vaccination strategies, replicating, live-attenuated viruses are known to 
stimulate stronger humoral and cell-mediated immune responses than killed or non-replicating 
virus since the entire viral antigen repertoire can be expressed. Indeed, vaccination of mice with 
VC2 resulted in strong humoral and cell-mediated immune responses that were protective against 
lethal intravaginal challenge of mice with virulent HSV-1 and HSV-2 strains.210 Proliferation 
assays performed on splenocytes showed increased responsiveness of CD4+ and CD8+ T cells 
when exposed to HSV-1 pooled epitopes from VC2 vaccinated mice in comparison to mock-
treated controls. Impressively, mice that were vaccinated showed no evidence of viral DNA in the 
ganglia, suggesting rapid, local immune response and immune-mediated clearance of virus 
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associated with VC2-vaccination.210 Strong, protective T cell-mediated immune responses were 
also demonstrated in a guinea pig HSV-2 model.214 In rhesus macaques, vaccination with VC2 
resulted in elevated titers of cross-protective, neutralizing IgG1 antibodies against HSV-1 and 
HSV-2. B cells were found to be increased in draining lymph nodes and proliferating CD4+ and 
CD8+ T cells were observed in the vaginal mucosa.215 The precise mechanism of the apparent, 
remarkable immunogenicity of VC2 is not fully established. However, along with the 
aforementioned safety advantage and the robustness of replication in permissible cell types, the 
demonstrated strong immunogenicity of VC2 supports its use further evaluation for potential as a 
potent vector for vaccines and other immune-stimulating therapies, including immune-modulating, 
oncolytic virotherapy strategies.  
Overview of Drug Discovery Strategies 
2D Culture. There are two main approaches to cancer modeling in drug discovery: the 
triangle approach and the diamond approach. The upside-down triangle approach (Figure 2.9) is 
often used to perform drug discovery and development studies. It involves initial high-throughput 
screening in two-dimensional (2D) culture using a high number of cell lines or primary cells and/or 
compounds or drug combinations. In vitro methods are used in place of and in combination with 
animal models. Most studies of melanoma have come from work done with 2D adherent cell 
culture assays. This method is good for getting preliminary results on cytotoxicity, protein 
expression, migration (simple scratch assay), and adhesion (Boyden chamber assay). However, 
some drug therapies depend on poor access to nutrition and/or oxygen, metabolic transformation 
in the animal, or stimulation of the immune response.216 2D assays are no assistance in these cases. 
Monoculture has the advantage of purity for RNA, DNA, and protein extraction.216,217 However, 
co-culture with keratinocytes causes a phenotype that is much more similar to that seen in vivo 
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because microenvironment can influence RNA expression or protein synthesis patterns.216-218 2D 
adherent cell culture models do not take into account that melanoma cells do not grow in 
isolation.216 
3D Culture. The next step is a semi-high-throughput screen in three-dimensional (3D) 
culture, which is chosen based on the conditions resulting from the 2D experiments. 3D cell 
cultures represent a good compromise between the lack of structure of a tumor in its 
microenvironment in 2D culture conditions and the extreme complexity of the in vivo models.56,216 
There are several 3D cell culture models including the 3D spheroid model,  the 3D skin 
reconstruction model, and the 3D neoangiogenesis model. In the 3D spheroid model, spheroids are 
implanted in a collagen gel matrix.56,65,216,219,220 It more closely mimics  the architecture and 
microenvironment, recreates the oxygen/nutrient gradient, and mimics tumor heterogeneity.216,220 
The 3D spheroid model is used for high-throughput proliferation, invasion and drug response 
assays mimicking distant metastatic melanoma.216 In the 3D skin reconstruction model, skin 
reconstructs consist of artificial skin rebuilt from isolated cell populations and composed of a 
stratified, terminally differentiated epidermal compartment of keratinocytes and melanocytes, and 
a well-established basement membrane deposited by skin cells.18,216,221 In human skin reconstructs, 
melanoma cells from different stages of progression have the same properties as in the patients’ 
skin, whereas advanced primary vertical growth phase (VGP) and metastatic melanoma cells 
readily invade the dermis.18,216,221,222 3D skin reconstruct models, which are technically demanding 
and require constant monitoring by trained personnel during culture times of up to 21 days, are 
mainly used for studying the biology and drug response of melanoma cells at early stages.216  In 
the 3D neoangiogenesis model, human endothelial cells are grown in collagen gel matrix to assess 
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therapeutics that target tumor vasculature. This model is very important to assess on- and/or off-
target anti-angiogenic activity of novel drugs.216 
 In Vivo Testing. The final step should be the appropriate animal experiments.216 In vitro 
pre-screening should lead to the involvement of significantly fewer animals, therefore, providing 
a cost-effective, time-effective, and ethically acceptable approach. In the diamond approach, cell 
lines can be isolated from a tumor growing in a human or a mouse and characterized in 2D and 
then 3D culture as previously described (Figure 2.9).216 Ultimately, preclinical testing must be 










Murine Modeling of Human Disease 
Inherent Differences in Mice and Humans. The house mouse, or Mus musculus, has been 
the mainstay of biomedical research for decades. There are a number of practical reasons that mice 
have been the workhorses for studying human diseases including ease of maintenance and 
breeding, the availability of inbred strains with minimal genetic variation, and many genetic and 
physiologic similarities to humans223,224; techniques for generating spontaneous mutations and the 
ability to generate transgenic and knock in/knock out strains also make them useful for studying 
mechanisms of various disease processes.225 Herein, important genetic and immunologic 
differences between mice and humans are highlighted and what they mean in the context of tumor 
modeling and comparative immuno-oncology using murine models. Understanding these 
differences and their imposing limitations and implications is helpful in choosing the best tumor 
modeling strategy for the specific scientific question at hand. Therefore, we first discuss inherent 
differences between human and mouse genetics and immunology that could impact studies using 
murine tumor models. Some have argued that mice are not useful preclinical models for cancer 
studies due to the poor predictability of preclinical mouse data on therapeutic performance in 
human clinical trials using some models; however, poor concordance may be more related to 
inadequate experimental design, use of an inappropriate model, and/or inaccurate or overstated 
conclusions of preclinical studies where species-related differences and/or unique features of the 
specific model aren’t considered in interpretation of results. When species-specific differences and 
differences in tumor modeling strategies are fully appreciated and accounted for, more meaningful 
conclusions can be drawn from studies involving murine tumor models and expectations of 
performance in human clinical trials can be more accurately predicted.  
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Genetics. When the Mouse Genome Sequencing Consortium published the mouse genome 
(based on C57BL/6J female mice) sequenced in its entirety for the first time ever in 2002225, just 
one year after the complete human genome was published,112,226 the ability to make meaningful 
comparisons between humans and mouse models of human disease was greatly increased. Since 
that time, at least 16 mouse strains have been sequenced. From the initial sequencing data, some 
preliminary genetic comparisons were made. Both mouse and human genomes were found to 
contain approximately 30,000 protein encoding genes and 99% of mouse genes have a human 
orthologue; 96% lie in a similar syntenic interval in the human genome.225 Approximately 80% of 
human and mouse coding genes were found to have single orthologues of one another; in other 
words, these are 1:1 orthologues in which the best match is present in a conserved syntenic interval 
between the species representing common ancestral genes.225 Such genetic homology is 
encouraging for those who aim to use mouse models to study human diseases. Additionally, in 
some instances, even where there is marked genetic divergence, the protein products of the gene 
homologues still have similar functions. However, despite genetic similarities and functional 
overlap of homologous genes, there are differences in many biological pathways and immune 
system makeup and immune responses, which may be related to differences in gene expression 
and regulation between species. The Mouse ENCODE (Encyclopedia of DNA Elements) 
Consortium is an international, collaborating group of scientists doing extensive work to illuminate 
those differences227-231; a better understanding of the mechanisms involved in differing patterns of 
gene expression that affect biological pathways and immune responses may lead to the 
development of increasingly better and more clinically relevant models of human disease in the 
future. Differences in the genome and genetic expression between mice and humans likely exist 
53 
 
as a result of varying selection over vast amounts of time with differences in environmental, 
physiologic, and immunologic pressures.  
Immunology. In 2011, an update on the hallmarks of cancer was published wherein 
“immune evasion” was officially recognized as playing a critical role in tumor growth and 
progression.2  Since that time, the field of cancer immunotherapy has exploded, and a number of 
novel immunotherapies have hit the market and shown promise in clinical trials. However, usually 
only a subset of patients responds to these therapies. Therefore, development of new therapies and 
combinatorial strategies is underway and most of this work is occurring in murine tumor models. 
While the overall structure of the immune system in general appears to be similar in mice and 
humans232,233, some significant differences are readily apparent. The differences in the human and 
murine immune systems have been thoroughly reviewed232; however, we aim to  highlight a few 
discrepancies between the two species and allude to how they could result in differences in 
responses to immunotherapy in murine tumor models and clinical trials.  
Innate Immunity. Perhaps among the most obvious difference is the makeup of 
the circulating leukocyte population, which is approximately 50-70% neutrophils/30-50% 
lymphocytes in humans and 10-25% neutrophils/75-90% lymphocytes in mice; however, 
the functional significance of this difference is not well-delineated.232 Additionally, mouse 
neutrophils do not express defensins while human neutrophils are a rich source of 
defensins; further differences in their expression and processing at mucosal surfaces exist 
between the species. For example, Paneth cells in the small intestine of mice produce 20 
different types of defensins while human Paneth cells only produce 2 types.232 This 
difference in defensin expression could result in differences in neutrophil function between 
mice and humans when migrating into tissue in response to inflammatory stimuli including 
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tumors; additionally, the increased expression of defensins in the mouse gastrointestinal 
tract could result in differences in defensin expression in  murine models of colorectal 
cancer from what would be expected in humans.  
Differences in five genetic clusters involving aspects of the immune system were 
found in the initial genetic comparison of mice and man.225 These include major 
histocompatibility complex (MHC) 1b genes, two clusters of antimicrobial β defensins, 
whey acidic protein (WAP) domain antimicrobial proteins, and type A ribonucleases.225  
Also, Ly6 and Ly49 gene families are markedly expanded on chromosomes 15 and 6; 
interestingly, homologues of Ly49 exist in humans and primates but are occupied in killer 
cell immunoglobulin-like receptors (KIR) family of natural killer receptors more 
extensively rather than C-type lectin Ly49 gene family that predominates in mice.234-236 
Despite the species-specific genetic differences in homologues of Ly49, both mouse and 
human genes encode proteins with similar genetic diversity and similar functions 
including inhibitory or activating activity of natural killer cells when binding to MHC-I- 
associated ligands that are either self or viral, respectively; the majority of proteins in the 
Ly49 family have inhibitory functions on NK cells.232,237  Other differences in NK cells 
between humans and mice include differing ligands for activating receptor, NKG2D; 
human NKG2D binds MHC-I-related chain A, MHC-I-related chain B, and the UL16 
protein binding family while mouse NKG2D bind H-60 and Rae1β. 232 Differences are 
also present in FcR receptors, which are found on macrophages, neutrophils, eosinophils, 
mast cells, and dendritic cells and can bind to antigen-antibody complexes; humans 
express two IgG receptors not found in mice, FcɣRIIA and FcɣRIIC.232 Differences in 
natural killer cell ligand expression and binding and differences in immunoglobulin 
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receptors between mice and humans could affect how cells of the innate immune system 
respond to tumor antigens in mice and humans in the tumor microenvironment.   
Murine macrophages are induced to exhibit M1 macrophage phenotype via IFN-
ɣ238; however, IFN-ɣ has not been shown to have a similar effect on human macrophages. 
There is controversy over whether human macrophages even express NO239 but some 
evidence suggests expression may be induced by IFN-αβ, IL-4 plus CD23, and various 
chemokines240.  
Another cell-type that has been shown to have the ability to present antigen are 
endothelial cells. In humans, endothelial cells may present to both CD4+ and CD8+ T 
cells; in contrast, mouse CD4+ cells cannot be activated by endothelial cells although 
CD8+ can be activated; this may be related to the fact that human endothelial cells 
express MHC-I and MHC-II, while mouse endothelial cells only expressed MHC-I.232,241 
Human endothelial cells also express the ligand for CD2, a costimulatory molecule 
(CD58 (LFA-3)242, while mouse endothelial cells express a different ligand for CD2 
(CD48), which has lower affinity; mouse T cell activation appears to be much less 
dependent on ligand binding with CD2, however.243 Further, human endothelial cells 
express CD40 and ICOS ligand, Gl-5, which murine endothelial cells do not.244,245 The 
more limited ability of mouse endothelial cells to present antigen in comparison to 
humans results in immune tolerance to vascularized engraftments, such as some 
transplanted tumor models, while in humans, vascularized grafts are frequently 
rejected.232 However, therapies that can target tumor associated vasculature as an anti-
tumor mechanism, such as some oncolytic viruses, may show reduced efficacy in mice 
compared to humans.  
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Adaptive Immunity. B cells are interesting in that they bridge the innate and 
adaptive immune responses via their ability to present antigen and also produce antibody, 
respectively. In humans, B cells can simultaneously express CD5 and CD23, while in 
mice they are mutually exclusive.232,246 Human plasma cells, but not mouse, express 
CD38.232 In addition to differences in immunoglobulin receptors previously noted, 
differences also exist in immunoglobulin isotypes. Mice generally have four IgG 
isotypes, IgG1, IgG2a, IgG2b, and IgG3.232 Strain differences exist; C57BL/6, 
C57BL/10, SJL, and NOD mice do not make IgG2a, but instead make a novel isotype, 
IgG2c.232 Humans also have four IgG isotypes, IgG1, IgG2, IgG3, and IgG4, although 
they are not direct homologues of the mouse proteins.232 Differences exist in the affinity 
of Ig’s for FcR and efficiency in fixing complement. Further, there are known differences 
in class switching in response to cytokines.232 Differences in the presence and 
significance of B cells in the tumor microenvironment and circulating antibodies against 
tumor antigens may occur between humans and murine tumor models as a result of these 
B cell and antibody isotype differences.  
 Regarding T cells, antigen binding T cell receptors (TCR’s) must be coupled with 
co-stimulation through binding of CD28 on T cells for optimal T cell activation and 
function. In mice, CD28 is expressed on nearly all CD4+ and CD8+ T cells, while, in 
humans, CD28 is expressed in only 80% of CD4+ and 50% of CD8+ T cells.232,247 
Murine T cells are not known to express MHC II, while human T cells can express MHC 
II molecules after activation which may amplify the immune response or create T cell 
anergy.232,248-250 Two additional co-stimulatory molecules, B7-H3 and DC-SIGN of the 
B7 family, have been suggested to have different roles in human and mouse immune 
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responses.232 The predominant T cell type in murine skin are ɣ/δ T cells, are present in 
the epidermis, and are referred to as dendritic epidermal T cells (DTEC), while in humans 
α/β T cells predominate and are present in the dermis. T cell differentiation into Th1 or 
Th2 types are important in determining the course of immune responses. IFN-α 
production, often in response to viral infections, by human cells including macrophages, 
induces CD4+ T cells to differentiate into a Th1 phenotype; however, in mice, IFN-α 
does not induce Th1.232,251 While clinical significance is unknown due to immense 
overlap in functions, differences in many chemokines have been noted between mouse 
and man.232,252,253 Increased expression of costimulatory molecules on murine T cells 
could result in enhanced anti-tumor T cell responses in mice in comparison to humans. 
Differences in cytokine function between species may result in differences in the 
expression of Th1 versus Th2 phenotypes in response to stimuli intended to induce anti-
tumor immune responses in murine models versus humans. Additionally, the difference 
in type and location of resident T cells in the skin may produce different responses to 
intratumoral therapies.  
The inherent significant differences in the murine and human immune systems 
make it easy to see why it is so difficult to attain concordance between preclinical mouse 
data and human clinical trials, particularly as it relates to cancer immunotherapy. Still, 
many advances, including the development of immune checkpoint inhibitors, have been 
made using preclinical mouse models. We have highlighted some of the inherent known 
immunologic differences between mice and humans as it potentially relates to using mice 
as models of human cancers. Now we will focus our attention on reviewing specific 
murine tumor modeling strategies.  
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Murine Cancer Modeling Approaches 
Our understanding of the overreaching pathogenetic mechanisms behind tumor initiation 
and progression has grown increasingly complex over time.1,2,254 As our understanding has grown, 
so have the available models for study. Appropriate choice of model is critical. Choice of murine 
tumor model depends largely upon the scientific question at hand. All models have advantages and 
disadvantages. Herein, we review tumor modeling strategies and their advantages and limitations 
as models of human cancer. While there are a large number of murine tumor models available, we 
will selectively refer to examples when necessary to demonstrate a conceptual point.  Two main 
strategies in murine tumor modeling involve generation of spontaneous tumors (carcinogen-
induced and genetically engineered mouse (GEM) models) or transplantable models, which may 
be xenogeneic or syngeneic. 
Carcinogen-Induced. Carcinogen-induced models, in some ways, may better mimic the 
heterogeneity of tumors in the human populations than transplantable models. Tumors are often 
more genetically diverse and heterogeneous in histology and immunogenicity. However, onset of 
tumor development and progression can vary markedly, making adherence to stringent 
experimental design in preclinical therapeutic studies difficult, and longer lag times can also make 
timely completion of studies challenging. Similar advantages and challenges result with GEM 
tumor modeling.  
Genetically Engineered Mouse (GEM) Models. Genetically engineered mouse (GEM) 
models used in cancer research involve genetic recombination to induce transgenic expression of 
oncogenes or inactivation of tumor suppressors in knock-in (KI) or knockout (KO) approaches, 
respectively. In many GEM models, the germline cells are altered resulting in the genetic mutation 
occurring in all cells or at least all cells within the tissue type that would express the gene. Over 
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40 different GEM murine models of melanoma exist and have been reviewed in a general GEM 
model review elsewhere.255 One common example is the MT-HGF/SF model. It has been 
previously shown that constitutive expression of hepatocyte growth factor/scatter factor (HGF/SF) 
transgene in mice results in increased activation of mesenchymal epithelial transition factor (MET) 
receptor tyrosine kinase and, hence, increases the presence of melanocytes in the basal layer of the 
epidermis more similar to the human melanocyte distribution in skin as opposed to within the 
follicular hair bulb where most melanocytes are present in mouse skin.255 This mutation increases 
susceptibility to transformation by UV radiation increasing the ability to more accurately model 
the usual steps in tumorigenesis and melanoma pathogenesis in humans.256,257 The MT-HGF/SF 
model involves exposing neonatal mice to UVB radiation at the neonatal phase and then 
monitoring for melanomagenesis over time.257   In the MT-HGF/SF model only 22% of animals 
develop a tumor and only 21% develop metastasis. Tumor development generally has a lag time 
of approximately 15 months.257 Incomplete penetrance with variability in lag times limits use of 
GEM models in most early preclinical drug development studies.  
Transplantable Models. Transplantable models have been used most extensively and 
have a number of practical advantages including improved synchrony of tumor development and 
growth, simplicity, and cost-effectiveness in comparison to GEM models.258 Tumor cells may be 
implanted orthotopically or heterotopically. Orthotopic implantation, wherein tumor cells are 
implanted in their “normal” location, is preferable when possible since microenvironment has a 
strong influence on tumor cell behavior and adherence to modelling natural disease as faithfully 
as possible is desirable. Tumor cells implanted heterotopically may differ in growth, behavior, and 
gene expression based on an abnormal tumor microenvironment; heterotopic engraftment into the 
subcutis of the flank is often chosen because of ease of monitoring in that location.258 There are a 
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number of imaging strategies now which facilitate orthotopic implantation monitoring including 
bioluminescent and fluorescent in vivo  imaging, as well as PET, MRI, and CT scanning.   While 
transplantable models are more economical, user friendly, and practical for larger scale studies, 
there are also some disadvantages to this general strategy. One is that tumor cells that have been 
propagated  in vitro are relatively homogeneous in comparison to tumor cells that have been 
growing in vivo under stronger selection pressure,  resulting in subclones with varying abilities to 
evade the immune response and metastasize.258 Another critique is that injection of the initial 
inoculum of cells results in the death of a number of the cells, which could have an “immunizing” 
effect and could influence anti-tumor immune responses in immune-oncology studies using these 
models.258 Injection of cells also typically results in (relatively) rapid growth that bypasses the 
multistep process of carcinogenesis and chronic inflammation involved in spontaneous tumor 
development and progression. Some of these critiques can be addressed within the transplantable 
modeling systems using a variety of strategies, while some researchers opt to utilize spontaneous 
tumor models that have their own specific advantages and disadvantages.  
Xenogenic Models. Xenogeneic models involve implanting human cancer cells in 
immunodeficient (athymic (nu/nu) or severe combined immunodeficiency (SCID)) mice. 
Due to the lack of significant components of the immune system, these models are largely 
unacceptable for use in most immune-oncology studies.259 Typically the more 
immunodeficient the mouse, the better the tumor engraftment rates and growth rates.259 
Most often the origin of the tumor cells is human cell line. A significant challenge is that 
most studies involve cell line-derived xenografts (CDX) that use human cancer cell lines 
that have been maintained under non-physiologic conditions for so long that they often 
don’t retain the properties of the original tumor and clinical trials undertaken due to 
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demonstrated efficacy in these models often fail.260-263  Since immunodeficient mice are 
required for implanting human cells, xenogeneic modeling is of minimal utility for testing 
drugs that aim to stimulate anti-tumor immune responses.  
Syngeneic Models. Syngeneic models usually involve homograft transplantation 
of a cancer cell line derived from the same inbred strain of mouse as that in which the 
cancer originally arose. Syngeneic tumor models have been used in murine cancer 
modeling for decades but had seen a decline in use for many years while there was 
expansion of development of targeted therapies that relied on expression of certain 
genotypes and the development of xenograft models to answer questions related to targeted 
approaches. The most commonly used immunocompetent strains are BALB/C and 
C57BL/6 due to their inbred nature which improves biocompatibility with engrafted tumor 
cells from the same strain.259 With the current understanding that the immune system plays 
an important role in the development and progression of cancer, and the focus shifting 
towards development of cancer immunotherapies, there has been a resurgence in the 
interest of developing and using syngeneic, immunocompetent models.259 Transplantable, 
syngeneic models are useful for early preclinical development of cancer immunotherapies 
and are the most commonly used. Syngeneic models are in fact considered to be critical for 
development of novel immunotherapies and are currently the only system that can be easily 
set up in an immunocompetent model for mechanism of action (MOA) and efficacy 
evaluations in immuno-oncology studies.259  
Homograft of Murine Cell Lines. In comparison to  CDX models of which 
hundreds of human cell lines are available, availability of murine tumor cell lines for use 
in syngeneic models is more limited including only a few dozen.259   Many of these cell 
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lines were created artificially from carcinogen-induced tumors and are critiqued for having 
genetically unstable mutations that often don’t represent those in human tumors.259 Some 
cell lines were created from spontaneously arising tumors in mice including the B16 murine 
melanoma cell line. One benefit of using a syngeneic model is that there is minimal 
expected immune rejection, which allows relatively good tumor engraftment success rates. 
Use of syngeneic tumor models also allows for evaluation of therapeutics designed to 
stimulate immune responses against cancer cells due to the immunocompetent nature of 
the host. Because tumor cells are injected, tumor development occurs more rapidly and 
onset can be more reasonably predicted than most GEM models, and, therefore, higher 
throughput testing is possible for screening of new compounds or immunotherapeutic 
strategies. Rapid tumor development and growth can also present challenges such as 
limiting the time frame for evaluating drug candidates before the tumors ulcerate or grow 
to a size requiring euthanasia based on IACUC regulations.259 There is controversy among 
tumor immunologists as to which is more accurate for assessment of anti-tumor immune 
responses, a GEM model or a syngeneic model.  Some suggest that the more insidious 
onset of tumor development in GEM mice may allow for a more “tolerogenic” phenotype 
in the TME with dysfunctional T cells more consistent with human oncogenesis. However, 
there have been few studies that evaluated and characterized the immune profiles of 
syngeneic models in comparison to GEM, although differences in immune responses can 
be observed in response to therapy depending on the type of model being used. As an 
example, an anti-tumor antibody response may be adequate for a therapeutic response in a 
ERBB2-transgeneic model of breast cancer while cell-mediated and humoral immunity are 
required for protection in a syngeneic transplantable model.264-266 
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Techniques such as decreasing cell density of inoculum at engraftment can increase 
lag times in transplantable syngeneic models267, which may allow for a more tolerogenic 
TME to develop. Therefore, the lowest cell density inoculum that will result in a reasonable 
tumor engraftment rate is desirable. Other factors such as cell type may also make a 
difference since immunogenicity of different cancer cell lines can vary and affect the 
immune profile and response to immunotherapies.268 To improve immunogenicity in some 
models, cell lines are engineered to express ovalbumin. Examples include MC38-OVA and 
B16-OVA.269,270 However, methods to purposely increase the immunogenicity of tumor 
cells artificially for modeling may also increase the incidence of spontaneous immune 
rejection of tumors after engraftment. Additionally, the clinical, translational significance 
of studies where therapies are shown to induce anti-tumor immune responses through 
specificity against ovalbumin is highly questionable since ovalbumin is not a tumor antigen 
and would not normally be present in human tumors.  
Homograft of Spontaneous Murine Tumors. Tumors that arise spontaneously or 
from GEM or carcinogen-induced models may be harvested and engrafted into additional 
mice. These tumors, similar to human PDX models, maintain original histology and 
molecular characteristics better than tumors from cell-line derived engraftment.259,271 
Having never been grown in vitro, these tumor don’t have the genetic shifts necessary for 
robust growth in cell culture which are not relevant to the genetic profiles of human tumors 
and have different cell biology than cell line-derived tumors.259 Advantages may include 
better predictability of efficacy in clinical trials similar to human PDX models and more 
predictability and consistency in preclinical modeling than strict GEM models; tumors 
harvested and re-engrafted from GEM have the advantage of maintaining the specific, 
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human-cancer relevant mutation that was induced, while also having the increased 
predictability and consistency of a transplantable model. Neoantigen load is reportedly 
similar in tumors from GEM mice and syngeneic cell lines and is important in generating 
anti-tumor immune responses.259 
Immunotherapy Testing in Syngeneic Models. Early failures of anti-cancer 
immunotherapies were largely attributed to the supposition that transplantable syngeneic 
models could not accurately recapitulate the tumor microenvironment and/or human anti-
tumor immune responses, and therefore could not predict clinical outcomes in humans.272  
Despite critiques that syngeneic, transplantable models don’t recapitulate human immune 
responses during tumor development and progression with as much accuracy as GEM 
models, studies involving transplantable, syngeneic models have led to some of the 
arguably greatest advances in immune-oncology to date. These include development of 
immune checkpoint inhibitors, the recognition of immunogenic cell death (ICD) as a 
mechanism of therapeutic benefit in radiation and chemotherapy, and the observed synergy 
in combinatorial therapy using traditional drugs in combination with immunotherapy.258 
Proof of concept of CTLA4 blockade was first demonstrated in BALB/c mice bearing 
51BLIM1O colon carcinoma cells and A/JCr mice bearing Sa1N fibrosarcoma cells, while 
PD1 blockade showed promise in studies where anti-PD1 mAb’s limited spread of B16 
melanoma cells injected into the liver of C57Bl/6 mice and CT26 colon cancer cells 
injected intravenously in BALB/c’s. PDL1 blockade first demonstrated efficacy in J558L 
myelomas in BALB/c mice.258,273-275  
For all the advances in cancer immunotherapy using transplantable, syngeneic 
models, there are still many questions to be answered. Combination therapy strategies 
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which optimize and synergize the effects of ICD associated with traditional cancer 
therapies and immune checkpoint inhibitors are currently being tested. Additionally, due 
to the observation of synergistic effects of combinatorial therapy of immune checkpoint 
inhibitors in human clinical trials276-278, there is a lot of interest in exploring combinational 
immunotherapy and most of this work is being done in syngeneic models due to their intact 
immune system and ease of use.261 Dosing regimen is a challenge in this strategy, and 
studies that test these regimens are often performed in transplantable models, such as 
MCA205 fibrosarcomas in C57BL/6 mice.279  
Clearly, transplantable mouse tumor models have been critical to the development 
of novel anti-cancer therapies and likely will play a vital role in early, proof-of-principle 
preclinical testing for years to come.  
As mentioned, choice of appropriate model to answer the specific scientific 
question is crucial. Given the fact that there are significant differences in the anatomy, 
physiology, and immunology between mice and humans, and that there is marked 
heterogeneity in the genetic and immune profiles in humans and the cancers they suffer 
from, it is unlikely that a single model will ever be able to adequately answer all scientific 
questions. Models aimed at initial screening for potential therapeutic efficacy should be 
designed to provide reasonably consistent growth, metastasis, and morphology in a 
predictable and timely manner with as much attention to modeling the natural progression 
of disease as is possible in a murine model. Immunotherapies that show promise may then 
advance to testing in more complex, but technically challenging and difficult to reproduce 
models, such as GEM. For most cancer researchers involved in early drug discovery, the 
most practical and reproducible models will include the cell-line derived xenografts (CDX) 
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as well as syngeneic murine transplantable models. In these models, attention to 
experimental design and protocol are critical to achieve consistency and reproducibility, 
which are major advantages to these systems in comparison to more complex GEM and 
PDX models. 
B16f10 Syngeneic Murine Melanoma Model. In regard to murine melanoma 
models, several murine melanoma cell lines have been isolated and used in 
immunocompetent models. These include Harding-Passey cells isolated from an ICR 
mouse, Cloudman S91 cells from a DBA mouse, and B16 cells from a C57BL/6 
mouse.280,281 The B16 cell line is the most widely used line for melanoma research due to 
its aggressively growing nature, and it remains the standard in the field for development of 
immunotherapies for melanoma.282,283 The B16F10 subclone was created by Fidler in the 
1970’s by serial passage in mice through intravenous injections and collection and culture 
of tumor cells that had colonized the lungs, an experiment that is now regarded as a classic 
in the literature.284,285 After 10 in vivo passages through intravenous tail vein injections, 
Fidler had created a subclone of B16, B16F10, which could be used much more efficiently 
in an experimental metastasis model than the original clone B16F0, which was known to 
be inefficient at colonizing the lungs after intravenous injection into the tail vein. Aiming 
to select for an even more invasive variant with potential for more efficient spontaneous 
metastasis, Fidler performed further selection experiments showing increased invasiveness 
after serial passage and selection of B16F10 cells through mouse bladder membrane and 
created the B16-BL6 subclone.284,285 In these experiments, mice injected with B16F10 cells 
that had been selected for invasiveness through the mouse bladder (B16-BL6) had evidence 
of spontaneous metastasis at 4 weeks in 6/8 (75%) animals injected in the pinna whereas 
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only 3/9 (33%) of the non-selected, B16F10-engrafted animals had evidence of 
spontaneous metastasis. Fidler went on to do extensive work showing that the B16 
subclones could be selected for tissue specific metastatic tropisms based on serial passage 
within the desired tissue.286 Fidler and Nicholson alluded to unpublished observations that 
prolonged maintenance in vitro under non-selecting conditions could dampen the 
differences in metastatic capabilities of the B16 subclones and suggested that early passage 
cells or re-selection in vivo may be necessary to achieve the desired metastatic effect.  
According to recent literature, the B16 melanoma line does not typically form 
spontaneous metastases after subcutaneous implantation.287 To simulate pulmonary 
metastasis with this model, B16F10 cells are injected into the tail vein in an acute 
experimental metastasis model as mentioned previously.283 Loss of the metastatic 
phenotype may be related to years of maintenance in vitro as alluded to by Fidler and 
Nicholson and could perhaps be enhanced by an in vivo selection step.   Additionally, 
changes in the inoculation site can often alter growth characteristics.288-290 Original 
experiments described by Fidler largely involved injecting B16 cells into the pinna or the 
footpad. However, engraftment into the footpad often requires limb amputation and is 
losing favor for humane considerations, not to mention technical complications.288,291,292 
Currently, most cancer researchers engraft B16 cells in the subcutis in the interscapular 
area or flank as is done for many transplantable models.Engraftment of B16F10 cells in 
that region results in marked variation in tumor morphology and growth and can therefore 
be challenging to measure for assessment of a therapeutic response; additionally, 
spontaneous metastasis from this site is not typical.    
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B16F10 cells have homologs of the human melanoma differentiation antigens 
(MDA), gp100/pmel17, MART-1/Melan-A, tyrosinase, TRP-1/gp75, and TRP-2, and 
cytotoxic T cells can be generated against the antigens in both humans and mice.283 
Humans express variable MHC class I while B16F10 melanoma cells express very low 
levels and are considered poorly immunogenic overall.283 Therefore, the B16F10 murine 
melanoma model may be a good model for efficacy testing for human melanoma patients 

















CHAPTER III: CHARACTERIZATION OF FACTORS AFFECTING 
GROWTH KINETICS AND SPONTANEOUS METASTASIS IN THE 
B16F10 SYNGENEIC MURINE MELANOMA MODEL 
 
Introduction 
Melanoma is the sixth most common type of cancer overall in humans and incidence has 
been increasing yearly in the U.S. for the last 30 years. When diagnosed at an early stage, 
patients may be cured via surgical excision of the tumor and can expect 5-year survival rates as 
high as 97%. However, at least 13% of melanoma patients already have metastasis to regional or 
distant sites by the time they are diagnosed with the disease. The most common first site of 
melanoma metastasis is the sentinel lymph node (SLN) and it has been shown in numerous 
studies that status of the SLN reflects that of the entire topography of regional lymph nodes. 293-
296  
Metastasis is a significant problem in the treatment of cancer, accounting for greater than 
90% of cancer-related deaths in people.297 Treatment options for metastatic melanoma in human 
patients have been particularly limited because metastatic melanoma is resistant to most 
traditional cancer therapies. Efforts to improve efficacy of novel treatment strategies while 
minimizing the incidence of adverse events are ongoing in clinical trials. In many cases these 
trials are occurring in advance of the preclinical studies that are intended to support them. 260   In 
other instances, preclinical studies were performed and showed promising results in the 
laboratory, but therapeutic benefit failed to translate to human clinical trials. Lack of appropriate 





The metastatic behavior of melanoma is a specific challenge in murine tumor modeling. 
Typically, an experimental metastasis model involves direct injection of neoplastic cells into the 
bloodstream, most commonly into the tail vein of mice. Pulmonary nodules resulting from 
intravenous injection are frequently referred to as “metastases”; however, intravenous injection 
represents production of a multitude of de novo tumors, since key steps in the metastatic cascade, 
such as invasion into the tissue, detachment, and migration into the vasculature (intravasation), 
are completely bypassed.283 In contrast, spontaneously metastasizing models allow the entire 
metastatic cascade to be modeled from invasion to colonization of distant sites.299  Additionally, 
spontaneously metastasizing models allow meaningful comparison of differences in protein or 
gene expression and/or immune cell infiltration between primary and metastatic lesions. 
The B16 cell line is the most widely used line for melanoma research due to its 
aggressive growth, and it remains the standard in the field for development of immunotherapies 
for melanoma. 282,283 Nonetheless, the B16 melanoma line does not typically form spontaneous 
metastases after subcutaneous implantation. 287 To simulate pulmonary metastasis with this 
model, B16F10 cells are typically injected into the tail vein in an acute experimental metastasis 
model as mentioned previously.283 Loss of the metastatic phenotype may in part be related to 
years of maintenance in vitro. 285 Additionally, changes in the inoculation site can often alter 
tumor growth characteristics. 288-290 Protocols that establish consistent growth and predictable, 
spontaneous metastasis in robust murine tumor models are therefore greatly needed in cancer 
drug development for early preclinical studies. Herein, we describe a C57BL/6/B16F10 mouse 
melanoma protocol that allows for the development of similar size B16F10 tumors on mouse 
pinna after initial engraftment in mouse interscapular or flank areas. This model allows for the 
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development of sizeable tumors within 2-3 weeks and efficient metastasis to regional lymph 
nodes.  
Materials and Methods 
Animals. Six to eight-week-old, C57BL/6J female mice were purchased from Jackson 
Laboratory (Bar Harbor, Maine). Animals were acclimated for at least three days prior to 
experimental use. Mice were identified using ear tags in the right pinna. Animals were housed 
under standard conditions with no more than five per cage. All procedures were approved by the 
Louisiana State University Institutional Animal Care and Use Committee and followed 
applicable governmental policies and regulations.   
Cell Culture Propagation. B16F10 murine melanoma cells were obtained from ATCC, 
maintained under sterile conditions at 37°C with 5% CO2, and propagated as adherent 
monolayers in T75 flasks containing Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% filtered, heat inactivated fetal bovine serum (FBS) and 100 µg/ml  
Primocin. Prior to use, cells were trypsinized, centrifuged, counted using a hemocytometer, and 
resuspended to the desired concentration in sterile phosphate-buffered saline. Trypan blue 
exclusion was performed to evaluate cell viability during counting; cell viability was at least 
90% for all experiments.   
In Vivo Propagation. Three C57BL/6 female mice were injected with 2 x 106 early 
passage B16F10 cells suspended in 100 µl of PBS in the interscapular subcutis after shaving and 
disinfection of the skin with a 70% isopropyl alcohol-soaked gauze. A 1 ml syringe with a 27 
gauge needle was used for injections. Subcutaneous engraftment occurred while animals were 
anesthetized with 2-3% isoflurane. At 10-14 days, mice were euthanized and tumors , which 
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measured 1-1.5 cm in diameter, were processed for pinna engraftment in additional mice. 
Tumors were isolated, placed in a sterile petri dish, minced with a scalpel blade, and placed in an 
incubator at37°C with 5% CO2 with 3 ml of trypsin for approximately 20 minutes. Cells were 
strained through a 40 µm strainer and complete DMEM with 100 µg/ml of Primocin was added 
before counting with a hemocytometer and evaluating for viability using trypan blue exclusion; 
cell viability was 90% or greater for experiments. Cells were centrifuged and resuspended in 
PBS at concentrations of 2 x 106 and 4 x 106 cells/milliliter and placed on ice for transportation 
and pinna engraftment within 1 hour of harvesting.  
Pinna Engraftment. Mice were anesthetized with 2-3% isoflurane and B16F10 cells 
were engrafted orthotopically in the dermis of the dorsal left dorsal pinna after disinfection of the 
skin with 70% isopropyl alcohol; a 1 ml syringe with a 27 gauge needle was used for injections. 
Five female C57BL/6J mice were engrafted with 4 x 105 early passage B16F10 cells propagated 
in cell culture as described. Seventeen mice were engrafted with 4 x 105 in 100 µl of sterile PBS 
and 12 mice were engrafted with 2 x 105 in 100 µl of sterile PBS. Tumors were measured 
approximately every 7-10 days using digital microcalipers and tumor volumes were calculated 
using the formula, π/6 x L x W x H. Tumors were allowed to grow between approximately 500-
1000 mm3, or until tumors began to ulcerate.   
Histology. After euthanasia, all mice underwent complete, routine postmortem 
examination. Tumors were measured and evidence of metastasis was recorded. Tissues were 
collected, fixed in 10% neutral buffered formalin, processed routinely, paraffin-embedded, 




Statistical Analysis. Statistical analyses were performed using GraphPad Prism 7.03. P 
values <0.05 were considered significant. Differences in survival times were evaluated by 
generating a Kaplan-Meier survival curve and significance determined using log-rank test. 
Sigmoidal and exponential growth models were fitted using nonlinear comparison of fits and 
Akaike’s information criteria (AIC); 95% confidence intervals of the fitted curves were graphed. 
Unpaired t tests (parametric, two-tailed) were used to compare the high and low cell density 
engraftment groups; F test was used to determine variance.  
Results 
In Vivo Characterization Of In Vitro-Propagated B16F10 Growth and Metastasis.  
Original experiments described by Fidler largely involved injecting B16 cells into the pinna or the 
footpad. Currently, most cancer researchers engraft B16 cells in the subcutis in the interscapular 
area or flank,283,287 as is done for many transplantable models. In our experience with the B16F10 
model, engraftment in this location results in marked variability in growth and morphology (Figure 
3.1); additionally, spontaneous metastasis is not typical.  
We aimed to characterize the in vivo growth kinetics of early passage B16F10 cells. Five 
mice were engrafted with 4 x 105 B16F10 murine melanoma cells in the pinna after propagation 
in cell culture (Figure 3.2). Growth varied markedly between the mice and was generally saltatory. 
One out of the five mice (20%) did not develop a tumor over four weeks. One animal had markedly 
delayed tumor development and did not develop a visible tumor until week 4. Of the four animals 
that developed tumors, tumor size at 3-4 weeks varied markedly with the smallest and largest 
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tumors differing by almost 1,000-fold. The marked variability in growth kinetics prevented the 
ability to fit the data to either exponential or sigmoidal mathematical growth models. 
Only one animal (25%) showed evidence of spontaneous metastasis at postmortem 
examination, which was to the lungs; none of the animals had metastasis to the sentinel lymph 
node. Marked variability of growth rates and lag times would make tumor growth synchronization 
challenging for high through-put expanded study, and the paucity of spontaneous metastases could 
also be a challenge for researchers wishing to test therapeutic efficacy in treating metastatic 
disease.  
 
Figure 3.1. (A) Schematic demonstrating typical engraftment protocol from cell culture into 
the interscapular region in the B16F10 murine melanoma model.  (B) Subcutaneous B16F10 
melanoma tumors in the interscapular region at 2 weeks post-engraftment. Engraftment of 






In Vivo Characterization Of In Vivo-Propagated B16F10 Growth and Metastasis. 
Tumor cells are influenced by strong selection pressure in the tumor microenvironment.300 
Bobek et al. described a protocol that involved a period of in vivo growth in the subcutis before 
engraftment in the pinna and reported spontaneous metastasis using their protocol. 301,302 
Therefore, we engrafted B16F10 cells in the interscapular subcutis, harvested the tumor, created a 
single-cell suspension and resuspended in PBS before engrafting 17 animals with 4 x 105 in vivo-
propagated cells in the left pinna (Figure 3.3).  
All 17 animals (100%) developed a tumor. Tumor growth was generally rapid and a 
measurable tumor was present within 7-8 days for most animals. Mice required euthanasia 
between 13 and 18 days after engraftment, with the median survival time being 15 days. 
Evaluation of tumor volumes over time and interpolation of a standard curve showed that 
 
Figure 3.2. Schematic demonstrating engraftment of B16F10 from cell culture (in vitro) into 
the pinnae of C57BL/6J mice. Mice were engrafted with 4 x 105 B16F10 cells after propagation 




the growth pattern was exponential; in a nonlinear comparison of goodness of fit test, the Akaike 
Information Criterion (AIC) probability that the exponential model was correct was 89.91% versus 
10.09% for the sigmoidal model. Additionally, at necropsy, 9/17 mice had lymph node metastases 
(53%), and 2 of 17 (12%) also developed lung metastasis, a marked improvement over engraftment 
directly from cell culture.  
 
 
Figure 3.3 Schematic demonstrating protocol for subcutaneous in vivo propagation and 
transplantation to pinnae of C57BL/6 mice. Mice were engrafted with 4 x 105 or 2 x 105 B16F10 
cells to evaluate the effect of cell density of the inoculum at engraftment on tumor growth and 




Based on the findings of Gregorio et al., who showed that the density of the cell inoculum 
affected frequency of spontaneous metastasis in a murine breast cancer model using 4T1 cells, 267 
we tested whether a lower number of inoculated B16F10 cells may increase metastasis. Therefore, 
we followed a similar pre-engraftment in vivo propagation protocol as before except that we 
engrafted animals with approximately 2 x 105 cells in the left pinna as compared to the 4 x 105 
cells engrafted in the previously described experiment. Of the twelve mice used in this experiment, 
one animal died unexpectedly shortly after engraftment and was therefore excluded from the 
analysis. Ten of the 11 remaining mice developed tumors at the site of engraftment  (10/11 or 91% 
engraftment efficiency), and the tumor morphology was remarkably uniform among most mice at 
3  and 4 weeks (Figure 3.4, Table 3.1). The time to development of a clearly visible and measurable 
melanoma tumor was three weeks.  
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ap<0.0001 (unpaired t test, parametric, two-tailed) 
bp=0.0026 (F test to compare variances) 
cp<0.0001 (unpaired t test, parametric, two-tailed) 




All 10 animals who were successfully engrafted with the lower density inoculum had gross 
and/or microscopic evidence of spontaneous metastasis to either lymph node or lung, but 
metastasis was primarily limited to the ipsilateral sentinel lymph node (mandibular lymph node) 
for most animals (Figure 3.5). Euthanasia was necessary between 21-32 days post-engraftment, 
averaging 27 days. Three animals were necropsied at 21 days (3 weeks) and 2 of these 3 or 67% 
animals had evidence of spontaneous metastasis to the ipsilateral regional (mandibular) lymph 
node at necropsy. The third mouse had micrometastasis to the lungs (33%), but lymph node 
metastasis was not identified in that mouse. At 28-32 days (4-4.5 weeks), 7/7 (100%) of the 
animals necropsied had metastasis to the ipsilateral mandibular lymph node and one of these (14%) 
also had micrometastasis to the lungs.  
Figure 3.4. C57BL/6J mice engrafted with 2 x 10^5 B16F10 cells intradermally in the pinna at 
3 weeks (top) and 4 weeks at the time of euthanasia (bottom). Tumor morphology and growth 


















Figure 3.5 Metastasis in high and low cell density engrafted mice.(A) Tumor 
growth of high (circles) and low (squares) cell density engraftments over time; 
symbols colored red indicate metastasis was detected. (B) Sentinel lymph node 
metastasis in a low cell density-engrafted mouse. (C) Photomicrograph of sentinel 
lymph node metastasis (asterisk); H&E 10x. (D). Focal area of lung metastasis in 
the left lung lobe of a low cell density engrafted mouse.(E) Photomicrograph of 




Plotting of survival times in a Kaplan Meier survival curve showed that mice engrafted 
with a lower cell density survived significantly longer (Log-rank p<0.0001) (Figure 3.6). While 
animals did experience an exponential growth phase, when interpolated to a standard curve, the 
growth pattern using the lower cell density was a better fit for a sigmoidal model; in a nonlinear 
comparison of goodness of fit test, the AIC probability that the sigmoidal model was correct was 
87.91% versus 12.09% for the exponential model in contrast to the high cell density engrafted 
group (Figure 3.7, Table 3.2).  These findings suggest that the improved metastatic efficiency may 
be related to increased survival times. The increase in survival time appears to be a function of 
increased lag time. The differences in lag time were significant between the two groups, while the 
duration of disease once tumors became apparent did not vary significantly, regardless of the cell 




Figure 3.6. Kaplan Meier Survival Curves Comparing Overall Survival of Mice Engrafted 
with 4 x 105 versus 2 x 105 cells. Overall survival times are increased in mice inoculated with 




Table 3.2. Fitting Parameters of In Vivo  Growth of B16F10 Cells at Different Cell Densities 
No. B16F10 cells 
inoculated 




Doubling time ± 
SEM (d) 
Specific Growth Rate 
(SGR) ± SEM 
(% Δ/d) 
4 x 105  
 
Exponential 89.91% 1.727±0.06227 0.4311±.09705 
2 x 105  
 
Sigmoidal 87.91% 2.456±0.4129 0.4043±.01395 
 
Discussion 
We report here the optimization of a syngeneic mouse model system for melanoma, that 
allows for relatively uniform growth of tumors and efficient metastasis to regional lymph nodes. 
This model depends on the in vivo growth of B16F10 cells in the subcutis of mice prior to pinna 
engraftment, which improves tumor growth synchronization and enhances spontaneous metastasis 
Figure 3.6. Kaplan Meier Survival Curves Comparing Overall Survival of Mice Engrafted 
with 4 x 105 versus 2 x 105 cells. Overall survival times are increased in mice inoculated with 
a lower cell density at engraftment, an effect of protracted lag times in tumor development. 
Log-rank p=<0.0001. 
Figure 3.7. Fitting in vivo growth of high and low cell density inoculum engraftment of 
B16F10 cells to mathematical growth models. (A)Composite of the tumor growth curves. (B) 
Sigmoidal and exponential growth models were fitted using nonlinear comparison of fits and 
Akaike’s information criteria (AIC) for mice engrafted with 4 x 105 cells (B) and 2 x 105 cells 
(C). The red line represents the interpolated line generated by the data. The black line 
represents the best fit curve. Dotted lines designate the 95% confidence interval of the fitted 
curve. Solid points represent the mean tumor volume with SEM bars. Specific growth rates 
were calculated using the formula, ln(v2/v1)/t2-t1 , and doubling times were calculated using 
the formula, ln2/SGR . 
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of B16F10 murine melanoma. In addition, a cell density of 2 x 105 cells at the time of the pinna 
engraftment increased lag times and enhanced metastatic efficiency.  
It is generally accepted that the ideal tumor model system would exhibit predictable gross 
morphology, growth, and metastatic behavior. 291,292 Prediction of the time of onset and incidence 
or engraftment rate are also critical for robust, preclinical testing in its early stages. 260  
Synchronization of tumor development is currently best achievable using transplantable models 
and the protocol described herein resulted in reasonable engraftment efficiency and 
synchronization in growth after a period of in vivo propagation in the subcutis. A relatively high 
degree of uniformity in morphology, growth, and spontaneous metastasis was achievable with the 
B16F10 murine melanoma model described here. Uniform tumor morphology may be partially 
related to the engraftment site chosen. Tumor cells are less mobile when injected into the small 
potential space of the pinna dermis as compared to the loose interscapular subcutis, and may 
therefore result in more consistent tumor morphology.  The pinna has been reported as a 
permissible site for engraftment of a wide variety of tissue types 303 and engraftment in this location 
as opposed to the subcutaneous tissue may be one factor in supporting tumor growth and 
potentiating spontaneous metastasis. The mouse pinna is an area with a rich vascular bed. 
Recruitment of tumor-associated vasculature is important for tumor engraftment success and 
growth. Additionally, the rich lymphatic supply in this region allows for easy access of neoplastic 
cells to lymphatic vessels, which could enhance metastatic capabilities to sentinel lymph nodes 
(“anatomical/mechanical” metastasis hypothesis). Spontaneous metastasis after pinna engraftment 
has been reported in a variety of tumor modeling protocols including Lewis lung carcinoma and 
melanoma 301,302,304,305. Additionally, from a practical standpoint, monitoring of tumor growth is 
easier in the poorly haired area of the mouse pinna than in the heavily haired areas on the trunk. 
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Engraftment in the poorly haired area of the pinna obviates the need for the extensive or frequent 
shaving necessary for monitoring tumor growth in the interscapular area or flank. All of these 
features make the mouse pinna a good site for successful tumor engraftment and sustained growth 
and spread of tumor cells in the B16F10 murine melanoma model.   
In the ideal tumor model system, tumor behavior, including metastasis, should also 
simulate natural progression of the disease as is seen in humans. Intradermal orthotopic injection 
in the pinna more accurately mimics natural progression than injection directly into subcutaneous 
fat, since tumor cells grow from the dermis into the subcutis as tumors become more invasive in 
human patients. The period of in vivo growth prior to transplantation to the dermis of experimental 
subjects may enhance local invasiveness of the tumor cells from the dermis to the subcutis and 
ultimately spread to lymph nodes since tumor microenvironment can influence metastatic behavior 
(“seed and soil” metastasis hypothesis). We observed that decreasing the density of the cell 
inoculum at engraftment increases the lag time to tumor development and overall survival times 
allowing sufficient time for highly predictable, spontaneous sentinel lymph node metastasis to 
occur. In most mice, metastasis to the sentinel lymph node was obvious at postmortem 
examination. Metastasis to the sentinel lymph nodes, which is the most common first site of 
metastasis in humans and predictive of the entire topography of regional lymph nodes, accurately 
and predictably models tumor behavior in melanoma patients with stage III disease.  
Interestingly, a two-fold lower cell density produced significantly higher levels of 
spontaneous metastasis in agreement with the findings of Gregorio et al. who described effects of 
inoculated cell density as a factor in growth dynamics and metastatic efficiency in a syngeneic 
breast cancer murine model.267 It may be that the general principle of decreasing cell density to 
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enhance predictable growth and spontaneous metastasis is applicable to a wide range of 
transplantable syngeneic models.  
Overall, tumor growth was much more predictable and uniform after cells were grown in 
the subcutis of a mouse before engraftment into the pinnae of other mice and growth data could be 
interpolated to a standard curve, unlike mice engrafted with in vitro propagated tumor cells. Under 
natural conditions, tumor growth in individuals is often observed to be saltatory, 306,307 but 
asynchronization can cause significant challenges in tumor modeling and in interpreting response 
to treatment in efficacy studies involving mice.  There are two commonly argued explanations for 
variations in growth observed in individuals over time, with neither hypothesis necessarily being 
mutually exclusive. One is that waves of angiogenesis and tumor infarction and necrosis cause 
alternating periods of adequate delivery of oxygen and nutrients followed by periods of oxygen 
and nutrient deprivation resulting in undulating variation in tumor growth capacity over time 307. 
The other hypothesis is that selection pressure results in the generation of mutated cells with 
inherently improved ability to adapt to the microenvironment and enhanced proliferative capacity; 
the mutant cancer cells can arise at varying times resulting in marked variation in tumor growth 
and growth rates even under experimental conditions.307 Our findings are highly supportive of the 
latter hypothesis in particular. A period of pre-engraftment in vivo selection may help to “pre-
select” for cells that are most able to adapt to the harsh conditions of the tumor microenvironment 
and result in more predictable growth in experimental subjects.   
Improved use of existing models will contribute to improved concordance of animal studies 
and human patient outcomes at clinical trial. Detailed analysis and characterization of factors that 
affect growth kinetics and metastatic phenotype in the B16F10 murine melanoma model will aid 
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in most efficient use of this model system. It is likely that the principles discussed herein may also 
be relevant for other transplantable tumor models and may have wide applicability in tumor 
























CHAPTER IV: DEVELOPMENT OF A SYNGENEIC 
IMMUNOCOMPETENT BIOLUMINESCENT AND FLUORESCENT 
MURINE MELANOMA MODEL FOR TESTING 
IMMUNOMODULATORY AND ONCOLYTIC HERPES SIMPLEX 
VIRUS-1 USING THE HIGHLY IMMUNOGENIC HSV-1 LIVE-
ATTENUATED VACCINE VC2 
 
Introduction 
Viruses that preferentially lyse cancer cells are described as being “oncolytic” or tumor-
lysing. Many different viruses have been tested as potential therapy for cancer in the last century, 
beginning as early as 1910, when a live-attenuated Rabies vaccine was observed to result in 
regression of cervical cancer in a patient.79 The field has expanded to include many different 
viruses and has become increasingly sophisticated as molecular tools to create purposeful viral 
genetic mutations that enhance cancer-killing abilities and safety have become more widely 
available.  Some viruses have a natural lytic phase in their life cycle and have a natural affinity for 
rapidly dividing cells (e.g. alpha-herpesviruses and parvoviruses).  
Herpes Simplex Virus type-1 (HSV-1) has long been hailed as a promising virus for the 
development of oncolytic virotherapy. The reasons cited are many. HSV-1 has a large genome 
with a number of non-essential genes that can be deleted to reduce pathogenicity or to insert 
therapeutic transgenes. Additionally, antiviral drugs exist that can control acute infection in the 
event of viral dissemination and/or adverse events.  In the 1990’s, the prospect of using viruses to 
treat tumors using an attenuated TK-negative HSV mutant showed promise in treating gliomas in 
a xenogeneic mouse model after intratumoral injection.127 Twenty-five years later, the first ever 
oncolytic virotherapy was approved by the FDA for the treatment of metastatic melanoma in 
people, a mutated HSV-1 virus referred to as Talimogene Laherperavec (T-VEC) or Imlygic. T-
VEC is a mutated oncolytic HSV-1 based virus with mutations in infectious cell protein (ICP) 34.5 
87 
 
and ICP47, while expressing US11 and human granulocyte macrophage-colony stimulating factor 
(GM-CSF). Viral expression of human GM-CSF was intended to improve antitumor immune 
responses and has demonstrated efficacy in some murine tumor models.207 Tumor growth 
inhibition and/or regression was observed in xenogeneic mouse models and in the syngeneic A20 
B cell lymphoma model. While the aforementioned preclinical studies showed impressive results 
in murine models, efficacy in human clinical trials has shown more variability with only a small 
subset of patients having durable responses. Further, adverse effects including herpetic oral 
lesions, viral dissemination, and herpetic keratitis have reportedly been associated with treatment 
in some patients. The reason that only a small subset of patients respond and yet others experience 
adverse effects is unknown, but more widely efficacious and safe treatment strategies are needed 
for melanoma patients.  
Some preclinical studies involving oncolytic HSV-1 mutants have shown that rapid 
infection and spread in vitro predicts better in vivo response; however, such studies have been most 
often performed in xenogeneic models and account only for direct lysis secondary to viral 
replication but do not account for host immune responses.117,118 The efficiency with which HSV-
1 infects, spreads, replicates and directly lyses cells may depend on both virus and host-specific 
factors. Viral factors include the presence or absence of ICP34.5, for example; in its absence, 
protein shutoff by the host is permanent and the virus fails to efficiently replicate, limiting spread 
and replicative lysis of the cell. This is a common deletion in oncolytic HSV-1 mutants tested in 
clinical trials since it is a neurovirulence factor and inhibits the virus’ ability to grow in non-
neoplastic cells; however, the reduced ability of the virus to replicate may also reduce potency in 
inducing anti-tumor effects.  Host factors may include the presence or absence of HSV-1 entry 
receptors such as nectin-1 and herpes virus entry mediator (HVEM). In fact, nectin-1 expression 
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has been identified as a marker of sensitivity to oncolytic HSV-1 in a xenogeneic squamous cell 
carcinoma mouse model; there was no correlation between therapeutic responses and HVEM 
expression in that study.308 It is difficult to know, however, if this result would translate to human 
patients with intact immune systems.  
There is disagreement among researchers working in oncolytic virotherapy development 
on the importance of tumor cell lysis versus stimulation of immune response by the virus. Some 
would argue that spread, persistence and continued replication within the tumor and/or 
microenvironment are less important than immunogenicity of the virus and the immune response 
in the early stages of viral infection.119 In fact, it has been reported that, regarding oncolytic HSV, 
in vitro cytotoxicity and viral persistence in vivo do not correlate with anti-tumor efficacy; it has 
instead been shown that expression of markers of immunogenic cell death, such as heatshock 
protein 70 and elevated levels of serum high mobility group box 1 (HMGB1), increased antigen 
presenting cells, and CD8+ T cell responses may be more likely associated with HSV-associated 
therapeutic benefits.119 
Based on these observations in the literature, which highlight the importance of 
immunogenicity over direct cytotoxicity in oncyolytic HSV-1 virotherapy, we aimed to test the 
ability of VC2, a highly immunogenic HSV-1 live-attenuated virus genetically engineered in our 
laboratory, to generate an anti-tumor response in absence of robust replicative cell lysis in the 
B16F10 syngeneic murine melanoma model, which shows little cytopathic effect after HSV-1 
infection due to a lack of nectin-1 entry receptors. We previously reported that a single, 
intramuscular vaccination with VC2 resulted in protective, strong cell-mediated and humoral 
immune responses against intravaginal lethal challenge with HSV-1 and HSV-2 in mice.210 We 
hypothesized that VC2 could have an adjuvant effect and generate a therapeutic immune response 
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in the TME in the poorly immunogenic B16F10 syngeneic murine melanoma model due to its 
marked immunogenicity. We also previously showed that VC2 replicates as efficiently as the 
parental F strain,but cannot enter ganglionic axons due to a specific mutation in UL20 and 
glycoprotein K (gK), which results in an inability to enter by fusion. (reference) This confers a 
significant safety advantage by preventing the establishment of latency, while still allowing 
efficient replication in permissible cells. As mentioned, oncolytic HSV-1 mutants developed for 
clinical trials typically include a deletion in late gene ɣ34.5 as a safety feature because of its 
association with neurovirulence, but this mutation significantly dampens viral replication, which 
may limit its therapeutic effect. VC2 overcomes this problem by allowing efficient replication in 
permissible cells without compromising overall safety.  
Safety and efficacy studies in immuno-oncology are generally performed in GEM or 
syngeneic models since an intact immune system is necessary for evaluating efficacy of immune-
stimulating therapeutics and for assessing for immunotoxic effects.259 We chose the syngeneic, 
immunocompetent B16F10 murine melanoma model over a xenogeneic model in order to evaluate 
immune response to VC2 virotherapy rather than direct cytotoxic/lytic effects of the virus. The 
B16F10 model is a notoriously difficult tumor model in which to elicit a therapeutic response due 
to its aggressively growing nature. Based on the lack of HSV-1 entry receptors and the known 
poor immunogenicity of the B16F10 cell line, we consider the syngeneic B16F10 murine 
melanoma model to be a good model for human melanoma patients that respond poorly to current 
oncolytic virotherapy and other immune modulating cancer therapies, who represent the majority 
of patients in clinical trials to date. These are the patients with the greatest need for more 




 We aimed to develop an immunocompetent murine melanoma model that allows sensitive 
observation of tumor growth during immunomodulatory therapy with the highly immunogenic 
HSV-1 vaccine strain developed in our laboratory, VC2. We developed a model that can detect 
acute responses using in vivo imaging with greater sensitivity than traditional microcaliper 
measurement by utilizing B16F10 cells expressing enhanced green fluorescent protein (eGFP) and 
firefly luciferase (fLuc) for advanced fluorescent microscopy and in vivo tumor monitoring 
capabilities (B16F10-fLuc-eGFP), respectively. This model system will be invaluable in 
evaluating acute response to treatment and testing dosing and combinatorial strategies with higher 
sensitivity and greater efficiency since responses to immune-stimulating anti-tumor therapies may 
be difficult to assess due to acute inflammation and swelling, referred to as “pseudoprogression”.  
Herein, we describe our modeling strategy and results of preliminary efficacy and safety 
testing of VC2 in a syngeneic, immunocompetent murine melanoma model. Due to potential 
advantages in replication and safety over the currently available oncolytic virotherapy, and due to 
the previously demonstrated remarkable immunogenicity of VC2, we hypothesized VC2 may have 
efficacy in inhibiting tumor growth and extending survival times in our double-labeled B16F10 
syngeneic murine melanoma model in absence of nectin-1 expression and direct, replicative cell 
lysis. The ability to exert anti-tumor effects in absence of nectin-1 expression could extend use of 
VC2 to a variety of tumor types regardless of receptor expression. We further aimed to characterize 
direct effects on tumor cell proliferation and immune cell infiltration in the tumor 
microenvironment (TME). Demonstration of the adjuvant effect of VC2 justifies its further 





Materials and Methods 
Cells. B16F10 cells (ATCC CRL-6475) transduced to express renhanced green fluorescent 
protein (eGFP) and firefly luciferase (fLuc), using lentiviral particles LV-Fluc-P2A-Neo (LV011) 
and LV-eGFP-PGK-Puro (LV031) (B16F10-Fluc-Neo/eGFP-Puro, Imanis Life Sciences, CL068) 
were utilized in all experiments. B16F10-fLuc-eGFP murine melanoma cells were maintained 
under sterile conditions at 37°C with 5% CO2, and propagated as adherent monolayers in T75 
flasks containing Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% filtered, 
heat inactivated fetal bovine serum (FBS) and 100 µg/ml Primocin. Prior to use, cells were 
trypsinized, centrifuged, counted using a hemocytometer, and resuspended to the desired 
concentration in sterile phosphate-buffered saline. Trypan blue exclusion assay was performed to 
evaluate cell viability during counting; cell viability was at least 90% for all experiments.   
Human Nectin-1 Stable Transduction. In order to confirm that the lack of cytolysis was 
due to an entry receptor deficiency in B16F10 cells and not a defect in another segment of the 
replication cycle, we created a stably transduced B16F10-fLuc-eGFP cell line expressing human 
nectin-1 using a third-generation lentiviral particle packaged vector we designed which was 
produced by Vector Builder (Cyagen). Nectin-1 was tagged with the red fluorescent protein 
mCherry at the C-terminus via fusion and expression was under control of CMV promoter. 
Hygromycin resistance under PGK promoter was used for selection. Prior to creating the stable 
cell line expressing nectin-1, a hygromycin kill curve was generated. B16F10-fLuc-eGFP cells 
were plated in 0.5 ml complete growth medium on a 24-well plate, 24 hours prior to administering 
antibiotic when cells were approximately 80% confluent. Hygromycin was applied at 
concentrations of 0-1,000 µg/ml in duplicate wells and media with antibiotic was changed every 
48 hours. Percent of cells killed was evaluated microscopically every 24 hours for 6 days. Cells 
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were highly sensitivity to hygromycin toxicity; 50 µg/ml was determined to be the optimal dose 
since 100% of cells died over the course of 6 days. For stable transfection, a 12-well plate was 
seeded with 50,000 B16F10-fLuc-eGFP cells per well in complete medium. Cell were inoculated 
with lentiviral particles at MOI of 1, 2, 5, and 10 in 3 wells each. Cells were observed once per 
day for 48 hours and red fluorescence was observed. Hygromycin at high (100 µg/ml) and optimal 
(50 µg/ml) concentrations was applied to one well at each lentiviral concentration with one well 
each receiving 0 µg/ml as a control. Media/antibiotic solution was changed every two days until 
only hygromycin resistant, red fluorescent cells remained. Cells were expanded and frozen at -
80°C until utilized in experiments.  
In Vitro Growth Curve B16F10 and B16F10-fLuc-eGFP. Prior to engraftment in mice, 
in vitro growth was evaluated to compare inherent proliferative capacity of B16F10-eGFP-fLuc 
cells to the parent B16F10 cell line. Cells were seeded at a density of 20,000/well in three 6-well 
plates. Cells from three wells were collected and counted using a hemocytometer once every 24 
hours for 5 days. A growth curve was similarly generated to compare B16F10-fLuc-eGFP and 
B16F10-fLuc-eGFP-nectin-1 but the initial seeding cell density was 50,000 cells/well.  
VC2 Viral Stock Preparation. VC2 stocks were prepared in baby hamster kidney (BHK) 
cells. T-150 flasks inoculated with virus were maintained under sterile conditions at 37°C with 5% 
CO2 for 24-48 hours until cells were rounded up but still adherent. Cells were scraped using a cell 
scraper and flask contents including cells and spent media were poured into 50 ml tubes. Tubes 
were centrifuged at 3,000 rpm, supernatant decanted, pellet submerged in liquid nitrogen until 
frozen, thawed in a 36°C warm water bath, and resuspended in 2 ml of supernatant. Centrifuge and 
freeze-thaw cycles were repeated 2 more times to free intracellular virions. The pellet was 
discarded and the viral stock solution was ultracentrifuged using at 27,000 rpm for 2 hours until a 
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viral pellet was visible. Viral pellet was resuspended in 1 ml of sterile PBS. Concentrated viral 
stock was titrated on African green monkey kidney (vero) cells; titer was determined to be 109 
plaque forming units (PFU)/ml. Stock was aliquoted into individual doses of 106  PFU in 100 ul of 
PBS in Eppendorf tubes and stored at -80°C.  
Tumor Induction and Monitoring. Twenty, 6 to 8-week-old, female C57BL/6J mice 
were anesthetized with 2-3% isoflurane and engrafted with 6 x 105 B16F10-fLuc-eGFP cells 
suspended in 100 µL of sterile PBS intradermally in the pinna with a 27 gauge needle on a 1 mL 
syringe after disinfection with 70% isopropyl alcohol. A subset of mice were evaluated via in vivo 
imaging at multiple points during the week of VC2 or mock treatment in order to compare 
bioluminescence to tumor volumes during assessment of acute response at days 0, 2, and 8 post-
treatment. Tumors were imaged using a Spectra Ami In Vivo Imaging System (IVIS) 10 minutes 
after intraperitoneal injection of 100 µl of d-luciferin potassium (Biogold).  Tumors were 
additionally measured every other day using digital microcalipers; volumes were calculated using 
the formula for an ellipsoid (V= (π/6) x L x W x H). Mice were euthanized when tumors averaged 
500 mm3. Tumor specific growth rates (SGR) were calculated as the percent change in tumor 
volume per day from two measured time points (SGR=ln(V2/V1)/(t2-t1)). At necropsy, tumors were 
removed with the pinna and weighed using a digital gram scale. Tumor volumes were compared 
statistically between the control and treatment groups at the time treatment was initiated and at the 
time of euthanasia for experimental validation; there was no significant difference in tumor 
volumes or variance in the control and treatment groups at the time treatment or mock-treatment 
was initiated (student’s t test, unpaired, two-tailed P=0.6457; F test, P=0.4727) or at the time of 




Intratumoral Injections. VC2 was delivered intratumorally in up to 4 doses of 106 PFU 
in volumes of 100 µl when tumors averaged 100 mm3. All procedures were approved by the 
Louisiana State University Institutional Animal Care and Use Committee. 
Histopathology. Tumors and additional tissues (liver, spleen, lung, kidney, brain, thymus) 
were fixed in 10% neutral buffered formalin, paraffin embedded, sectioned at 4 µm with a 
microtome, mounted on glass slides, and stained routinely with hematoxylin and eosin (H&E). 
Slides were evaluated by a board-certified veterinary pathologist.   
Digital Image Analysis of Oncolysis. Whole slides containing H&E-stained sections of 
tumor were digitally scanned using a Hamamatsu Nanozoomer slide scanner. To objectively 
evaluate and compare the amount of tumor lysis in VC2-treated and control tumors, Nanozoomer 
viewing software was used to measure the area (mm2) of tumor and the area of necrosis and results 
were expressed as % necrosis within histologic section (necrosis mm2/tumor mm2 x 100%). 
Measurements were made at 1x magnification. 
Immunohistochemistry and Semiquantification. Immunohistochemistry was 
performed using a Dako Autostainer Link 48 (Serial No. AS2012D1105). Slides were preheated 
for 40 seconds in citrate buffer pH 6.0 in a coplin jar and then microwaved in a PELCO 3450, 
Laboratory Microwave Processor (Ted Pella Inc., Cat. No. 3450) for 10 minutes in citrate buffer 
at 92°C using standard heat-induced epitope retrieval (HIER) protocol. For blocking, slides were 
incubated in normal goat serum (Vector Laboratories, S-1000) diluted 1:50 in Tris-buffered 
saline-tween (TwBS) for 10 minutes. Endogenenous enzyme blocking was performed using 3% 
hydrogen peroxide for a 10-minute incubation period. Primary antibodies were diluted in Dako 
Antibody Diluent (Ref.S0809) and applied to tissues for 1 hour. Biotinylated goat α-rabbit IgG 
antibody (Vector BA-1000) diluted 1:200 in TwPBS was applied for 30 minutes. ImmPACT 
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Nova Red, Peroxidase substrate kit (Vector Laboratories, SK-4805) was applied to the tissues for 
8 minutes for the horseradish peroxidase reaction. Counterstain was with normal strength 
hematoxylin (ANATECH LTD., Ref. 812) for 8 minutes. After counterstaining, slides were 
cover slipped and examined by a board-certified veterinary pathologist.    
Ki-67 Proliferation Index. Immunohistochemistry for Ki-67 was performed to 
compare number of active cycling tumor cells in VC2-treated versus mock-treated 
groups. Polyclonal rabbit α-Ki-67 antibody (Abcam; ab15580) diluted 1:500.   Within a 
40x high power field (HPF), 100 cells were designated as either positive or negative for 
nuclear immunoreactivity for Ki-67; counting was done using digitally scanned virtual 
slides and cells were marked with a circle when counted so as not to count any cell more 
than once in the analysis. Ki-67 proliferation index was expressed as a percentage of 
positive cells (number of positive cells/100 x 100%). 
Immune Infiltration. Immunohistochemistry was performed as described above 
for CD3, IBA-1, and arginase-1. Polyclonal rabbit α-CD3 antibody (Dako, Cat. No. 
A0452) was used at a dilution of 1:300, polyclonal rabbit α-IBA-1 (Wako Pure Chemical 
Industries, Ltd., Code No. 019-19741) at 1:500, and polyclonal rabbit α-arg-1 (Novus 
Biologicals (NBP1-32731) at 1:1200. Slides were evaluated by a board-certified 
veterinary pathologist and semiquantification was performed; areas of infiltration at the 
tumor-stroma interface were evaluated, and immunoreactive cells were counted in ten 
40x high power fields and recorded. 
Microvascular Density (MVD). Immunohistochemistry using a polyclonal rabbit 
α-CD31 antibody (Abcam, ab124432) diluted 1:1000 was performed as described to 
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highlight vascular profiles within the tumor. MVD was determined by counting vascular 
profiles in a 20x field (Weidner’s method).  
HSV-1 Immunoreactivity. Immunohistochemistry using a polyclonal rabbit α-
HSV-1 antibody (Dako, Cat. No. B0114) diluted 1:1000 was performed in order to detect 
virus within a treated tumor at 6 days post infection.  
Safety Assessments. Mice were observed and body weight recorded daily. Body 
temperature was also assessed daily using IPT-300 temperature sensing transponders implanted 
subcutaneously in the subcutis of the interscapular area. Necropsy was performed and vital 
organs (liver, spleen, lung, kidneys) weighed. Tissues were collected, fixed in 10% neutral 
buffered formalin, processed routinely, paraffin-embedded, sectioned at 4 µm with a microtome, 
and stained with hematoxylin and eosin (H&E) as previously mentioned. 
Results 
In Vitro Growth Curve B16F10 and B16F10-fLuc-eGFP.Prior to engraftment in mice, 
in vitro growth was evaluated to compare proliferative capacity of B16F10-eGFP-fLuc cells to the 
parent B16F10 cell line. Cells were seeded at a density of 20,000/well in three 6-well plates. Cells 
from three wells were collected and counted using a hemocytometer once every 24 hours for 5 
days. There was no significant difference in growth between B16F10-fLuc-eGFP cells and the 
B16F10 parent line (Fig. 1). Growth pattern best fit an exponential growth curve for both B16F10 













In Vitro Luciferase Assay. B16F10-fLuc-eGFP cells were titrated on a 96-well plate and 
evaluated using the Spectra Ami imaging system within 10 minutes of applying luciferin 
substrate. There was strong correlation between the number of cells inoculated per well and 
photon emission in vitro (Fig. 2)  (Pearson r=0.9966; P<0.0001****). 
In Vivo Luciferase Assay. In order to determine whether luciferase expression correlated 
with cell number in vivo, mice were engrafted with 2 x 105 or 6 x 105 cells in each pinna (Figure 
4.3). Mice were imaged within an hour of engraftment approximately 10 minutes after 
intraperitoneal administration of luciferin. Significant correlation between the number of cells 




Figure 4.1. B16F10 v. B16F10-fLuc-eGFP In Vitro Growth Curve. No significant differences 
in growth were observed in vitro between B16F10-fLuc-eGFP (blue) and B16F10 (black). 


























Figure 4.2. In Vitro Luciferase Assay. Photon emission significantly, positively correlates with 
cell number in vitro.  
 
Figure 4.3.  In Vivo Luciferase Assay. 
There was significant correlation with 
engrafted number of cells and photon 
emission in vivo (P=0.0007). Increasing the 
engraftment cell density from 2 x 105 to 6 x 
105 resulted in a significant increase in 
photon emission (P=0.0007). More 
variation resulted when a higher number of 




Engraftment technique was evaluated statistically using an unpaired, two-tailed student’s t 
test. As would be expected, photon emission was significantly higher in mice engrafted with 6 x 
105 cells versus 2 x 105 cells (P=0.0007***); however, variance in photon emission was also 
significantly higher in mice engrafted with 6 x 105 cells (P<0.0001****).  
In Vivo Enhanced Green Fluorescent Protein (eGFP) Expression. B16F10-fLuc-eGFP 
melanoma tumors expressed eGFP in vivo (Figure 4.4). Fluorescent microscopy aids in detection 
of micrometastases in the sentinel lymph nodes at postmortem examination (Figure 4.5). 
Expression of fluorescent proteins is the only technique to achieve single cell resolution in a whole 












Figure 4.4. Macroscopic tumor morphology. Image showing tumor growth on the left pinna 
(A). Recruitment of vasculature to support tumor growth magnified (2x) on a Zeiss dissecting 








Figure 4.6. B16F10-fLuc-eGFP green fluorescent tumor (20X) with single-cell resolution 
(40X) in a tumor ex vivo (inset).  
 
Figure 4.5. eGFP expression enhances detection of micrometastasis at postmortem 
examination. The sentinel lymph node (circled) shows no macroscopic evidence of metastasis 
(A). At 2x magnification using a Zeiss fluorescent dissecting microscope, micrometastases 





Stable Transduction of B16F10-Fluc-Egfp Murine Melanoma Cells with Human 
Nectin-1. B16F10 murine melanoma cells have typically been regarded as non-permissible to 
HSV-1 infection. However, after in vitro infection with VC2, virus can be detected in the 
cytoplasm via immunofluorescent microscopy (1° antibody: rabbit anti-HSV-1 polyclonal, 2° 










 In cells which lack entry receptors, HSV-1 enters via atypical endocytosis/phagocytosis 
but replication may not occur. Nectin-1 receptor expression has been shown to be a marker of 
sensitivity to oncolytic herpesvirus treatment in another common skin cancer, squamous cell 
carcinoma.  In order to evaluate whether lack of cytolysis was due to an entry receptor deficiency 
in B16F10 cells, we created a stably transfected B16F10-fLuc-eGFP cell line with human nectin-
1; nectin-1 was tagged with the red fluorescent protein mCherry fused to the C-terminus to create 
the B16F10-fLuc-eGFP-nectin-1 line. Transfected cells strongly, diffusely expressed red 
Figure 4.7. VC2 (red fluorescence) infects B16F10-fLu-eGFP in vitro but does not result in 




fluorescent protein on the plasma membrane and emitted a yellow color after merging due to co-











In Vitro Growth Curve B16F10-fLuc-eGFP and B16F10-fLuc-eGFP-nectin-1.  
We evaluated in vitro growth of the nectin-1 expressing line in comparison to the parental line, 
B16F10-fLuc-eGFP (Figure 4.9). There was no significant difference between cell lines at any 
time point over the course of five days. The B16F10-fLuc-eGFP and B16F10-fLuc-eGFP-nectin-
1 cell lines had doubling times of 1.544 and 1.839 days, respectively. An exponential growth 
curve fit both B16F10-fLuc-eGFP (R2=0.9129) and B16F10-fLuc-eGFP-nectin-1 (R2=0.8685) 
cell lines.  
Figure 4.8. B16F10-fLuc-eGFP stable transfection with human nectin-1 tagged with 
mCherry. Top panel shows non-tranfected (B16F10-fLuc-eGFP) cells under green and red 
fluorescent filters, respectively, and lastly merged. Bottom panel shows cells transfected with 
human nectin-1 (B16F10-fLuc-eGFP-nectin-1) similarly under green and red fluorescent 
filters. Nectin-1 expression results in a phenotypic change manifested as cellular clumping 
















































In Vitro VC2 Cytotoxicity in B16F10-fLuc-eGFP And B16F10-fLuc-eGFP-Nectin-1 
Cells. B16F10-fLuc-eGFP-nectin-1 cells were infected with VC2 at an MOI of 0.001, 0.01, 0.1, 
and 1.0 examined using fluorescent microscopy prior to trypsinization and counting of live cells 
using trypan blue exclusion assay once every 24 hours for 3 days post infection (Figure 4.10). 
There was no significant growth inhibition of B16F10-fLuc-eGFP-nectin-1 cells at 24 and 48 
hours at any MOI evaluated in comparison to mock-infected cells. At 72 hours, there was no 
difference between MOI 0.001 and mock-infected cells, but there was significant decrease in live 
cells at MOI 0.1 (P=0.0119*) and 1.0 (P=0.0158*). In comparison, B16F10-fLuc-eGFP cells 
were not significantly decreased at any time point over the full 72 hours at an MOI of 0.01, 0.1, 




Figure 4.9.  In Vitro Growth Curve B16F10-fLuc-eGFP (blue) and B16F10-fLuc-eGFP-
nectin-1 (red). No significant differences in growth were observed. Growth fit an exponential 








Figure 4.10. In Vitro VC2 Dose-response Curves: B16F10-fLuc-eGFP and B16F10-fLuc-
eGFP-nectin-1. Number of live cells was significantly decreased at 72 hours after infection 
with VC2 at MOI 0.1 and 1.0 in comparison to mock treatment in melanoma cells expressing 
nectin-1 (A). No difference was observed in a similar experiment utilizing cells that were not 







Cytolytic effect was increased in nectin-1 receptor containing cells in comparison to non-nectin-
1 expressing cells in a dose and time-dependent manner and was apparent on fluorescent 
microscopy (Figure 4.11). Significant cytolysis was not observed microscopically in the cells 
lacking nectin-1.  
 
Bioluminescence Cytotoxicity Assay. The ability to detect cell death related to VC2 
infection via bioluminescence was assessed. Cells were infected at an MOI of 0.1, 1.0, 10, and 
100. Results of the bioluminescence cytotoxicity assay were similar to that found from trypan 
blue exclusion assay (Figure 4.12). Significant cytotoxicity and reduction of bioluminescent 
signal was not observed with VC2 infection of B16F10-fLuc-eGFP except at MOI 100, but cell 
Figure 4.11. In Vitro VC2 Dose-dependent, Nectin-1 Receptor-dependent Cytolytic Effect 
(B16F10-fLuc-eGFP and B16F10-fLuc-eGFP-nectin-1). Nectin-1 expression results in 
marked clumping due to its function as an adhesion molecule; this phenotypic change is 
apparent in the mock-treated cells. Increased cytolysis is apparent microscopically at 72 




viability and bioluminescence was significantly decreased when B16F10-fLuc-eGFP cells 
expressing human nectin-1 were infected in comparison to cells lacking the receptor. 









 VC2 Replication In B16F10-fLuc-eGFP Versus B16F10-fLuc-eGFP-Nectin-1. 
Increased cell was suspected to be related to improved entry, replication, and lysis in nectin-1 
expressing melanoma cells. We generated a replication curve for VC2 in the murine melanoma 
cells in the presence or absence of nectin-1 expression. Cells were infected at an MOI of 0.01 
and titers determined over the course of 36 hours. VC2 grew to higher titers in B16F10-fLuc-
eGFP-nectin-1 cells than in the B16F10-fLuc-eGFP cells lacking nectin-1 expression (Figure 
4.13).  
 
Figure 4.12. In Vitro Bioluminescence Cytotoxicity Assay B16F10-fLuc-eGFP and B16F10-
fLuc-eGFP-nectin-1. Increased cell death after VC2 infection of nectin-1-expressing cells can 
be detected using bioluminescence in vitro.Cell death was similar between VC2 and parental 










In Vivo B16F10-fLuc-eGFP and B16F10-fLuc-eGFP-nectin-1 Engraftment 
Efficiency. Engraftment rate was evaluated using a cell density inoculum of 2 x 105 cells and 6 x 
105 cells. When mice were engrafted with the higher cell density, 4/5 or 80% developed a 
macroscopic tumor (Figure 4.14), while only 3/5 or 60% developed a tumor when engrafted with 
2 x 105 cells (not shown). B16F10-fLuc-eGFP cells expressing human nectin-1 formed tumors in 
immunocompetent mice; however, engraftment efficiency was reduced in comparison to the 
nectin-1-negative cell line when 6 x 105 were similarly engrafted in the pinna with only 3/5 or 
60% of animals forming a macroscopic tumor within a two to three-week time frame.  
Nectin-1 expression was observed within tumors via fluorescent microscopy 
demonstrating red fluorescence. Nectin-1 receptors also appeared to be functional within tumors 
since immunohistochemical staining for HSV-1 showed strong immunoreactivity in necrotic 
areas at 72 hours post-infection. Nectin-1-expressing tumors had extensive areas of intratumoral 
necrosis in comparison with nectin-1 negative tumors even in uninfected controls. 
Figure 4.13. In Vitro VC2 replication curves B16F10-fLuc-eGFP and B16F10-fLuc-eGFP-
nectin-1. VC2 titers increase over the course of 36 hours post-infection in melanoma cells 




Comparison of necrosis in VC2 treated nectin-1 positive and nectin-1 negative cells after 
infection is therefore not possible due to the phenotype difference induced by nectin-1 













To summarize our findings during development of the B16F10-fLuc-eGFP/nectin-1 
syngeneic murine melanoma model, we found that expression of luciferase and enhanced green 
fluorescent protein had no effect on tumor cell growth in comparison to the parental B16F10 cell 
line in vitro. Further, stable transfection of the human nectin-1 receptor also had no negative 
impact on in vitro tumor cell growth. We showed that bioluminescence correlates with cell 
number in vitro and in vivo after engraftment in mice. We determined that nectin-1 expression is 
Figure 4.14. Engraftment efficiency of 80% using cell density inoculum of 6 x 105 B16F10-
fLuc-eGFP cells. Top panel shows bioluminescent imaging on the day of engraftment.  
Bottom panel shows 4/5 mice which developed a macroscopic tumor (one mouse failed to 




an important factor in tumor cell lysis in the B16F10-fLuc-eGFP murine melanoma cell line in 
response to VC2 infection in vitro and that lysis occurs in a dose-dependent manner. In vivo, we 
found that B16F10-fLuc-eGFP cells express the luciferase and eGFP reporter genes well and 
form tumors in immunocompetent mice with acceptable tumor induction rates; B16F10-fLuc-
eGFP-nectin-1 cells also form tumors but with reduced engraftment efficiency. B16F10-fLuc-
eGFP-nectin-1 tumors express nectin-1 receptors in vivo which are functional for VC2 entry 
based on immunohistochemical staining for HSV-1 within tumors.  
Experimental Validation and Model Assessment. During model development, we 
found that VC2 only resulted in significant cytotoxicity of tumor cells in the presence of nectin-1 
receptors in vitro. However, in vitro cytotoxicity testing cannot account for host immune 
responses and immunogenic cell death, which have been shown to be important in generating 
effective, durable anti-tumor immune responses. We aimed to test the ability of our model to 
evaluate therapeutic response to the highly immunogenic VC2 HSV-1 live attenuated vaccine 
strain administered intratumorally in absence of a direct cytolytic effect. We hypothesized that 
immunogenicity of the virus alone could have a strong adjuvant effect in stimulating anti-tumor 
immune responses and have therapeutic immune-modulating effects in the tumor 
microenvironment. We also hypothesized that bioluminescence would be more sensitive for 
detection of therapeutic response than tumor volume in the face of an inflamed tumor 
microenvironment, an intended effect of immunogenic, immune-modulating VC2 virotherapy. 
Improved overall survival was the desired endpoint.  
Twenty 8 to10 week-old female C57BL/6 mice with B16F10-fLuc-eGFP melanoma 
tumors on the pinna were divided into two groups, a control group consisting of nine mice and a 
treatment group consisting of 11 mice. Tumors averaged approximately 100 mm3 when 106 PFU 
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VC2 or mock treatment with PBS was initiated and animals were euthanized when tumors had 
grown significantly (P=0.0001***) averaging 500 mm3 (Figure 4.15); no significant differences 
were found in tumor volume between the two groups prior to the initiation of therapy or at the 
time of postmortem examination.  
Up to four doses of 1 x 106 PFU of VC2 in 100 µl were administered intratumorally to 
the treated group within a week’s time, while mock-treated mice received the same volume and 
dosing frequency of PBS. All 20 animals were monitored for tumor growth using measurement 
with digital microcalipers during the course of treatment to monitor progression of the primary 
tumor. Four mock-treated control mice and eight VC2-treated mice were also monitored using in 
vivo imaging to detect tumor bioluminescence during the week of treatment with VC2 
virotherapy to assess the utility of bioluminescent imaging to detect acute response to 
intratumoral virotherapy treatment in comparison to traditional micro-caliper measurement.  
Prior to initiation of VC2 virotherapy or mock treatment, there was highly significant 
correlation between tumor volume and photon emission from tumors during  imaging (Pearson r 
correlation coefficient=0.8549, P=0.0004***). However, when paired tumor volume and 
bioluminescence values were compared during the week of treatment, there was reduced 
correlation in the VC2-treated group (Pearson r correlation coefficient=0.4225; P=0.0354*) in 
comparison to the mock treated group (Pearson r correlation coefficient=0.8258; P=0.0009***) 






















Figure 4.15. Experimental validation. Tumors treated when volumes averaged 100 mm3 and 
animals euthanized when significant growth had occurred averaging 500 mm3  (A). Variation 
was present in tumor volume at the time of initiation of treatment (B) and at the time of 




Figure 4.16. Correlation of bioluminescence and tumor volume in mock-treated and VC2-
treated mice during the week of treatment. Significant correlation is observed in PBS-treated 
controls but correlation is not significant in VC2 treated animals. Data points represent 
photon emission and tumor volume for days 0, 2, and 8 after initiation of treatment for each 














When growth curves were produced and superimposed on each other for individual 
animals based on tumor volume and tumor bioluminescence, we found that the tumor growth 
trends generally paralleled each other for the control group (Figure 4.17), but growth curves 
frequently showed differing trends in the VC2 treated group depending on whether tumor 
volume or bioluminescence was assessed (Figure 4.18). Tumor bioluminescence was often 
decreasing in the VC2-treated group despite the appearance of increasing tumor volume. Based 
on the highly immunogenic nature of the VC2 vaccine, we hypothesized that the discrepancy 
could be due to acute necrosis and inflammation associated with acute immune response to the 
virus. We suspected that the immune-stimulating effects in the tumor microenvironment resulted 
in tumor swelling or “pseudoprogression” rather than true tumor cell proliferation and 
progression. We therefore aimed to evaluate and compare tumor necrosis and inflammation 
within the tumor microenvironment in the VC2 and mock-treated control groups. 
Tumor Necrosis (Oncolysis). HSV-1 is regarded as having a lytic life cycle, since death 
of the host cell is the ultimate outcome of productive infection. We aimed to evaluate the amount 
of tumor lysis we could detect on histopathology from tumors treated with VC2 versus mock-
injected tumors. In order to objectively quantify the amount of lysis present, we used digital 
image analysis to outline and quantify the area (mm2) of the tumor section and the area of 
necrosis and express the value as percent necrosis within the tissue section (Figure 4.19). We 
found that there was a trend towards increased tumor lysis in sections from VC2-treated tumors, 
although differences were not statistically significant (unpaired, two-tailed, student t 
test;P=0.3890). However, as survival was our endpoint, animals were euthanized at varying time 














Figure 4.17. Growth trends parallel in mock-treated mice comparing assessment of growth 
using tumor volume v. tumor bioluminescence during the week of treatment. Tumor volumes 
(black) and bioluminescence (red) show an increasing trend. Representative bioluminescent 





























Figure 4.18. Opposing growth trends in VC2 treated mice comparing tumor volume (black) 
v. bioluminescence (red) during treatment due to acute inflammation and swelling 
(“pseudoprogression”). Representative bioluminescent images (G) and (H) correspond with 








Therefore, we thought it was possible that the amount of necrosis could vary with regard 
to the amount of time that passed before euthanasia occurred. In the VC2-treated group, larger 
areas of necrosis were observed when sections of the tumor were examined with more proximity 
to the time of the last VC2 injection (Pearson r correlation coefficient=-0.7833; P=0.0125*). In 
order to ensure this correlation was not a mechanical effect resulting from injection, we also 
evaluated the control group separately and found no significant correlation between the amount 
of necrosis on histopathology and the time elapsed post-injection of PBS (Pearson r (correlation 
coefficient) =-0.503; P=0.3073). Although there were no significant differences in size of tumors 
between the VC2 and mock-treated groups at the time of necropsy, we wanted to rule out the 
possibility that increased necrosis may be related to the size of the tumor rather than the time 
elapsed after injection of virus. No correlation was found for size and degree of necrosis for the 
control (Pearson r (correlation coefficient) =-0.2902; P=0.5769) or VC2-treated groups (Pearson 
r (correlation coefficient) =-0.05462; P=0.8890). Our interpretation is that increased 
necrosis/tumor lysis may be more evident at earlier time points after VC2 treatment based on our 
analysis showing increased tumor necrosis when less time elapsed between VC2 treatment and 
examination of tumor tissue.  We also performed immunohistochemistry for HSV-1 on a tumor 
that was inoculated with VC2 6 days prior. We found marked cytoplasmic immunoreactivity, 
which was more intense in cells adjacent to and within areas of intratumoral lysis (Figure 4.20). 
Although VC2 likely replicates in stroma and other cells in the tumor microenvironment more 
efficiently than the B16F10-fLuc-eGFP tumor cells lacking nectin-1, immunofluorescent staining 





Figure 4.19. Increased necrosis in VC2 treated tumors. Intratumoral necrosis was quantified 
using digital image analysis and expressed as a percentage (H&E, 1x magnification). Although 
there was slightly more necrosis in tumor sections from VC2-treated mice on average, 
differences were not statistically significant. Extent of necrosis correlates negatively with time 
post VC2 treatment. No relationship was found in controls for necrosis and time post PBS 
injection.  
 
Figure 4.20. Immunohistochemistry showing HSV-1 infected cells adjacent to and within areas 
of necrosis in a VC2-treated tumor. The PBS-treated negative control shows no 





Response to VC2 in the Tumor Microenvironment. We hypothesized that the highly 
immunogenic VC2 vaccine would stimulate an immune response in the tumor 
microenvironment. We observed that, although there was no statistical difference in tumor 
volumes at necropsy between VC2 and control groups (P=0.2781), tumor mass at necropsy was 
increased for VC2 treated animals (P=0.0287*). We suspected this increase in tumor mass could 
be related to increased infiltration by immune cells. We also suspected the previously mentioned 
discrepancy in correlation between tumor bioluminescence and tumor volume during VC2 
treatment could have been the result of increased inflammation in the tumor microenvironment 
in VC2-treated mice, which resulted in increasing tumor volumes and the clinical perception of 
tumor progression although bioluminescent imaging suggested tumors were regressing. We 
therefore aimed to evaluate whether mice treated with VC2 had evidence of enhanced immune 
Figure 4.21. Immunofluorescent staining showing VC2 co-localized to the cell membrane 
and cytoplasm of B16F10-fLuc-eGFP cells within a tumor. (Dapi mounting medium, rabbit 
anti-HSV-1 polyclonal primary antibody, goat anti-rabbit secondary antibody conjugated to 





responses in the tumor microenvironment compared to mock-treated control mice using 
immunohistochemistry.  
We found that in VC2-treated mice, macrophages were significantly increased in the 
tumor microenvironment (unpaired, two-tailed t test; P=0.0033) (Figure 4.22); importantly, we 
also found that arginase-1 expression, a typical marker of the anti-inflammatory, pro-tumorigenic 
M2 macrophage phenotype in mice, was decreased (unpaired, two-tailed t test, P=0.0003) in 
comparison to mock-treated controls (Figure 4.22). The increase in macrophages was also 
accompanied by an increase in CD3+ T cells in the tumor microenvironment (unpaired, two-
tailed t test; P=0.0458) (Figure 4.22). Infiltration by T cells is a positive prognostic indicator in 
human patients with melanoma and is frequently observed in biopsies of patients with regressing 
lesions.   
 
Figure 4.22. Inflammatory cells in the TME via immunohistochemistry. VC2 caused an increase 
















Figure 4.22 cont’d. Inflammatory cells in the TME via immunohistochemistry. VC2 caused an 
increase in macrophages, with decreased arginase-1, and increased CD3+ T cells.  
 
Microvascular Density. Although B16F10 cells themselves support only non-productive 
infection with VC2, other cell types in the tumor microenvironment would be expected to be able 
to support robust replication including fibroblasts and endothelial cells. B16F10-fLuc-eGFP 
tumors are markedly vascular, containing tortuous tumor-associated vessels (Figure 4.23). We 
hypothesized that VC2-treated tumors may have reduced vascularity due to destruction via viral 
replication, destruction via inflammation as a bystander response, or as a result of decreased 























Microvascular density was slightly reduced in VC2-treated mice and approached statistical 















Figure 4.24. Intratumoral microvascular density via IHC for CD31, 20x (Weidner method).  
Microvascular density was decreased for VC2-treated mice and approached significance.  
 
Overall Survival. VC2-treated mice trended towards increased survival times in 
comparison with mock-treated animals. Mice that received VC2 treatment had a median survival 
time (MST) of 15 days, almost twice that of control mice which was 8 days, although the 
Figure 4.23. Tortuous tumor associated vasculature in a B16F10-fLuc-eGFP tumor. Tumor 




difference in survival was not found to be significant when a Kaplan Meier curve and log-rank 
test were generated (P=0.153) (Figure 4.25); notably, one VC2-treated mouse had a complete 















Primary tumor growth is the major limiting factor in survival in most transplantable 
murine tumor models. For this reason, we wanted to evaluate what effect, if any, VC2 had on 
tumor growth rates. Tumor specific growth rate (SGR) is calculated using tumor volumes over 
Figure 4.25. Kaplan Meier Survival Curve. The difference in curves was nonsignificant using 
log-rank test. However, median survival time (MST) was increased (15 days) for VC2-treated 
mice in comparison to mock-treated mice (8 days). One mouse had a complete response (CR).  
 
Figure 4.26. Complete Response (CR) in a VC2-treated mouse. No evidence of disease in 




time. Growth rates were evaluated for control and VC2-treated animals the week before 
treatment, the week during treatment, and the week following treatment using the formula, 
SGR=ln(V2/V1)/(t2-t1), which calculates the percent change in tumor volume per day from two 
measured time points.  VC2-treated mice trended towards decreasing growth rates during 
treatment in comparison to mock-treated controls, but differences between the two groups were 
not statistically significant (Figure 4.27). The reduction in tumor growth rates may be 
underestimated since the formula is based on tumor volumes rather than bioluminescence, which 









When overall growth rates were calculated and compared with survival time, we found 
differences in the impact of overall specific growth rate on overall survival between mock-
treated and VC2-treated mice. There was no correlation in growth rate and overall survival in 
mock-treated mice ((Pearson r (correlation coefficient) =-0.2379; P=0.5705) (Figure 4.28), while 
VC2- treated mice showed a significant, negative correlation ((Pearson r (correlation coefficient) 
Figure 4.27. Decreased growth rates in VC2 treated mice (red) in comparison to mock treated 





=-0.8159; P=0.0022) (Figure 4.28). In the treated group, animals with slower growth rates lived 
longer. Our interpretation is that mock treatment had no effect on growth rates and therefore no 
relationship could be established when evaluated for correlation with survival.   
 Response to immune modulating cancer therapies, and oncolytic virotherapy 
specifically, varies markedly in human patients as previously mentioned. Additionally, high 
variability in response within treatment groups is typical in immuno-oncology studies involving 
preclinical testing of immunotherapies in mice in comparison to more traditional pharmacology 
studies.259 We therefore desired to identify any factor that could have led to improved responses, 
i.e. longer survival times, in some animals treated with VC2 as compared to other animals within 
the treatment group. We found that tumor volume at the time treatment was initiated correlated 
significantly with overall survival in the VC2 treated group, but not the control group. Although 
tumor volumes averaged 100 mm3 at the start of treatment, some variation in individual tumor 
volumes between mice at the time treatment was noted; however, as was demonstrated in Figure 
16b there was no statistical difference in tumor volumes between VC2 and control groups prior 
to experimental manipulation (unpaired t test, P=0.6457) and variance between the two groups 
was also insignificant (F test, P=0.4727). Nonetheless, there was a significant, direct, negative 
correlation between the tumor volume at the start of initiation of treatment and overall survival 
(Pearson r (correlation coefficient) =-0.6397; P=0.0340) (Figure 4.28). Put simply, animals 
treated with VC2 lived longer when treatment was initiated when the tumors were smaller. This 
is in concordance with a survey of preclinical immuno-oncology studies that showed that only 
small tumors typically responded well, and only those resulted in delayed tumor growth.259,309  
There was no significant correlation between initial tumor volume and survival times for the 
control group  (Pearson r (correlation coefficient)=-0.0559; P=0.8954) (Figure 4.28). We 
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wondered if smaller tumors simply grew more slowly and may not be a result of treatment. This 
was not the case. When we looked for a relationship between tumor size and growth rate, control 
mice showed no significant correlation (Pearson r (correlation coefficient) =-0.6146; P=0.1049), 
while there appeared to be a strongly significant relationship between starting tumor size and 
growth rate in the VC2-treated mice (Pearson r (correlation coefficient) =-0.8772; P=0.0005). 
Mice that received VC2 treatment had slower overall tumor growth rates than mice that received 
mock treatment, and slower tumor growth rates correlated significantly with smaller tumors at 
the time therapy was initiated. Since all animals received a dose of 1 x 106 PFU per injection, 
tumors that were slightly smaller, in essence, received a higher dose. The finding that mice 
treated with tumors that were smaller had reduced tumor growth rates and that those reduced 
growth rates correlated with longer survival times, suggests that VC2 may reduce tumor growth 
rates and extend overall survival in a dose-dependent manner even in absence of the entry 
receptor, nectin-1. We hypothesized that reduced cell cycling could be another mechanism by 






Figure 4.28. Survival is significantly correlated with tumor growth rates and initial tumor 










Ki-67 Proliferation Index. Tumor cell proliferation is characteristic of melanoma 
progression and Ki-67 is a common biomarker used in melanoma and other cancers; Ki-67 index 
holds independent prognostic value in melanoma patients.310We evaluated Ki-67 expression to 
determine if VC2 virotherapy had any effect on cell cycling. Ki-67 is a more sensitive indicator 
of cell cycling than mitotic index since it is a marker for cells in all stages of the cell cycle, while 
mitotic index only gives an indication of cells in M phase. Tumors from mice treated with VC2 
had significantly reduced Ki-67 expression (P<0.0001) in comparison to mock-treated controls 
(Figure 4.29). This finding suggests that a modulation of the cell cycle may be one mechanism in 
which VC2 reduces tumor growth rates and prolongs survival. 
 
Figure 4.28 cont’d. Survival is significantly correlated with tumor growth rates and initial 
tumor volume at the time treatment was initiated in VC2-treated but not mock-treated mice.  
 






Safety. Safety assessments of mice receiving VC2 virotherapy showed that treatment was 
well-tolerated. Treated animals maintained their body condition as well or better than mock-
treated mice. At the time of postmortem examination, VC2-treated mice weighed more on 
average although the difference was not significant (P=0.0542) (Figure 4.30). 
Body temperature was monitored via subcutaneously implanted temperature sensing 
transponders. No clinically significant pyrexia was observed in treated animals at any time. Vital 
organs were weighed at postmortem exam and splenomegaly was the only significant 
abnormality observed in VC2 treated mice (P=0.0388) (Figure 4.31); morphometric digital 
image analysis showed that VC2 treated mice had significant lymphoid hyperplasia in 
comparison to mock treated controls (P=0.0068) (Figure 4.32). Splenomegaly and lymphoid 
hyperplasia in VC2 treated animals suggests a systemic immune response to virotherapy, 
although it is undetermined if this response is tumor-specific.  
 
Figure 30. VC2-treated mice had increased body weight in comparison to control mice 







Melanoma is a notoriously difficult cancer to treat in human patients and is resistant to 
most traditional cancer therapies including chemotherapy and radiation. Novel therapies that 
stimulate anti-tumor immune responses have shown promise, including oncolytic virotherapy; 
however, preclinical testing in murine tumor models have often not been predictive of response 
in human patients. Response to the FDA-approved oncolytic herpesvirus T-VEC has shown 
Figure 4.31. Splenic mass is significantly increased in VC2-treated mice at postmortem 
examination.  
 
Figure 4.32. Statistically significant lymphoid hyperplasia was demonstrated in the spleens of 





limited efficacy in a subset of patients in clinical trials despite robust responses in mice and some 
human patients have experienced adverse effects. The mechanisms of variability in response are 
not well-understood. We aimed to create a murine melanoma model for testing immune-
modulating therapeutic effects of novel, genetically-engineered herpesviruses.  
         In our early work, we observed poor infection efficiency of B16F10-fLuc-eGFP murine 
melanoma cells with oncolytic herpesviruses and poor sensitivity to cell killing although VC2 
could be detected in the cytoplasm of B16F10-fLuc-eGFP cells at 12 hours via 
immunofluorescent microscopy. We hypothesized that decreased in vitro sensitivity to HSV-1 
mutants may be related to lack of nectin-1 receptors, which have been shown to be predictive of 
oncolytic HSV-1 sensitivity in a murine squamous cell carcinoma model. We therefore created a 
stably transfected murine melanoma cell line expressing human nectin-1 and demonstrated 
improved viral replication and cytolysis in vitro.  
The detection of virus in the cytoplasm B16F10-fLuc-eGFP cells after in vitro infection 
but lack of significant cytopathic effect suggests the virus may enter but not replicate and lyse 
the tumor cells in absence of nectin-1. Cells may become infected with HSV-1 through gD 
receptor binding to herpes virus entry mediator (HVEM), nectin-1, or 3-O-sulfated heparan 
sulfate and fusion or via receptor independent atypical endocytosis/phagocytosis. When entry 
receptors are present, virions may enter via fusion or endocytosis. However, when appropriate 
receptors are not present, HSV-1 must enter via endocytosis only, which occurs rapidly. In fact, 
it has been shown that Chinese hamster ovary cells (CHO), which are known to lack HSV-1 
entry receptors and are widely considered to be non-permissible, are able to be efficiently 
infected with HSV-1 at a rate similar to Vero cells and CHO cells transduced to express nectin-
1.311 Therefore, entry via the endocytic pathway appears to be independent of viral entry receptor 
129 
 
expression. However, infection of cells lacking entry receptors via the endocytic pathway does 
not result in a productive infection and release of infectious viral progeny.311 Infection of such 
cells is considered to be non-productive since infectious progeny are not produced and enveloped 
virions are degraded via fusion of the endocytic membrane with lysosome.   
While this would markedly limit the spread and pathogenicity of a virus in tumor cells 
lacking entry receptors in vitro, the complexity of the tumor microenvironment (TME) would 
include a host of cells which may better support productive infection such as cancer-associated 
fibroblasts (CAF), immune cells, and endothelial cells of tumor-associated vasculature. These 
cell-types, and others in the TME, supply a replication niche for virus to persist and allow waves 
of infection of even poorly permissible tumor cells lacking entry receptors via endocytosis. 
Productive infection in stroma and tumor-associated vasculature could have multiple direct and 
indirect therapeutic anti-tumor benefits. Induction of immunogenic cell death (ICD) associated 
with efficient viral replication in these cells may release danger-associated molecular patterns 
(DAMPs) such as adenosine triphosphate (ATP) and high mobility group box-1 (HMGB-1) to 
enhance the innate immune response in the tumor microenvironment. On the other hand, direct 
effects could include directly eliminating a portion of CAF and disrupting tumor-associated 
vasculature, creating a microenvironment that is less supportive of tumor growth. The ability of a 
live attenuated virus to create a replication niche in the tumor microenvironment and amplify its 
presence and effect through replication could decrease the need for frequent injections by 
supplying a continuous supply of virus for infection of tumor cells. We detected intratumoral 
VC2 at 6 days post infection in association with necrotic areas despite the lack of nectin-1 
receptors. Even in the absence of direct lysis in the B16F10-fLuc-eGFP cell line lacking nectin-
130 
 
1, cell death may still occur via immunogenic cell death secondary to indirect ER stress, a factor 
impossible to account for in vitro.   
Another factor impossible to account for in vitro is host immune response. Some studies 
have shown that rapid infection and spread in vitro predicts better in vivo response; however, 
such studies have been performed in xenogeneic models and therefore do not account for 
immune responses.117,118 Some would argue that spread, persistence and continued replication 
within the tumor and/or microenvironment are less important than immunogenicity of the virus 
and immune response in the early stages of viral infection. In fact, it has been reported that, 
regarding oncolytic HSV, in vitro cytotoxicity and viral persistence in vivo do not correlate with 
anti-tumor efficacy. It has instead been shown that expression of markers of immunogenic cell 
death, such as heatshock protein 70 and elevated levels of serum HMGB-1, increased antigen 
presenting cells, and CD8+ T cell responses may be more likely associated with HSV-associated 
therapeutic benefits.119  
We therefore aimed to test the ability of the highly immunogenic HSV-1 live attenuated 
vaccine strain, VC2, in stimulating a therapeutic immune response against melanoma tumors in 
mice. In comparison to cancer drug discovery that focuses cytotoxic and/or targeted approaches, 
relevant models for immuno-oncology approaches are more limited and are urgently needed.259 
Models are specifically needed which can answer questions regarding why only certain subsets 
of patients respond, how to predict responders, and how to extend or improve responses in 
resistant or only partially responsive patients.259 Syngeneic murine tumor models are commonly 
used in preclinical immuno-oncology studies but there are many challenges including a short 
window for evaluating response before tumors ulcerate or reach a size requiring euthanasia based 
on IACUC standards.259  We utilized B16F10-fLuc-eGFP murine melanoma cells lacking nectin-
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1 receptors in order to demonstrate the immunogenicity of the virus alone in absence of robust 
replication and direct lysis and destruction of tumor cells. We additionally demonstrated that 
monitoring bioluminescence improved sensitivity in detecting acute responses to virotherapy 
over traditional caliper measurement. Bioluminescence is the most sensitive method for 
monitoring tumor progression in vivo. Most often, luciferase-expressing cancer cells are used in 
models where tumor cells are implanted internally or in experimental metastasis models where 
the tumor cells are injected directly into the vascular system. In our model system, tumor cells 
are orthotopically engrafted intradermally in the poorly haired region of the pinna for the ease of 
visual monitoring and measuring tumors with calipers. However, response to therapies intended 
to stimulate an immune response against tumors are difficult to monitor by traditional caliper 
measurements due to pseudoprogression. Pseudoprogression is the appearance of disease 
progression clinically or via diagnostic imaging that is occasionally seen in cancer patients 
receiving immunotherapy treatment. The precise mechanism is poorly defined, but it is 
hypothesized that pseudoprogression is the result of tumor enlargement secondary to acute 
inflammation and necrosis, which represent the intended effects of stimulating an immune 
response against the tumor, rather than true proliferation of the tumor cells. This phenomenon 
has been observed in melanoma patients being treated with immune checkpoint inhibitors 
including nivolumab and ipilimumab who show a discrepancy between overall survival time and 
progression-free interval; patients may appear to acutely progress in response to treatment but 
ultimately show response manifested as improved overall survival down the road. In most 
transplantable murine melanoma models, the time frame for generating a therapeutic response 
with a candidate drug is short. The course of in vivo experiments is limited by outgrowth of the 
primary tumor since the tumors grow rapidly and often ulcerate quickly after a tumor has 
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become macroscopically visible necessitating euthanasia. When the time course for evaluation of 
therapeutic response may be as short as one week, sensitive assessment of early response to 
drugs is critical. As pseudoprogression may result in premature discontinuation of drugs in 
human patients in clinical trials, it may also lead to premature discontinuation of testing of 
promising therapies in preclinical trials with mouse models. In clinical trials with human 
patients, treatment may be discontinued, and overall therapeutic efficacy may still be observed as 
improved overall survival times in some cases. However, in preclinical testing, mice may be 
euthanized prematurely due to the appearance of rapid tumor growth in response to immune 
modulating drugs and effect the overall survival times and ultimately the outcome of whether to 
continue the drug development strategy.  More sensitive evaluation of response to therapy should 
improve development of effective therapeutic strategies since acute responses will be more 
apparent and inform dosing strategies in subsequent studies.  
We hypothesized that the discrepancy between correlation of tumor volumes and tumor 
bioluminescence during VC2 treatment could indeed be related to acute necrosis and 
inflammation during the early stages of virotherapy. In the VC2-treated group, larger areas of 
necrosis were observed when sections of the tumor were examined when less time had elapsed 
since the last VC2 injection. Early responses may be undetected or underestimated since necrosis 
may be a more prominent histologic change in the early stages of VC2 virotherapy and 
differences in virus-treated and control groups may be less apparent when tumors are examined 
at later time points.  
 There are a number of pathways that the cell can utilize to trigger death and result in 
tumor lysis in response to HSV-1 infection including apoptosis and necroptosis, and the 
mechanism of cell death has an influence on the immune response. Cancer cells may have 
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mutations that make these cell death pathways ineffective. Further, HSV-1 has evolved 
mechanisms of evading these pathways in order to keep the cell alive to buy time for replication. 
However, even if these pathways are initially skirted by the virus, cells will ultimately still die as 
a result of ER stress either directly or indirectly, in a process referred to as immunogenic cell 
death. Immunogenic cell death is recognized as an important factor in eliciting antitumor 
immune responses through traditional cancer therapies such as chemotherapy and radiation as 
well as oncolytic virotherapy using HSV-1-based viruses.  
Cell death may also occur even in a nonproductive infection, related to ICP0 expression 
by HSV-1, which is a tegument protein referred to as an “apoptoxin”. ICP0 can activate caspase-
3 and trigger apoptosis without the need for viral replication to occur; it is possible that, at a high 
enough dose of virus, significant amounts of ICP0 may be able to induce apoptosis even in 
absence of replication in cells that do not support productive infection. However, in cells that 
permit viral replication, transcription of early and late genes may inhibit apoptotic pathways; this 
extends the life of the cell to allow time for replication. When HSV-1 is successful in preventing 
apoptosis, necroptosis is another pathway by which the cell can trigger its own death to limit 
viral spread and replication.160 In humans, HSV-1 has evolved mechanisms to also evade this 
pathway of cell death. R1 prevents necroptosis in human cells, but not in mouse cells, where 
RIP3 is efficiently activated by ICP6 after HSV-1 infection in a manner independent of TNFR, 
TLR3, or DAI.178,179 This is one factor responsible for limiting viral replication in mouse cells in 
general, a non-natural host. Therefore, it is expected that, in permissive human cells infected 
with wild-type HSV-1, virus would replicate to much higher titers than in mouse cells. Further, 
the outcome of the infection and mechanism of cell death may be different based on dose of 
virus, species, and cell type. This is important to keep in mind when performing preclinical 
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mouse studies where a wide variety of tumor modeling strategies and tumor cell types are used. 
Since B16F10 murine melanoma cells do not support productive infections with HSV-1, direct 
cytotoxicity is likely minimal at the doses of VC2 we used in our in vivo experiments, although 
some apoptosis secondary to ICP0 is possible. Necroptosis is unlikely to occur to much degree 
since ICP6 is involved in triggering this pathway in HSV-1 infections and requires initiation of 
replication in order to be expressed. Type I immunogenic cell death is considered likely to be a 
predominating mechanism of cell death in tumor cells lacking entry receptors required for 
efficient replication in oncolytic HSV-1 virotherapy.  
Effective anti-tumor immune responses require functional innate and adaptive immune 
systems. The initial step in mounting adaptive immunity is efficient recognition and presentation 
of antigens by antigen presenting cells of the innate immune system including macrophages and 
dendritic cells.  M1 type macrophages, or “classically activated” macrophages, are effective at 
antigen presentation, produce pro-inflammatory cytokines, and have anti-tumorigenic effects 
overall. M2 type or “alternatively activated” macrophages are ineffective antigen-presenters, 
produce immunosuppressive cytokines, and play many roles in supporting tumor growth and 
progression. We detected reduced expression of arginase-1 by macrophages, a canonical marker 
of the M2 phenotype in mice, in the TME of VC2-treated tumors although macrophages overall 
were generally increased suggesting repolarization to an M1 phenotype. We also detected 
increased numbers of CD3+ T cells in the TME in VC2-treated mice. T cells are important in 
generating adaptive anti-tumor immunity and have been observed in the TME of regressing 
tumors in human melanoma patients.  
In addition to increased tumor lysis and inflammation associated with VC2 treatment, we 
also found reduced Ki-67 expression in VC2-treated tumors indicating a lower proportion of 
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cells actively proliferating in the cell cycle. Evidence suggests that HSV-1 has evolved a 
complex and sophisticated ability to modulate the cell cycle in order to infect and replicate.147 
Soon after entry, HSV-1 is known to elicit a cell cycle block to limit host protein production in 
order to use cellular machinery for early stages of viral replication; subsequently, HSV-1 
reverses the cell cycle block through expression of late gene ɣ34.5 in order to replicate with 
maximum efficiency. Since HSV-1 can enter cells lacking entry receptors through endocytosis, 
we hypothesized that VC2 entry of B16F10-fLuc-eGFP may elicit cell cycle block, since this 
effect is known to occur without replication even in the presence of non-replicating HSV-1 L 
particles. The finding that Ki-67 proliferation index was significantly decreased in VC2-treated 
tumors was compatible with our hypothesis that VC2 may initiate a cell-cycle block as one 
mechanism of slowing tumor growth.  
In summary, we have developed an immunocompetent murine melanoma model for 
testing oncolytic and immunomodulatory HSV-1 viruses. We demonstrated utility of the model 
in assessing response to therapy with increased sensitivity using bioluminescent imaging. We 
demonstrated strong immune responses in the tumor microenvironment in VC2-treated mice. 
The apparent remarkable immunogenicity of VC2 makes it a promising candidate for further 
development as a viral vector for immune modulating cancer therapy. Studies are being repeated 
in the model alongside nectin-1 expressing tumors, since the described experiments were 
performed in absence of nectin-1 largely to test the adjuvant capabilities of VC2 and suitability 
as a vector for further development. Translational, direct comparison of efficacy and mechanisms 
of action based on the presence or absence of nectin-1 receptors in the ongoing, aforementioned 
studies may be difficult since phenotypic differences resulting from transduction of nectin-1 
(including increased necrosis and inflammation in nectin-1 expressing tumors at baseline) will 
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make interpretation of differences challenging in direct comparison of treated nectin-1 
expressing and non-nectin-1 expressing tumors.  However, such side-by-side comparisons may 
be generally informative for determining safe dosing and/or combinatorial drug strategies in 
preparation for clinical trials where patient receptor expression may vary within and between 



















CHAPTER V: CONCLUDING REMARKS 
Summary and Discussion 
Malignant behavior of tumor cells has been shown to be greatly influenced by tumor 
microenvironment. This idea was first proposed by Steven Paget in the 1800’s in his “seed and 
soil hypothesis”. His hypothesis was greatly bolstered by work done by Fidler and colleagues 
using the B16 murine melanoma model to generate sublines with a propensity to metastasize to 
specific organs. In our early work in characterizing the growth kinetics and metastatic properties 
of the B16F10 murine melanoma cell line in C57BL/6 mice, we demonstrated that in vivo 
propagation of B16F10 tumor cells prior to engraftment of the pinnae of additional mice results 
in improved synchronization of tumor development and improved metastasis to the sentinel 
lymph nodes (SLN) as opposed to direct engraftment of cells from cell culture. We also showed 
that decreasing cell density of the inoculum at engraftment results in further improvement in 
synchronization of tumor development and metastasis to SLN. Our results highlight the 
importance of tumor microenvironment on growth and behavior of the B16F10 murine 
melanoma cell line and offers improved tumor modeling strategies for cancer researchers using 
transplantable syngeneic murine tumor models. 
It is particularly interesting to consider the role of tumor microenvironment in the 
enhancement of malignancy and the metastatic phenotype. Stephen Paget’s early observations 
and the work of many others have confirmed that metastatic phenotype depends not only on 
anatomic proximity to the nearest capillary or lymphatic beds (which is one important factor) but 
also on intrinsic properties of the “seed” or cancer cell, which may be influenced to a large extent 
by the “soil” or microenvironment.312 Current thought is that both the “anatomical/mechanical” 
and “seed and soil hypotheses” are not mutually exclusive and both hypotheses hold merit as 
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factors in metastatic phenotypes.  It is now widely accepted that tumor cells must adapt to 
survive in the harsh tumor microenvironment. One study provided a mathematical model that 
established that growth within a heterogeneous extracellular matrix in the tumor 
microenvironment results in clonal selection of invasive cells with the following properties: 1.) 
decreased lag times, 2.) elevated consumption of oxygen, 3.) increased migration, and 4.) 
decreased cell-cell adhesion.Alternatively, tumors grown in a more homogeneous environment 
showed no clonal dominance and less invasive characteristics with smooth tumor margins.313,314 
Aggressive, adaptive phenotypes may be related in part to the inherent genetic and epigenetic 
instability and mutations in cancer cells,313,315 and it has been shown that cancer cells growing 
within an actual tumor have a mutation rate higher than the same cells grown in vitro.316 This 
may be due to features in the microenvironment such as low pH, low availability of nutrients and 
glucose, and hypoxia, as well as immunoediting. Tumor cells proliferate rapidly creating periods 
of hypoxia followed by increased angiogenesis and return of blood supply and, therefore, oxygen 
and nutrients. This may result in waves of oxygenation and deoxygenation which create reactive 
oxygen species (ROS) and single and double-stranded DNA breaks with decreased DNA damage 
repair that further enhance mutagenesis and a potentially increasingly more aggressive, unstable 
phenotype.313  Additionally, literature suggests that the tumor microenvironment stroma may be 
playing a direct role in enhancing malignant, metastatic phenotypes. Cancer-associated 
fibroblasts may be directly involved in secreting factors that act in a paracrine manner to 
stimulate cancer cells to adopt a more aggressive phenotype.313 Such factors secreted by 
fibroblasts include TGF-beta (transforming growth factor beta), which is known to enhance an 
immunosuppressive microenvironment and is involved in epithelial to mesenchymal transition 
(EMT), a phenotype associated with increased invasiveness. Others include hepatocyte growth 
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factor (HGF), epidermal growth factor (EGF), insulin like growth factor (IGF), and fibroblast 
growth factor (FGF), which have been implicated in promoting invasion and metastasis.313 
During immunoediting, selective pressure induced by chronic inflammation in the tumor 
microenvironment creates emergence of tumor subclones with increasing resistance to immune 
killing. Acquired characteristics such as expression of immunosuppressive cytokines, 
downregulation of MHC-I receptors, and expression of ligands to inhibitory receptors on 
immune cells such as PDL-1 can be promoted by ineffective immune responses. Such 
interactions between the tumor microenvironment and tumor cells may help explain how in vivo 
selection can augment the metastatic phenotype in tumor modeling. Additionally, the realization 
that the tumor microenvironment plays such a critical role in shaping disease progression and 
outcome presents an opportunity to intervene therapeutically.  
Intratumoral immune-modulating virotherapy is a novel strategy for modulating the 
tumor microenvironment and inducing therapeutic anti-tumor responses. Oncolytic virotherapy is 
a rapidly expanding field and a number of strategies are being employed to enhance cancer-
killing and immune-stimulating abilities of herpesviruses through careful, purposeful genetic 
engineering. We hypothesized that a genetically engineered, live-attenuated HSV-1 vaccine 
generated in our laboratory (VC2) could have therapeutic immune-stimulating properties in the 
tumor microenvironment in a novel murine melanoma model developed in our laboratory for 
testing oncolytic and immune-modulating herpesviruses. Our hypothesis was based on the 
observation of strong cell-mediated and humoral immune responses generated by VC2 during 
vaccinology studies. The ability of VC2 to replicate efficiently in permissive cells without 
compromising safety is a significant advantage over the currently FDA-approved oncolytic 
virotherapy, T-VEC. Because we performed in vivo testing in a model system where murine 
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melanoma cells lacked nectin-1 receptors, which we demonstrated are important in HSV-1 
replication and cytolysis in vitro in B16F10 cells, the immune stimulating therapeutic effects can 
be attributed largely to the remarkable immunogenicity and adjuvanticity of VC2, which 
supports its development as a vector for immune-stimulating cancer therapy. The effect of VC2 
in modulating the tumor microenvironment is particularly interesting in light of our early work in 
tumor modeling where we showed that tumor cell microenvironment influences growth kinetics 
and metastatic behavior of B16F10 murine melanoma cells.  
We also demonstrated the utility of bioluminescent, in vivo imaging in monitoring 
response to immune-stimulating therapies such as oHSVs. Mice may be prematurely euthanized 
when clinical assessment of tumor progression is based on tumor volume from caliper 
measurements alone since immune-stimulating therapies result in acute necrosis, inflammation, 
and swelling of the tumor, a phenomenon referred to as pseduoprogression. More sensitive 
evaluation of response to therapy should improve development of effective therapeutic strategies 
since acute responses will be more apparent and direct dosing strategies in subsequent studies. 
Current and Future Directions 
 There has long been a debate in the field of oncolytic virotherapy regarding whether the 
direct lytic effect of the virus on tumor cells or the immune response stimulated by the virus is 
more important in generating anti-tumor effects. We suspected that both were important and that 
efficient viral infection and spread within the tumor and potent, direct lysis of tumor cells would 
have a synergistic effect with the immune response. We found in the studies described herein 
that expression of nectin-1 by tumor cells strongly impacts the ability of the virus to infect and 
lyse tumor cells in vitro. Therefore, current work is underway to explore the impact of 
expression of the HSV-1 receptor, nectin-1, by melanoma tumor cells (B16F10-eGFP-fLuc-
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nectin-1) in immunocompetent mice. In preliminary studies, we have found that VC2 does, in 
fact, appear to exhibit superior spread and persistence within tumors expressing nectin-1 in 
comparison to non-nectin-1 expressing tumors, based on immunohistochemical staining for 
HSV-1. However, although overall survival was increased for VC2-treated animals in 
comparison to mock-treated, there was no significant difference in survival between animals 
bearing nectin-1 versus non-nectin-1-expressing tumors. These findings suggest that the adjuvant 
effect of the virus in stimulating an immune response may be the more critical factor in 
determining in vivo response in comparison to oncolytic ability. This is good news for the field 
of oncolytic virotherapy and for patients since entry receptor expression can vary between tumor 
types, between patients, and even within a single tumor. It also supports the current thought in 
immuno-oncology that stimulating an appropriate anti-tumor immune response is key to 
triggering durable tumor growth inhibition. However, these findings also challenge the validity 
of the way current oncolytic virotherapy research is conducted and create new potential 
challenges in early preclinical screening of viruses for therapeutic potential. Historically, viruses 
have been initially tested in cell lines in vitro and chosen for superior tumor cell lysing abilities 
before moving into animal studies. But, if tumor lysis in vitro does not correlate with therapeutic 
responses in vivo, a new system for early screening will be necessary which accounts for 
immunostimulatory properties of the virus and not just direct oncolytic ability.  
Additional current and future directions involve testing various strategies using VC2 as a 
vector for cancer immunotherapy. A VC2 mutant expressing granulocyte macrophage-colony-
stimulating factor (GM-CSF) has been generated in our laboratory for direct comparison with 
FDA-approved T-VEC.  GM-CSF is a cytokine normally secreted by macrophages, T cells, mast 
cells, natural killer cells, endothelial cells and fibroblasts, and is intended to enhance the immune 
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response. Specifically, GM-CSF can stimulate stem cells to develop into granulocytes and 
monocytes. In the tumor microenvironment, GM-CSF is expected to participate in the 
inflammatory cascade and promote the maturation of macrophages and dendritic cells. Since we 
have shown that intratumoral injections of VC2 result in increased infiltration by macrophages 
and repolarization from an M2 to an M1 phenotype, we expect that GM-CSF expression by VC2 
could enhance this effect and improve therapeutic response. We also expect that efficacy will be 
superior to TVEC in immunocompetent models since we have chosen our vector virus, VC2, 
based on adjuvanticity while the TVEC vector, JS1, was chosen for its in vitro lytic capabilities. 
We also expect that significant differences in the safety profile will be observed since TVEC has 
not been genetically engineered to prevent entry into ganglionic axons and establishment of 
latency, while we have shown extensively that VC2 cannot enter ganglionic axons.  
An additional VC2 mutant expressing melanoma antigens, including TRP-1, TRP-2, 
tyrosinase, gp100, and melan-A, has been generated for testing as a prophylactic and therapeutic 
cancer vaccine. These melanoma antigens are expressed by the B16F10 murine melanoma cell 
line as well as human melanoma. Melanoma tumors in veterinary species, including canine and 
equine patients, also express these antigens.   
Combinatorial strategies using VC2 with immune checkpoint inhibitors are also of 
interest. Combination therapy targeting multiple mechanisms of tumor growth and progression 
are typical in modern medical oncology. Immune checkpoint inhibitors which target and block 
co-inhibitory molecules that dampen immune responses, including antibodies against cytotoxic 
lymphocyte antigen-4 (CTLA-4), programmed death receptor-1 (PD-1), and programmed death 
ligand-1 (PDL-1), are commonly used in melanoma patients. Immune checkpoint blockade is 
intended to “take the brakes off” of the immune system, while virotherapy is intended to “press 
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on the gas”. Combining these two strategies is intended to maximize effective immune responses 
against tumor antigens and create a synergistic effect.317 Benefits of combination immune 
checkpoint blockade and oncolytic virotherapy have been demonstrated with T-VEC in human 
clinical trials.318   
 All data compiled from vaccinology and immuno-oncology studies in our laboratory to 
date support that VC2 is a potent immunostimulatory virus with an exceptional safety profile in 
animals. It is unknown how VC2 would perform in human patients, but current data and ongoing 
work will support a research category investigational new drug (IND) application through the 















1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. 
 
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674. 
 
3. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. 
Nature 2007;445:851-857. 
 
4. Cichorek M, Wachulska M, Stasiewicz A, et al. Skin melanocytes: biology and development. 
Postepy Dermatol Alergol 2013;30:30-41. 
 
5. Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease. 
Development 2015;142:620-632. 
 
6. Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl 
2013;11:81-91. 
 
7. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and 
noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American 
College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 
1998;83:1664-1678. 
 
8. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. 
9. Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003;37:67-90. 
 
10. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J 
Cancer 1997;73:198-203. 
 
11. Nelemans PJ, Groenendal H, Kiemeney LA, et al. Effect of intermittent exposure to sunlight 
on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect 
1993;101:252-255. 
 
12. White E, Kirkpatrick CS, Lee JA. Case-control study of malignant melanoma in Washington 
State. I. Constitutional factors and sun exposure. Am J Epidemiol 1994;139:857-868. 
13. Wang SQ, Setlow R, Berwick M, et al. Ultraviolet A and melanoma: a review. J Am Acad 
Dermatol 2001;44:837-846. 
 
14. Stern RS, Study PFu. The risk of melanoma in association with long-term exposure to 
PUVA. J Am Acad Dermatol 2001;44:755-761. 
 
15. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 
1993;55:742-747. 
 
16. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-278. 
145 
 
17. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European 
consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer 2016;63:201-217. 
 
18. Meier F, Nesbit M, Hsu MY, et al. Human melanoma progression in skin reconstructs : 
biological significance of bFGF. Am J Pathol 2000;156:193-200. 
 
19. Urso C, Rongioletti F, Innocenzi D, et al. Histological features used in the diagnosis of 
melanoma are frequently found in benign melanocytic naevi. J Clin Pathol 2005;58:409-412. 
 
20. Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod 
Pathol 2006;19 Suppl 2:S34-40. 
 
21. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging 
and classification. J Clin Oncol 2009;27:6199-6206. 
 
22. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma 
patients: validation of the American Joint Committee on Cancer melanoma staging system. J 
Clin Oncol 2001;19:3622-3634. 
 
23. Callender GG, Egger ME, Burton AL, et al. Prognostic implications of anatomic location of 
primary cutaneous melanoma of 1 mm or thicker. Am J Surg 2011;202:659-664; discussion 664-
655. 
 
24. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Identification of prognostic 
groups and estimation of individual prognosis for 5093 patients. Cancer 1995;75:2484-2491. 
25. Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma 
population. Ann Surg Oncol 1994;1:487-494. 
 
26. Joosse A, Collette S, Suciu S, et al. Superior outcome of women with stage I/II cutaneous 
melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer 
phase III trials. J Clin Oncol 2012;30:2240-2247. 
 
27. Masback A, Olsson H, Westerdahl J, et al. Prognostic factors in invasive cutaneous 
malignant melanoma: a population-based study and review. Melanoma Res 2001;11:435-445. 
 
28. Vossaert KA, Silverman MK, Kopf AW, et al. Influence of gender on survival in patients 
with stage I malignant melanoma. J Am Acad Dermatol 1992;26:429-440. 
 
29. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of 
cutaneous melanoma. Cancer 1980;45:3012-3017. 
 
30. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year 





31. Soong SJ, Shaw HM, Balch CM, et al. Predicting survival and recurrence in localized 
melanoma: a multivariate approach. World J Surg 1992;16:191-195. 
 
32. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized 
primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint 
Committee on Cancer melanoma staging database. J Clin Oncol 2011;29:2199-2205. 
 
33. Nagore E, Oliver V, Botella-Estrada R, et al. Prognostic factors in localized invasive 
cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. 
Melanoma Res 2005;15:169-177. 
 
34. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Vascular involvement in the prognosis of 
primary cutaneous melanoma. Arch Dermatol 2001;137:1169-1173. 
 
35. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Tumor vascularity in the prognostic 
assessment of primary cutaneous melanoma. J Clin Oncol 2002;20:1826-1831. 
 
36. Xu X, Chen L, Guerry D, et al. Lymphatic invasion is independently prognostic of metastasis 
in primary cutaneous melanoma. Clin Cancer Res 2012;18:229-237. 
 
37. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors 
among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus 
macrometastases. J Clin Oncol 2010;28:2452-2459. 
 
38. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with 
clinical outcome. JAMA 1998;280:1410-1415. 
 
39. Martenson ED, Hansson LO, Nilsson B, et al. Serum S-100b protein as a prognostic marker 
in malignant cutaneous melanoma. J Clin Oncol 2001;19:824-831. 
 
40. Tarhini AA, Stuckert J, Lee S, et al. Prognostic significance of serum S100B protein in high-
risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin 
Oncol 2009;27:38-44. 
 
41. Bandarchi B, Jabbari CA, Vedadi A, et al. Molecular biology of normal melanocytes and 
melanoma cells. J Clin Pathol 2013;66:644-648. 
 
42. Aitken J, Welch J, Duffy D, et al. CDKN2A variants in a population-based sample of 
Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-452. 
 
43. Bataille V. Genetics of familial and sporadic melanoma. Clin Exp Dermatol 2000;25:464-
470. 
 
44. Nagore E, Climent J, Planelles MD, et al. Analysis of the CDKN2A and CDK4 genes and 




45. Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations 
and relative risk for cutaneous malignant melanoma: an international population-based study. 
Cancer Epidemiol Biomarkers Prev 2006;15:1520-1525. 
 
46. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in 
genesis of many tumor types. Science 1994;264:436-440. 
 
47. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene 
in multiple human cancers. Nature 1994;368:753-756. 
 
48. Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAF, NRAS, and 
PTEN in primary cutaneous melanoma. J Invest Dermatol 2006;126:154-160. 
 
49. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of 
melanoma. J Clin Oncol 2006;24:4340-4346. 
 
50. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N 
Engl J Med 2005;353:2135-2147. 
 
51. Bandarchi B, Ma L, Navab R, et al. From melanocyte to metastatic malignant melanoma. 
Dermatol Res Pract 2010;2010. 
 
52. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA 
copy number changes. Am J Pathol 2003;163:1765-1770. 
 
53. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant 
nevi and melanomas. J Natl Cancer Inst 1988;80:1159-1164. 
 
54. Greulich KM, Utikal J, Peter RU, et al. c-MYC and nodular malignant melanoma. A case 
report. Cancer 2000;89:97-103. 
 
55. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of 
oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-1246. 
 
56. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int 
J Cancer 2003;104:527-532. 
 
57. Dhawan P, Singh AB, Ellis DL, et al. Constitutive activation of Akt/protein kinase B in 
melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 
2002;62:7335-7342. 
 
58. Karim RZ, Li W, Sanki A, et al. Reduced p16 and increased cyclin D1 and pRb expression 
are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol 2009;17:361-
367. 
 
59. Mukherji B. Immunology of melanoma. Clin Dermatol 2013;31:156-165. 
148 
 
60. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274. 
 
61. Carrega P, Pezzino G, Queirolo P, et al. Susceptibility of human melanoma cells to 
autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of 
unlicensed NK cells. PLoS One 2009;4:e8132. 
 
62. Lozupone F, Pende D, Burgio VL, et al. Effect of human natural killer and gammadelta T 
cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res 
2004;64:378-385. 
 
63. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in 
human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223. 
 
64. Andreu P, Johansson M, Affara NI, et al. FcRgamma activation regulates inflammation-
associated squamous carcinogenesis. Cancer Cell 2010;17:121-134. 
 
65. Affara NI, Ruffell B, Medler TR, et al. B cells regulate macrophage phenotype and response 
to chemotherapy in squamous carcinomas. Cancer Cell 2014;25:809-821. 
 
66. Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated 
macrophages by tumour-derived lactic acid. Nature 2014;513:559-563. 
 
67. Nielsen SR, Schmid MC. Macrophages as Key Drivers of Cancer Progression and 
Metastasis. Mediators Inflamm 2017;2017:9624760. 
 
68. Ruffell B, Chang-Strachan D, Chan V, et al. Macrophage IL-10 blocks CD8+ T cell-
dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic 
cells. Cancer Cell 2014;26:623-637. 
 
69. Hagemann T, Lawrence T, McNeish I, et al. "Re-educating" tumor-associated macrophages 
by targeting NF-kappaB. J Exp Med 2008;205:1261-1268. 
 
70. !!! INVALID CITATION !!! {}. 
 
71. Cai X, Yin Y, Li N, et al. Re-polarization of tumor-associated macrophages to pro-
inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol 2012;4:341-343. 
 
72. Bulliard Y, Jolicoeur R, Windman M, et al. Activating Fc gamma receptors contribute to the 
antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 
2013;210:1685-1693. 
 
73. Dahan R, Sega E, Engelhardt J, et al. FcgammaRs Modulate the Anti-tumor Activity of 
Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell 2015;28:285-295. 
 
74. Old LJ. Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. 
Cancer Res 1981;41:361-375. 
149 
 
75. Lloyd KO, Old LJ. Human monoclonal antibodies to glycolipids and other carbohydrate 
antigens: dissection of the humoral immune response in cancer patients. Cancer Res 
1989;49:3445-3451. 
 
76. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune 
responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-11813. 
 
77. Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. 
Annu Rev Immunol 2006;24:175-208. 
 
78. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the 
T cell response. Nat Rev Immunol 2012;12:269-281. 
 
79. Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and 
gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 2008;56 Suppl 1:3s-59s. 
 
80. Hoster HA, Zanes RP, Jr., Von Haam E. Studies in Hodgkin's syndrome; the association of 
viral hepatitis and Hodgkin's disease; a preliminary report. Cancer Res 1949;9:473-480. 
 
81. Taylor AW. Effects of glandular fever infection in acute leukaemia. Br Med J 1953;1:589-
593. 
 
82. Huebner RJ, Rowe WP, Schatten WE, et al. Studies on the use of viruses in the treatment of 
carcinoma of the cervix. Cancer 1956;9:1211-1218. 
 
83. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 
2007;15:651-659. 
 
84. Diaconu I, Cerullo V, Hirvinen ML, et al. Immune response is an important aspect of the 
antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 
2012;72:2327-2338. 
 
85. Miyamoto S, Inoue H, Nakamura T, et al. Coxsackievirus B3 is an oncolytic virus with 
immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 
2012;72:2609-2621. 
 
86. Donnelly OG, Errington-Mais F, Steele L, et al. Measles virus causes immunogenic cell 
death in human melanoma. Gene Ther 2013;20:7-15. 
 
87. Prestwich RJ, Errington F, Ilett EJ, et al. Tumor infection by oncolytic reovirus primes 
adaptive antitumor immunity. Clin Cancer Res 2008;14:7358-7366. 
 
88. Toda M, Martuza RL, Kojima H, et al. In situ cancer vaccination: an IL-12 defective 
vector/replication-competent herpes simplex virus combination induces local and systemic 
antitumor activity. J Immunol 1998;160:4457-4464. 
150 
 
89. Toda M, Rabkin SD, Kojima H, et al. Herpes simplex virus as an in situ cancer vaccine for 
the induction of specific anti-tumor immunity. Hum Gene Ther 1999;10:385-393. 
 
90. Thorne SH, Contag CH. Integrating the biological characteristics of oncolytic viruses and 
immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther 2008;15:753-
758. 
 
91. Breitbach CJ, Arulanandam R, De Silva N, et al. Oncolytic vaccinia virus disrupts tumor-
associated vasculature in humans. Cancer Res 2013;73:1265-1275. 
 
92. Breitbach CJ, De Silva NS, Falls TJ, et al. Targeting tumor vasculature with an oncolytic 
virus. Mol Ther 2011;19:886-894. 
 
93. Benencia F, Courreges MC, Conejo-Garcia JR, et al. Oncolytic HSV exerts direct 
antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005;16:765-778. 
 
94. Fountzilas C, Patel S, Mahalingam D. Review: Oncolytic virotherapy, updates and future 
directions. Oncotarget 2017;8:102617-102639. 
 
95. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen 
Virol 2000;81:2605-2609. 
 
96. Dubin G, Fishman NO, Eisenberg RJ, et al. The role of herpes simplex virus glycoproteins in 
immune evasion. Curr Top Microbiol Immunol 1992;179:111-120. 
 
97. Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: Fed Ex for 
cancer therapy. Mol Ther 2009;17:1667-1676. 
 
98. Fields BN, Knipe DM, Howley PM. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven 
Publishers, 1996. 
 
99. Sanchala DS, Bhatt LK, Prabhavalkar KS. Oncolytic Herpes Simplex Viral Therapy: A 
Stride toward Selective Targeting of Cancer Cells. Front Pharmacol 2017;8:270. 
 
100. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the 
brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5:881-887. 
 
101. Ikeda K, Wakimoto H, Ichikawa T, et al. Complement depletion facilitates the infection of 
multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J 
Virol 2000;74:4765-4775. 
 
102. Wakimoto H, Ikeda K, Abe T, et al. The complement response against an oncolytic virus is 
species-specific in its activation pathways. Mol Ther 2002;5:275-282. 
 
103. Yoo JY, Pradarelli J, Haseley A, et al. Copper chelation enhances antitumor efficacy and 
systemic delivery of oncolytic HSV. Clin Cancer Res 2012;18:4931-4941. 
151 
 
104. Gatta V, Petrovic B, Campadelli-Fiume G. The Engineering of a Novel Ligand in gH 
Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors. PLoS 
Pathog 2015;11:e1004907. 
 
105. Leoni V, Gatta V, Palladini A, et al. Systemic delivery of HER2-retargeted oncolytic-HSV 
by mesenchymal stromal cells protects from lung and brain metastases. Oncotarget 
2015;6:34774-34787. 
 
106. Zhou G, Roizman B. Construction and properties of a herpes simplex virus 1 designed to 
enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A 2006;103:5508-5513. 
107. Uchida H, Marzulli M, Nakano K, et al. Effective treatment of an orthotopic xenograft 
model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol 
Ther 2013;21:561-569. 
 
108. Shibata T, Uchida H, Shiroyama T, et al. Development of an oncolytic HSV vector fully 
retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. Gene Ther 
2016;23:479-488. 
 
109. Kwon H, Bai Q, Baek HJ, et al. Soluble V domain of Nectin-1/HveC enables entry of 
herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D. 
J Virol 2006;80:138-148. 
 
110. Nakano K, Asano R, Tsumoto K, et al. Herpes simplex virus targeting to the EGF receptor 
by a gD-specific soluble bridging molecule. Mol Ther 2005;11:617-626. 
 
111. Baek H, Uchida H, Jun K, et al. Bispecific adapter-mediated retargeting of a receptor-
restricted HSV-1 vector to CEA-bearing tumor cells. Mol Ther 2011;19:507-514. 
 
112. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human 
genome. Nature 2001;409:860-921. 
 
113. Anderson DB, Laquerre S, Ghosh K, et al. Pseudotyping of glycoprotein D-deficient herpes 
simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus 
attachment and entry. J Virol 2000;74:2481-2487. 
 
114. Shintani M, Takahashi G, Hamada M, et al. Effect of ultrasound on herpes simplex virus 
infection in cell culture. Virol J 2011;8:446. 
 
115. McKee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma 
xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 
2006;66:2509-2513. 
 
116. Otsuki A, Patel A, Kasai K, et al. Histone Deacetylase Inhibitors Augment Antitumor 




117. Wollmann G, Tattersall P, van den Pol AN. Targeting human glioblastoma cells: 
comparison of nine viruses with oncolytic potential. J Virol 2005;79:6005-6022. 
 
118. Bennett JJ, Delman KA, Burt BM, et al. Comparison of safety, delivery, and efficacy of two 
oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 
2002;9:935-945. 
 
119. Workenhe ST, Simmons G, Pol JG, et al. Immunogenic HSV-mediated oncolysis shapes the 
antitumor immune response and contributes to therapeutic efficacy. Mol Ther 2014;22:123-131. 
120. Alain T, Kim TS, Lun X, et al. Proteolytic disassembly is a critical determinant for reovirus 
oncolysis. Mol Ther 2007;15:1512-1521. 
 
121. Marcato P, Shmulevitz M, Pan D, et al. Ras transformation mediates reovirus oncolysis by 
enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 
2007;15:1522-1530. 
 
122. Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: usurpation of 
the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-3362. 
 
123. Gasparri F, Wang N, Skog S, et al. Thymidine kinase 1 expression defines an activated G1 
state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. Eur J Cell 
Biol 2009;88:779-785. 
 
124. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001;357:1513-1518. 
 
125. Field HJ, Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes 
simplex virus in mice. J Hyg (Lond) 1978;81:267-277. 
 
126. Jamieson AT, Gentry GA, Subak-Sharpe JH. Induction of both thymidine and 
deoxycytidine kinase activity by herpes viruses. J Gen Virol 1974;24:465-480. 
 
127. Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means 
of a genetically engineered virus mutant. Science 1991;252:854-856. 
 
128. Sokolowski NA, Rizos H, Diefenbach RJ. Oncolytic virotherapy using herpes simplex 
virus: how far have we come? Oncolytic Virother 2015;4:207-219. 
 
129. Wagner MJ, Sharp JA, Summers WC. Nucleotide sequence of the thymidine kinase gene of 
herpes simplex virus type 1. Proc Natl Acad Sci U S A 1981;78:1441-1445. 
 
130. Coen DM, Kosz-Vnenchak M, Jacobson JG, et al. Thymidine kinase-negative herpes 
simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc 
Natl Acad Sci U S A 1989;86:4736-4740. 
 
131. Peters C, Rabkin SD. Designing Herpes Viruses as Oncolytics. Mol Ther Oncolytics 2015;2. 
153 
 
132. Schubert A, Gentner E, Bohn K, et al. Single nucleotide polymorphisms of thymidine 
kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated 
with different resistance phenotypes. Antiviral Res 2014;107:16-22. 
 
133. Preston VG, Palfreyman JW, Dutia BM. Identification of a herpes simplex virus type 1 
polypeptide which is a component of the virus-induced ribonucleotide reductase. J Gen Virol 
1984;65 ( Pt 9):1457-1466. 
 
134. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase 
activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an 
ICP6 lacZ insertion mutant. J Virol 1988;62:196-205. 
 
135. Chou J, Kern ER, Whitley RJ, et al. Mapping of herpes simplex virus-1 neurovirulence to 
gamma 134.5, a gene nonessential for growth in culture. Science 1990;250:1262-1266. 
 
136. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes 
neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed 
cell death in neuronal cells. Proc Natl Acad Sci U S A 1992;89:3266-3270. 
 
137. MacLean AR, ul-Fareed M, Robertson L, et al. Herpes simplex virus type 1 deletion 
variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ 
between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991;72 ( Pt 3):631-639. 
 
138. Markert JM, Malick A, Coen DM, et al. Reduction and elimination of encephalitis in an 
experimental glioma therapy model with attenuated herpes simplex mutants that retain 
susceptibility to acyclovir. Neurosurgery 1993;32:597-603. 
 
139. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-
hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 
1994;54:3963-3966. 
 
140. Randazzo BP, Kesari S, Gesser RM, et al. Treatment of experimental intracranial murine 
melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 1995;211:94-101. 
 
141. Meignier B, Martin B, Whitley RJ, et al. In vivo behavior of genetically engineered herpes 
simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl 
monkeys (Aotus trivirgatus). J Infect Dis 1990;162:313-321. 
 
142. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes 
simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 
1988;158:602-614. 
 
143. Wong RJ, Kim SH, Joe JK, et al. Effective treatment of head and neck squamous cell 
carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001;193:12-21. 
154 
 
144. Advani SJ, Chung SM, Yan SY, et al. Replication-competent, nonneuroinvasive genetically 
engineered herpes virus is highly effective in the treatment of therapy-resistant experimental 
human tumors. Cancer Res 1999;59:2055-2058. 
 
145. Takakuwa H, Goshima F, Nozawa N, et al. Oncolytic viral therapy using a spontaneously 
generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in 
immunocompetent mice. Arch Virol 2003;148:813-825. 
 
146. Nakao A, Kasuya H, Sahin TT, et al. A phase I dose-escalation clinical trial of 
intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients 
with advanced pancreatic cancer. Cancer Gene Ther 2011;18:167-175. 
 
147. Flemington EK. Herpesvirus lytic replication and the cell cycle: arresting new 
developments. J Virol 2001;75:4475-4481. 
 
148. Dargan DJ, Subak-Sharpe JH. The effect of herpes simplex virus type 1 L-particles on virus 
entry, replication, and the infectivity of naked herpesvirus DNA. Virology 1997;239:378-388. 
 
149. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 
complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the 
eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-
stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A 1997;94:843-848. 
 
150. Olgiate J, Ehmann GL, Vidyarthi S, et al. Herpes simplex virus induces intracellular 
redistribution of E2F4 and accumulation of E2F pocket protein complexes. Virology 
1999;258:257-270. 
 
151. Hobbs WE, 2nd, DeLuca NA. Perturbation of cell cycle progression and cellular gene 
expression as a function of herpes simplex virus ICP0. J Virol 1999;73:8245-8255. 
 
152. Lomonte P, Everett RD. Herpes simplex virus type 1 immediate-early protein Vmw110 
inhibits progression of cells through mitosis and from G(1) into S phase of the cell cycle. J Virol 
1999;73:9456-9467. 
 
153. Song B, Liu JJ, Yeh KC, et al. Herpes simplex virus infection blocks events in the G1 phase 
of the cell cycle. Virology 2000;267:326-334. 
 
154. Ehmann GL, McLean TI, Bachenheimer SL. Herpes simplex virus type 1 infection imposes 
a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells. 
Virology 2000;267:335-349. 
 
155. Giraud G, Ramqvist T, Ragnarsson-Olding B, et al. DNA from BK virus and JC virus and 
from KI, WU, and MC polyomaviruses as well as from simian virus 40 is not detected in non-




156. Hossain A, Holt T, Ciacci-Zanella J, et al. Analysis of cyclin-dependent kinase activity after 
herpes simplex virus type 2 infection. J Gen Virol 1997;78 ( Pt 12):3341-3348. 
 
157. He B, Chou J, Liebermann DA, et al. The carboxyl terminus of the murine MyD116 gene 
substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to 
preclude the premature shutoff of total protein synthesis in infected human cells. J Virol 
1996;70:84-90. 
 
158. McKie EA, MacLean AR, Lewis AD, et al. Selective in vitro replication of herpes simplex 
virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a 
potentially effective clinical therapy. Br J Cancer 1996;74:745-752. 
 
159. Chou J, Chen JJ, Gross M, et al. Association of a M(r) 90,000 phosphoprotein with protein 
kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 
alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of 
herpes simplex virus 1. Proc Natl Acad Sci U S A 1995;92:10516-10520. 
 
160. Yu X, He S. The interplay between human herpes simplex virus infection and the apoptosis 
and necroptosis cell death pathways. Virol J 2016;13:77. 
 
161. Langelier Y, Bergeron S, Chabaud S, et al. The R1 subunit of herpes simplex virus 
ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation. 
J Gen Virol 2002;83:2779-2789. 
 
162. Leopardi R, Van Sant C, Roizman B. The herpes simplex virus 1 protein kinase US3 is 
required for protection from apoptosis induced by the virus. Proc Natl Acad Sci U S A 
1997;94:7891-7896. 
 
163. Zhou G, Galvan V, Campadelli-Fiume G, et al. Glycoprotein D or J delivered in trans 
blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact 
genes expressing both glycoproteins. J Virol 2000;74:11782-11791. 
 
164. Zhou G, Roizman B. The domains of glycoprotein D required to block apoptosis depend on 
whether glycoprotein D is present in the virions carrying herpes simplex virus 1 genome lacking 
the gene encoding the glycoprotein. J Virol 2001;75:6166-6172. 
 
165. Aubert M, Blaho JA. Viral oncoapoptosis of human tumor cells. Gene Ther 2003;10:1437-
1445. 
 
166. Aubert M, O'Toole J, Blaho JA. Induction and prevention of apoptosis in human HEp-2 
cells by herpes simplex virus type 1. J Virol 1999;73:10359-10370. 
 
167. Nguyen ML, Kraft RM, Blaho JA. African green monkey kidney Vero cells require de novo 




168. Hardwicke MA, Vaughan PJ, Sekulovich RE, et al. The regions important for the activator 
and repressor functions of herpes simplex virus type 1 alpha protein ICP27 map to the C-
terminal half of the molecule. J Virol 1989;63:4590-4602. 
 
169. Montgomery RI, Warner MS, Lum BJ, et al. Herpes simplex virus-1 entry into cells 
mediated by a novel member of the TNF/NGF receptor family. Cell 1996;87:427-436. 
 
170. Medici MA, Sciortino MT, Perri D, et al. Protection by herpes simplex virus glycoprotein D 
against Fas-mediated apoptosis: role of nuclear factor kappaB. J Biol Chem 2003;278:36059-
36067. 
 
171. Wang X, Patenode C, Roizman B. US3 protein kinase of HSV-1 cycles between the 
cytoplasm and nucleus and interacts with programmed cell death protein 4 (PDCD4) to block 
apoptosis. Proc Natl Acad Sci U S A 2011;108:14632-14636. 
 
172. Garrido C, Bruey JM, Fromentin A, et al. HSP27 inhibits cytochrome c-dependent 
activation of procaspase-9. FASEB J 1999;13:2061-2070. 
 
173. Creagh EM, Carmody RJ, Cotter TG. Heat shock protein 70 inhibits caspase-dependent and 
-independent apoptosis in Jurkat T cells. Exp Cell Res 2000;257:58-66. 
 
174. Ahmed M, Lock M, Miller CG, et al. Regions of the herpes simplex virus type 1 latency-
associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo. J 
Virol 2002;76:717-729. 
 
175. Henderson G, Peng W, Jin L, et al. Regulation of caspase 8- and caspase 9-induced 
apoptosis by the herpes simplex virus type 1 latency-associated transcript. J Neurovirol 2002;8 
Suppl 2:103-111. 
 
176. Sanfilippo CM, Blaho JA. ICP0 gene expression is a herpes simplex virus type 1 apoptotic 
trigger. J Virol 2006;80:6810-6821. 
 
177. Guo H, Omoto S, Harris PA, et al. Herpes simplex virus suppresses necroptosis in human 
cells. Cell Host Microbe 2015;17:243-251. 
 
178. Wang X, Li Y, Liu S, et al. Direct activation of RIP3/MLKL-dependent necrosis by herpes 
simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense. Proc Natl Acad Sci U S A 
2014;111:15438-15443. 
 
179. Huang Z, Wu SQ, Liang Y, et al. RIP1/RIP3 binding to HSV-1 ICP6 initiates necroptosis to 
restrict virus propagation in mice. Cell Host Microbe 2015;17:229-242. 
 





181. de Gruijl TD, Janssen AB, van Beusechem VW. Arming oncolytic viruses to leverage 
antitumor immunity. Expert Opin Biol Ther 2015;15:959-971. 
 
182. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with 
enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 
2001;98:6396-6401. 
 
183. Hill A, Jugovic P, York I, et al. Herpes simplex virus turns off the TAP to evade host 
immunity. Nature 1995;375:411-415. 
 
184. Castelo-Branco P, Passer BJ, Buhrman JS, et al. Oncolytic herpes simplex virus armed with 
xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate 
cancer. Gene Ther 2010;17:805-810. 
 
185. Wong RJ, Patel SG, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy 
in murine squamous cell carcinoma. Hum Gene Ther 2001;12:253-265. 
 
186. Ino Y, Saeki Y, Fukuhara H, et al. Triple combination of oncolytic herpes simplex virus-1 
vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor 
efficacy. Clin Cancer Res 2006;12:643-652. 
 
187. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 
in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000;97:2208-
2213. 
 
188. Antoszczyk S, Spyra M, Mautner VF, et al. Treatment of orthotopic malignant peripheral 
nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol 2014;16:1057-1066. 
 
189. Gaston DC, Odom CI, Li L, et al. Production of bioactive soluble interleukin-15 in complex 
with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One 
2013;8:e81768. 
 
190. Han ZQ, Assenberg M, Liu BL, et al. Development of a second-generation oncolytic 
Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med 2007;9:99-106. 
 
191. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced 
oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303. 
 
192. Barnard Z, Wakimoto H, Zaupa C, et al. Expression of FMS-like tyrosine kinase 3 ligand 
by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic 
intracranial malignant glioma. Neurosurgery 2012;71:741-748; discussion 748. 
 
193. Kefalides NA, Ziaie Z. Herpes simplex virus suppression of human endothelial matrix 
protein synthesis is independent of viral protein synthesis. Lab Invest 1986;55:328-336. 
158 
 
194. Goodwin JM, Schmitt AD, McGinn CM, et al. Angiogenesis inhibition using an oncolytic 
herpes simplex virus expressing endostatin in a murine lung cancer model. Cancer Invest 
2012;30:243-250. 
 
195. Tsuji T, Nakamori M, Iwahashi M, et al. An armed oncolytic herpes simplex virus 
expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric 
cancer. Int J Cancer 2013;132:485-494. 
 
196. Zhang G, Jin G, Nie X, et al. Enhanced antitumor efficacy of an oncolytic herpes simplex 
virus expressing an endostatin-angiostatin fusion gene in human glioblastoma stem cell 
xenografts. PLoS One 2014;9:e95872. 
 
197. Hardcastle J, Kurozumi K, Dmitrieva N, et al. Enhanced antitumor efficacy of vasculostatin 
(Vstat120) expressing oncolytic HSV-1. Mol Ther 2010;18:285-294. 
 
198. Jha BK, Dong B, Nguyen CT, et al. Suppression of antiviral innate immunity by sunitinib 
enhances oncolytic virotherapy. Mol Ther 2013;21:1749-1757. 
 
199. Jha BK, Polyakova I, Kessler P, et al. Inhibition of RNase L and RNA-dependent protein 
kinase (PKR) by sunitinib impairs antiviral innate immunity. J Biol Chem 2011;286:26319-
26326. 
 
200. Poppers J, Mulvey M, Khoo D, et al. Inhibition of PKR activation by the proline-rich RNA 
binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 2000;74:11215-11221. 
 
201. Mulvey M, Poppers J, Ladd A, et al. A herpesvirus ribosome-associated, RNA-binding 
protein confers a growth advantage upon mutants deficient in a GADD34-related function. J 
Virol 1999;73:3375-3385. 
 
202. Cassady KA, Gross M, Roizman B. The herpes simplex virus US11 protein effectively 
compensates for the gamma1(34.5) gene if present before activation of protein kinase R by 
precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation 
factor 2. J Virol 1998;72:8620-8626. 
 
203. Taneja S, MacGregor J, Markus S, et al. Enhanced antitumor efficacy of a herpes simplex 
virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci U S A 
2001;98:8804-8808. 
 
204. Mohr I, Sternberg D, Ward S, et al. A herpes simplex virus type 1 gamma34.5 second-site 
suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely 
attenuated in animals. J Virol 2001;75:5189-5196. 
 
205. York IA, Roop C, Andrews DW, et al. A cytosolic herpes simplex virus protein inhibits 




206. Fruh K, Ahn K, Djaballah H, et al. A viral inhibitor of peptide transporters for antigen 
presentation. Nature 1995;375:415-418. 
 
207. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of 
defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating 
factor. Mol Ther 2000;2:324-329. 
 
208. Chouljenko VN, Iyer AV, Chowdhury S, et al. The amino terminus of herpes simplex virus 
type 1 glycoprotein K (gK) modulates gB-mediated virus-induced cell fusion and virion egress. J 
Virol 2009;83:12301-12313. 
 
209. Chouljenko VN, Iyer AV, Chowdhury S, et al. The herpes simplex virus type 1 UL20 
protein and the amino terminus of glycoprotein K (gK) physically interact with gB. J Virol 
2010;84:8596-8606. 
 
210. Stanfield BA, Stahl J, Chouljenko VN, et al. A single intramuscular vaccination of mice 
with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein 
UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-
2 strains. PLoS One 2014;9:e109890. 
 
211. Foster TP, Chouljenko VN, Kousoulas KG. Functional and physical interactions of the 
herpes simplex virus type 1 UL20 membrane protein with glycoprotein K. J Virol 2008;82:6310-
6323. 
 
212. Saied AA, Chouljenko VN, Subramanian R, et al. A replication competent HSV-1(McKrae) 
with a mutation in the amino-terminus of glycoprotein K (gK) is unable to infect mouse 
trigeminal ganglia after cornea infection. Curr Eye Res 2014;39:596-603. 
 
213. Musarrat F, Jambunathan N, Rider PJF, et al. The Amino Terminus of Herpes Simplex 
Virus 1 Glycoprotein K (gK) Is Required for gB Binding to Akt, Release of Intracellular 
Calcium, and Fusion of the Viral Envelope with Plasma Membranes. J Virol 2018;92. 
 
214. Stanfield BA, Rider PJF, Caskey J, et al. Intramuscular vaccination of guinea pigs with the 
live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal 
Th17 and regulatory Tr1 responses. Vaccine 2018;36:2842-2849. 
 
215. Stanfield BA, Pahar B, Chouljenko VN, et al. Vaccination of rhesus macaques with the live-
attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal 
center responses resulting in sustained production of highly neutralizing antibodies. Vaccine 
2017;35:536-543. 
 
216. Beaumont KA, Mohana-Kumaran N, Haass NK. Modeling Melanoma In Vitro and In Vivo. 
Healthcare (Basel) 2013;2:27-46. 
 
217. Fukunaga-Kalabis M, Martinez G, Liu ZJ, et al. CCN3 controls 3D spatial localization of 
melanocytes in the human skin through DDR1. J Cell Biol 2006;175:563-569. 
160 
 
218. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores 
keratinocyte-mediated growth control and down-regulates expression of invasion-related 
adhesion receptors. Am J Pathol 2000;156:1515-1525. 
 
219. Santiago-Walker A, Li L, Haass NK, et al. Melanocytes: from morphology to application. 
Skin Pharmacol Physiol 2009;22:114-121. 
 
220. Smalley KS, Haass NK, Brafford PA, et al. Multiple signaling pathways must be targeted to 
overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 
2006;5:1136-1144. 
 
221. Berking C, Herlyn M. Human skin reconstruct models: a new application for studies of 
melanocyte and melanoma biology. Histol Histopathol 2001;16:669-674. 
 
222. Haass NK, Smalley KS, Li L, et al. Adhesion, migration and communication in melanocytes 
and melanoma. Pigment Cell Res 2005;18:150-159. 
 
223. Perlman RL. Mouse models of human disease: An evolutionary perspective. Evol Med 
Public Health 2016;2016:170-176. 
 
224. Fox JG. The mouse in biomedical research. 2nd ed. Amsterdam ; Boston: Elsevier, AP, 
2007. 
 
225. Mouse Genome Sequencing C, Waterston RH, Lindblad-Toh K, et al. Initial sequencing and 
comparative analysis of the mouse genome. Nature 2002;420:520-562. 
 
226. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 
2001;291:1304-1351. 
 
227. Pope BD, Ryba T, Dileep V, et al. Topologically associating domains are stable units of 
replication-timing regulation. Nature 2014;515:402-405. 
 
228. Yue F, Cheng Y, Breschi A, et al. A comparative encyclopedia of DNA elements in the 
mouse genome. Nature 2014;515:355-364. 
 
229. Cheng Y, Ma Z, Kim BH, et al. Principles of regulatory information conservation between 
mouse and human. Nature 2014;515:371-375. 
 
230. Stergachis AB, Neph S, Sandstrom R, et al. Conservation of trans-acting circuitry during 
mammalian regulatory evolution. Nature 2014;515:365-370. 
 
231. Carninci P. Genomics: mice in the ENCODE spotlight. Nature 2014;515:346-347. 
 
232. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human 




233. Haley PJ. Species differences in the structure and function of the immune system. 
Toxicology 2003;188:49-71. 
 
234. Natarajan K, Dimasi N, Wang J, et al. MHC class I recognition by Ly49 natural killer cell 
receptors. Mol Immunol 2002;38:1023-1027. 
 
235. Natarajan K, Dimasi N, Wang J, et al. Structure and function of natural killer cell receptors: 
multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002;20:853-
885. 
 
236. Kelley J, Walter L, Trowsdale J. Comparative genomics of natural killer cell receptor gene 
clusters. PLoS Genet 2005;1:129-139. 
 
237. Schenkel AR, Kingry LC, Slayden RA. The ly49 gene family. A brief guide to the 
nomenclature, genetics, and role in intracellular infection. Front Immunol 2013;4:90. 
 
238. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-916. 
 
239. Schneemann M, Schoedon G. Species differences in macrophage NO production are 
important. Nat Immunol 2002;3:102. 
 
240. Weinberg JB. Nitric oxide production and nitric oxide synthase type 2 expression by human 
mononuclear phagocytes: a review. Mol Med 1998;4:557-591. 
 
241. Choo JK, Seebach JD, Nickeleit V, et al. Species differences in the expression of major 
histocompatibility complex class II antigens on coronary artery endothelium: implications for 
cell-mediated xenoreactivity. Transplantation 1997;64:1315-1322. 
 
242. Hughes C, Savage C, Pober J. Endothelial cells augment T cell interleukin 2 production by 
a contact-dependent mechanism involving CD2/LFA-3 interaction. Journal of Experimental 
Medicine 1990;171:1453-1467. 
 
243. van der Merwe PA. A subtle role for CD2 in T cell antigen recognition. Journal of 
Experimental Medicine 1999;190:1371-1374. 
 
244. Karmann K, Hughes C, Schechner J, et al. CD40 on human endothelial cells: inducibility by 
cytokines and functional regulation of adhesion molecule expression. Proceedings of the 
National Academy of Sciences 1995;92:4342-4346. 
 
245. Ensminger SM, Spriewald BM, Fischlein T, et al. Mouse endothelial CD40 expression does 
not play a role during the development of transplant arteriosclerosis. Endothelium 2003;10:111-
117. 
 
246. Gordon CJ, Grafton G, Wood PM, et al. Modelling the human immune response: can mice 
be trusted? Commentary. Curr Opin Pharmacol 2001;1:431-435. 
162 
 
247. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu 
Rev Immunol 1996;14:233-258. 
 
248. Taams LS, van Eden W, Wauben MH. Antigen presentation by T cells versus professional 
antigen-presenting cells (APC): differential consequences for T cell activation and subsequent T 
cell-APC interactions. Eur J Immunol 1999;29:1543-1550. 
 
249. Barnaba V, Watts C, de Boer M, et al. Professional presentation of antigen by activated 
human T cells. Eur J Immunol 1994;24:71-75. 
 
250. Denton MD, Geehan CS, Alexander SI, et al. Endothelial cells modify the costimulatory 
capacity of transmigrating leukocytes and promote CD28-mediated CD4+ T cell alloactivation. 
Journal of Experimental Medicine 1999;190:555-566. 
 
251. Farrar JD, Smith JD, Murphy TL, et al. Selective loss of type I interferon-induced STAT4 
activation caused by a minisatellite insertion in mouse Stat2. Nat Immunol 2000;1:65-69. 
 
252. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. 
Immunity 2000;12:121-127. 
 
253. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. American 
Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2002;283:R7-R28. 
 
254. Weinberg RA. Coming full circle-from endless complexity to simplicity and back again. 
Cell 2014;157:267-271. 
 
255. Perez-Guijarro E, Day CP, Merlino G, et al. Genetically engineered mouse models of 
melanoma. Cancer 2017;123:2089-2103. 
 
256. De Fabo EC, Noonan FP, Fears T, et al. Ultraviolet B but not ultraviolet A radiation 
initiates melanoma. Cancer Res 2004;64:6372-6376. 
 
257. Noonan FP, Recio JA, Takayama H, et al. Neonatal sunburn and melanoma in mice. Nature 
2001;413:271-272. 
 
258. Zitvogel L, Pitt JM, Daillere R, et al. Mouse models in oncoimmunology. Nat Rev Cancer 
2016;16:759-773. 
 
259. Li QX, Feuer G, Ouyang X, et al. Experimental animal modeling for immuno-oncology. 
Pharmacol Ther 2017;173:34-46. 
 
260. Merlino G, Flaherty K, Acquavella N, et al. Meeting report: The future of preclinical mouse 




261. Sanmamed MF, Chester C, Melero I, et al. Defining the optimal murine models to 
investigate immune checkpoint blockers and their combination with other immunotherapies. Ann 
Oncol 2016;27:1190-1198. 
 
262. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in 
cancer treatment. Am J Transl Res 2014;6:114-118. 
 
263. Gillet JP, Calcagno AM, Varma S, et al. Redefining the relevance of established cancer cell 
lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S 
A 2011;108:18708-18713. 
 
264. Dranoff G. Experimental mouse tumour models: what can be learnt about human cancer 
immunology? Nat Rev Immunol 2011;12:61-66. 
 
265. Rovero S, Amici A, Di Carlo E, et al. DNA vaccination against rat her-2/Neu p185 more 
effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J 
Immunol 2000;165:5133-5142. 
 
266. Reilly RT, Machiels JP, Emens LA, et al. The collaboration of both humoral and cellular 
HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-
expressing tumors. Cancer Res 2001;61:880-883. 
 
267. Gregorio AC, Fonseca NA, Moura V, et al. Inoculated Cell Density as a Determinant Factor 
of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model. PLoS One 
2016;11:e0165817. 
 
268. Lechner MG, Karimi SS, Barry-Holson K, et al. Immunogenicity of murine solid tumor 
models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother 
2013;36:477-489. 
 
269. Allard B, Allard D, Stagg J. Methods to Evaluate the Antitumor Activity of Immune 
Checkpoint Inhibitors in Preclinical Studies. Methods Mol Biol 2016;1458:159-177. 
 
270. Quetglas JI, Labiano S, Aznar MA, et al. Virotherapy with a Semliki Forest Virus-Based 
Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. Cancer Immunol Res 
2015;3:449-454. 
 
271. Talmadge JE, Singh RK, Fidler IJ, et al. Murine models to evaluate novel and conventional 
therapeutic strategies for cancer. Am J Pathol 2007;170:793-804. 
 
272. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer 
vaccines. Curr Opin Immunol 2004;16:143-150. 
 
273. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 
blockade. Science 1996;271:1734-1736. 
164 
 
274. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly 
immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005;17:133-
144. 
 
275. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from 
host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 
2002;99:12293-12297. 
 
276. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced 
melanoma. N Engl J Med 2013;369:122-133. 
 
277. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of 
advanced human cancer--response. Clin Cancer Res 2013;19:5542. 
 
278. Melero I, Berman DM, Aznar MA, et al. Evolving synergistic combinations of targeted 
immunotherapies to combat cancer. Nat Rev Cancer 2015;15:457-472. 
 
279. Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic Chemotherapy Sensitizes Tumors to 
Checkpoint Blockade Therapy. Immunity 2016;44:343-354. 
 
280. Timmons JJ, Cohessy S, Wong ET. Injection of Syngeneic Murine Melanoma Cells to 
Determine Their Metastatic Potential in the Lungs. J Vis Exp 2016. 
 
281. Teicher BA. Tumor models in cancer research. 2nd ed. New York: Humana Press, 2011. 
282. Zaidi MR, Day CP, Merlino G. From UVs to metastases: modeling melanoma initiation and 
progression in the mouse. J Invest Dermatol 2008;128:2381-2391. 
 
283. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc 
Immunol 2001;Chapter 20:Unit 20 21. 
 
284. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant 
tumor. Science 1977;197:893-895. 
 
285. Fidler IJ, Nicolson GL. Fate of recirculating B16 melanoma metastatic variant cells in 
parabiotic syngeneic recipients. J Natl Cancer Inst 1977;58:1867-1872. 
 
286. Nicolson GL, Brunson KW, Fidler IJ. Specificity of arrest, survival, and growth of selected 
metastatic variant cell lines. Cancer Res 1978;38:4105-4111. 
 
287. Mathieu V, Le Mercier M, De Neve N, et al. Galectin-1 knockdown increases sensitivity to 
temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 
2007;127:2399-2410. 
 
288. Morikawa K, Walker SM, Nakajima M, et al. Influence of organ environment on the 




289. Volpe JP, Milas L. Influence of tumor transplantation methods on tumor growth rate and 
metastatic potential of solitary tumors derived from metastases. Clin Exp Metastasis 1990;8:381-
389. 
 
290. Visonneau S, Cesano A, Torosian MH, et al. Growth characteristics and metastatic 
properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol 
1998;152:1299-1311. 
 
291. Schuh JC. Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol 
2004;32 Suppl 1:53-66. 
 
292. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals 
in cancer research. Br J Cancer 2010;102:1555-1577. 
 
293. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic 
mapping for early stage melanoma. Arch Surg 1992;127:392-399. 
 
294. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma 
lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I 
or II melanoma patients. J Clin Oncol 1999;17:976-983. 
 
295. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative 
sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 
1998;16:2253-2260. 
 
296. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant 
melanoma. Arch Surg 1995;130:654-658; discussion 659-660. 
 
297. Gomez-Cuadrado L, Tracey N, Ma R, et al. Mouse models of metastasis: progress and 
prospects. Dis Model Mech 2017;10:1061-1074. 
 
298. Byrne-Hoffman C, II D. A Quantitative Systems Pharmacology Perspective on Cancer 
Immunology. Processes 2015;3:235. 
 
299. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005;26:513-523. 
 
300. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat 
Rev Cancer 2003;3:453-458. 
 
301. Bobek V, Kolostova K, Pinterova D, et al. A clinically relevant, syngeneic model of 
spontaneous, highly metastatic B16 mouse melanoma. Anticancer Res 2010;30:4799-4803. 
 
302. Rebhun RB, Lazar AJ, Fidler IJ, et al. Impact of sentinel lymphadenectomy on survival in a 




303. Chen BJ, Jiao Y, Zhang P, et al. Long-term in vivo imaging of multiple organs at the single 
cell level. PLoS One 2013;8:e52087. 
 
304. Bobek V, Kolostova K, Pinterov D, et al. Syngeneic lymph-node-targeting model of green 
fluorescent protein-expressing Lewis lung carcinoma. Clin Exp Metastasis 2004;21:705-708. 
 
305. Hoshida T, Isaka N, Hagendoorn J, et al. Imaging steps of lymphatic metastasis reveals that 
vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells 
to lymph nodes: therapeutic implications. Cancer Res 2006;66:8065-8075. 
 
306. Stadtlander CT. Introduction to mathematical oncology. J Biol Dyn 2016;10:501-505. 
 
307. Kuang Y, Nagy JD, Eikenberry SE. Introduction to Mathematical Oncology. BocaRaton, 
FL.: CRC Press, 2016. 
 
308. Yu Z, Adusumilli PS, Eisenberg DP, et al. Nectin-1 expression by squamous cell carcinoma 
is a predictor of herpes oncolytic sensitivity. Mol Ther 2007;15:103-113. 
 
309. Wen FT, Thisted RA, Rowley DA, et al. A systematic analysis of experimental 
immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 
2012;1:172-178. 
 
310. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal 
Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 
2005;23:8048-8056. 
 
311. Nicola AV, Straus SE. Cellular and viral requirements for rapid endocytic entry of herpes 
simplex virus. J Virol 2004;78:7508-7517. 
 
312. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer 
Metastasis Rev 1989;8:98-101. 
 
313. Weber CE, Kuo PC. The tumor microenvironment. Surg Oncol 2012;21:172-177. 
 
314. Anderson AR, Weaver AM, Cummings PT, et al. Tumor morphology and phenotypic 
evolution driven by selective pressure from the microenvironment. Cell 2006;127:905-915. 
 
315. Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the 
concept of microenvironment-induced mutagenesis. Mutat Res 2005;569:75-85. 
 
316. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor 
microenvironment. Cancer Res 1996;56:5754-5757. 
 
317. Robert C. Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy. 
Trends Mol Med 2017;23:983-985. 
167 
 
318. Ribas A, Dummer R, Puzanov I, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell 






























Natalie Fowlkes graduated from Louisiana State University School of Veterinary Medicine, Baton 
Rouge with a DVM degree. She joined the anatomic pathology training program 
at Louisiana State University (LSU) in 2010. Natalie Fowlkes is a member of the American 
College of Veterinary Pathologists (Dipl ACVP). In 2015, she joined a Doctor of Philosophy 
graduate program at Louisiana State University, focusing on murine melanoma tumor model 
development and oncolytic virotherapy research under the mentorship of Dr. Konstantin G. 
Kousoulas.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
